B10

(54) Title: REGULATION OF HUMAN SERINE/THREONINE PROTEIN KINASE

(57) Abstract: Reagents that regulate human serine/threonine protein kinase and reagents which bind to human serine/threonine protein kinase gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, COPD, cardiovascular disorders, urinary disorders, obesity, diabetes, and peripheral and central nervous system disorders.

WO 02/070678 A2

REGULATION OF HUMAN SERINE/THREONINE PROTEIN KINASE

This application claims the benefit of and incorporates by reference US provisional application Serial No. 60/265,903 filed February 5, 2001 and Serial No. 60/308,104
5   filed July 30, 2001.

TECHNICAL FIELD OF THE INVENTION

The invention relates to the regulation of human serine/threonine protein kinase.

10

BACKGROUND OF THE INVENTION

Intercellular signaling regulates a variety of important biological functions. For example, transforming growth factor type beta (TGF-β) regulates the proliferation
15   and differentiation of a variety of cell types binding to and activating cell surface receptors which possess serine/threonine kinase activity. Atfi *et al.* (*Proc. Natl. Acad. Sci. U.S.A.* **92**, 12110-04, 1995) have shown that TGF-β activates a 78-kDa protein (p78) serine/threonine kinase; the p78 kinase was activated only in cells for which TGF-β acts as a growth inhibitory factor. Because of the important functions
20   of kinases such as p78, there is a need in the art to identify new kinases and methods of regulating these new kinases for therapeutic effects.

SUMMARY OF THE INVENTION

25   It is an object of the invention to provide reagents and methods of regulating a human serine/threonine protein kinase. This and other objects of the invention are provided by one or more of the embodiments described below.

One embodiment of the invention is a serine/threonine protein kinase polypeptide
30   comprising an amino acid sequence selected from the group consisting of:

amino acid sequences which are at least about 75% identical to the amino acid sequence shown in SEQ ID NO: 2; and

the amino acid sequence shown in SEQ ID NO: 2;

Yet another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a serine/threonine protein kinase polypeptide comprising an amino acid sequence selected from the group consisting of:

amino acid sequences which are at least about 75% identical to the amino acid sequence shown in SEQ ID NO: 2; and

the amino acid sequence shown in SEQ ID NO: 2;

Binding between the test compound and the serine/threonine protein kinase polypeptide is detected. A test compound which binds to the serine/threonine protein kinase polypeptide is thereby identified as a potential agent for decreasing extracellular matrix degradation. The agent can work by decreasing the activity of the serine/threonine protein kinase.

Another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a polynucleotide encoding a serine/threonine protein kinase polypeptide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 1;

the nucleotide sequence shown in SEQ ID NO: 1;

- 3 -

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 4; and

5   the nucleotide sequence shown in SEQ ID NO: 4.

Binding of the test compound to the polynucleotide is detected. A test compound which binds to the polynucleotide is identified as a potential agent for decreasing extracellular matrix degradation. The agent can work by decreasing the amount of the

10   serine/threonine protein kinase through interacting with the serine/threonine protein kinase mRNA.

Another embodiment of the invention is a method of screening for agents which regulate extracellular matrix degradation. A test compound is contacted with a

15   serine/threonine protein kinase polypeptide comprising an amino acid sequence selected from the group consisting of:

amino acid sequences which are at least about 75% identical to the amino acid sequence shown in SEQ ID NO: 2; and

20
the amino acid sequence shown in SEQ ID NO: 2;

A serine/threonine protein kinase activity of the polypeptide is detected. A test compound which increases serine/threonine protein kinase activity of the polypeptide

25   relative to serine/threonine protein kinase activity in the absence of the test compound is thereby identified as a potential agent for increasing extracellular matrix degradation. A test compound which decreases serine/threonine protein kinase activity of the polypeptide relative to serine/threonine protein kinase activity in the absence of the test compound is thereby identified as a potential agent for decreasing

30   extracellular matrix degradation.

- 4 -

Even another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a serine/threonine protein kinase product of a polynucleotide which comprises a nucleotide sequence selected from the group consisting of:

5

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 1;

the nucleotide sequence shown in SEQ ID NO: 1 ;

10

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 4; and

the nucleotide sequence shown in SEQ ID NO: 4.

15

Binding of the test compound to the serine/threonine protein kinase product is detected. A test compound which binds to the serine/threonine protein kinase product is thereby identified as a potential agent for decreasing extracellular matrix degradation.

20

Still another embodiment of the invention is a method of reducing extracellular matrix degradation. A cell is contacted with a reagent which specifically binds to a polynucleotide encoding a serine/threonine protein kinase polypeptide or the product encoded by the polynucleotide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

25

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 1;

30   the nucleotide sequence shown in SEQ ID NO: 1;

- 5 -

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 4; and

the nucleotide sequence shown in SEQ ID NO: 4.

5

Serine/threonine protein kinase activity in the cell is thereby decreased.

The invention thus provides a human serine/threonine protein kinase that can be used to identify test compounds that may act, for example, as activators or inhibitors at the

10   enzyme's active site. Human serine/threonine protein kinase and fragments thereof also are useful in raising specific antibodies that can block the enzyme and effectively reduce its activity.

BRIEF DESCRIPTION OF THE DRAWINGS

15   Fig. 1   shows the DNA-sequence encoding a serine/threo-
                    nine protein kinase polypeptide (SEQ ID NO:4).

      Fig. 2   shows the amino acid sequence deduced from the
                    DNA-sequence of Fig.1 (SEQ ID NO:2).

      Fig. 3   shows the amino acid sequence of the protein

20   identified by swissnew/015075/DCK1_HUMAN-
                    SERINE/THREONINE-PROTEIN   KINASE
                    DCAMKL1 (EC2.7.1-) (DOUBLECORTIN-LIKE
                    AND CAM KINASE LIKE 1)(SEQ ID NO:3).

      Fig. 4   shows the DNA-sequence encoding a serine/threo-

25   nine protein kinase polypeptide (SEQ ID NO:1).

      Fig. 5   shows the amino acid sequence of a serine/threo-
                    nine protein kinase polypeptide (SEQ ID NO:5).

      Fig. 6   shows the DNA-sequence encoding a serine/threo-
                    nine protein kinase polypeptide (SEQ ID NO:6).

30   Fig. 7   shows the amino acid sequence of a serine/threo-
                    nine protein kinase polypeptide (SEQ ID NO:7)

Fig. 8   shows the DNA-sequence encoding a serine/threo-
                nine protein kinase polypeptide (SEQ ID NO: 8)

Fig. 9   shows the DNA-sequence encoding a serine/threo-
                nine protein kinase polypeptide (SEQ ID NO:9)

Fig. 10   shows the DNA-sequence encoding a serine/threo-
                nine protein kinase polypeptide (SEQ ID NO:10)

Fig. 11   shows the DNA-sequence encoding a serine/threo-
                nine protein kinase polypeptide (SEQ ID NO:11)

Fig. 12   shows the BLASTP - alignment of 411 (SEQ ID
                NO:2) against aageneseq|Y42696|Y42696Rat
                serine-threonine protein kinase PK80 sequence.

Fig. 13   shows the BLASTP - alignment of 411 (SEQ ID
                NO:2) against swissnew|O15075|DCK1_HUMAN-
                SERINE/THREONINE-PROTEIN KINASE
                DCAMKL1 (EC 2.7.1.-) (DOUBLECORTIN-
                LIKE AND CAM KINASE-LIKE 1) (SEQ ID
                NO:3).

Fig. 14 shows the BLASTP - alignment of 411 (SEQ ID NO:2)
                against swissnew|O15075|DCK1_HUMAN
                SERINE/THREONINE-PROTEIN KINASE
                DCAMKL1 (EC 2.7.1.-) (DOUBLECORTIN-
                LIKE AND CAM KINASE-LIKE
                1).//:swiss|O15075|DCK1_HUMAN
                SERINE/THREONINE-PROTEIN KINASE
                DCAMKL1 (EC 2.7.1.-) (DOUBLECORTIN-
                LIKE AND CAM KINASE-LIKE 1) (KIAA0369)
                (SEQ ID NO:3).

Fig. 15   shows the HMMPFAM - alignment of 411 (SEQ
                ID NO:2) against pfam|hmm|pkinaseEukaryotic
                protein kinase domain.

- 7 -

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to an isolated polynucleotide from the group consisting of:

a)   a polynucleotide encoding a serine/threonine protein kinase
     polypeptide comprising an amino acid sequence selected from the
     group consisting of:
     amino acid sequences which are at least about 50% identical to
     the amino acid sequence shown in SEQ ID NO: 2; and
     the amino acid sequence shown in SEQ ID NO: 2;

b)   a polynucleotide comprising the sequence of SEQ ID NO: 1 or 4;

c)   a polynucleotide which hybridizes under stringent conditions to a
     polynucleotide specified in (a) and (b) and encodes a serine/threonine
     protein kinase polypeptide;

d)   a polynucleotide the sequence of which deviates from the
     polynucleotide sequences specified in (a) to (c) due to the

- 8 -

degeneration of the genetic code and encodes a serine/threonine protein kinase polypeptide; and

e)   a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d) and encodes a serine/threonine protein kinase polypeptide.

Furthermore, it has been discovered by the present applicant that a novel serine/threonine protein kinase, particularly a human serine/threonine protein kinase, can be used in therapeutic methods to treat cancer, COPD, a cardiovascular disorder, a urinary disorder, obesity, diabetes or a peripheral or central nervous system disorder. Human serine/threonine protein kinase comprises the amino acid sequence shown in SEQ ID NO:2. A coding sequence for human serine/threonine protein kinase is shown in SEQ ID NO:1 and 4. This sequence is located on chromosome 3. This is a full-length sequence obtained by genewise and genscan analysis of the genomic sequence AC032001.2 and the rat serine-threonine protein kinase PK80 sequence. Related ESTs (SEQ ID NOS:9-11) are expressed in testis and pooled germ cell tumors.The protein having SEQ ID NO:2 is clearly identified as a eukaryotic protein kinase, more specifically as a serine/threonine kinase, by pfam homology. The function of this protein as a serine/threonine kinase also is supported by the identification of a protein-kinase-ST region and a protein-kinase -ATP region by prosite analysis. Three-dimensional structure is inferred by clear homology from residues 536 to 806 in 1A06.

SEQ ID NO:2 has a doublecortin region at its N-terminus in addition to the protein-kinase ST region with the active aspartic acid residue. Alignments are given in FIGS. 1-3 and 7. Doublecortin (DCX) is a brain-specific protein, important in migration of cortical neurons and implicated in X-linked lissencephaly and double cortex syndrome.

Human serine/threonine protein kinase is believed to be useful in therapeutic methods to treat disorders such as cancer, COPD, cardiovascular disorders, urinary

disorders, obesity, diabetes, and peripheral and central nervous system disorders. Human serine/threonine protein kinase also can be used to screen for human serine/threonine protein kinase activators and inhibitors.

5   *Polypeptides*

Human serine/threonine protein kinase polypeptides according to the invention comprise at least 6, 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 350, 375, 400, 450, 500, 550, 600, 650, 700, 750, 800, or 835 contiguous amino

10   acids selected from the amino acid sequence shown in SEQ ID NO:2 or a biologically active variant thereof, as defined below. A serine/threonine protein kinase polypeptide of the invention therefore can be a portion of a serine/threonine protein kinase protein, a full-length serine/threonine protein kinase protein, or a fusion protein comprising all or a portion of a serine/threonine protein kinase protein.

15

Biologically Active Variants

Human serine/threonine protein kinase polypeptide variants that are biologically active, *e.g.*, retain a serine/threonine protein kinase activity, also are serine/threonine

20   protein kinase polypeptides. Preferably, naturally or non-naturally occurring serine/threonine protein kinase polypeptide variants have amino acid sequences which are at least about 75, 80, 85, 90, 96, 96, 98, or 99% identical to the amino acid sequence shown in SEQ ID NO:2 or a fragment thereof. Percent identity between a putative serine/threonine protein kinase polypeptide variant and an amino acid

25   sequence of SEQ ID NO:2 is determined by conventional methods. See, for example, Altschul *et al.*, *Bull. Math. Bio. 48*:603 (1986), and Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA 89*:10915 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "BLOSUM62" scoring matrix of Henikoff &

30   Henikoff, 1992.

- 10 -

Those skilled in the art appreciate that there are many established algorithms available to align two amino acid sequences. The "FASTA" similarity search algorithm of Pearson & Lipman is a suitable protein alignment method for examining the level of identity shared by an amino acid sequence disclosed herein and the

5   amino acid sequence of a putative variant. The FASTA algorithm is described by Pearson & Lipman, *Proc. Nat'l Acad. Sci. USA 85*:2444(1988), and by Pearson, *Meth. Enzymol. 183*:63 (1990). Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (*e.g.*, SEQ ID NO: 2) and a test sequence that have either the highest density of identities (if the ktup

10   variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only those residues that contribute to the highest score. If there

15   are several regions with scores greater than the "cutoff" value (calculated by a predetermined formula based upon the length of the sequence the ktup value), then the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the

20   Needleman-Wunsch- Sellers algorithm (Needleman & Wunsch, *J. Mol. Biol.48*:444 (1970); Sellers, *SIAM J. Appl. Math.26*:787 (1974)), which allows for amino acid insertions and deletions. Preferred parameters for FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62. These parameters can be introduced into a FASTA program by modifying the scoring

25   matrix file ("SMATRIX"), as explained in Appendix 2 of Pearson, *Meth. Enzymol. 183*:63 (1990).

FASTA can also be used to determine the sequence identity of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons,

30   the ktup value can range between one to six, preferably from three to six, most preferably three, with other parameters set as default.

- 11 -

Variations in percent identity can be due, for example, to amino acid substitutions, insertions, or deletions. Amino acid substitutions are defined as one for one amino acid replacements. They are conservative in nature when the substituted amino acid has similar structural and/or chemical properties. Examples of conservative replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

Amino acid insertions or deletions are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity of a serine/threonine protein kinase polypeptide can be found using computer programs well known in the art, such as DNASTAR software. Whether an amino acid change results in a biologically active serine/threonine protein kinase polypeptide can readily be determined by assaying for serine/threonine protein kinase activity, as described for example, in Example 4.

Fusion Proteins

Fusion proteins are useful for generating antibodies against serine/threonine protein kinase polypeptide amino acid sequences and for use in various assay systems. For example, fusion proteins can be used to identify proteins that interact with portions of a serine/threonine protein kinase polypeptide. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.

A serine/threonine protein kinase polypeptide fusion protein comprises two polypeptide segments fused together by means of a peptide bond. The first polypeptide segment comprises at least 6, 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 350, 375, 400, 450, 500, 550, 600, 650, 700, 750, 800, or 835

contiguous amino acids of SEQ ID NO:2 or of a biologically active variant, such as those described above. The first polypeptide segment also can comprise full-length serine/threonine protein kinase protein.

5   The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion protein construction include β-galactosidase, β-glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT).

10   Additionally, epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions.

15   A fusion protein also can be engineered to contain a cleavage site located between the serine/threonine protein kinase polypeptide-encoding sequence and the hetero-logous protein sequence, so that the serine/threonine protein kinase polypeptide can be cleaved and purified away from the heterologous moiety.

20   A fusion protein can be synthesized chemically, as is known in the art. Preferably, a fusion protein is produced by covalently linking two polypeptide segments or by standard procedures in the art of molecular biology. Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which comprises coding sequences selected from SEQ ID NO:1 or 4 in proper

25   reading frame with nucleotides encoding the second polypeptide segment and expressing the DNA construct in a host cell, as is known in the art. Many kits for constructing fusion proteins are available from companies such as Promega Corporation (Madison, WI), Stratagene (La Jolla, CA), CLONTECH (Mountain View, CA), Santa Cruz Biotechnology (Santa Cruz, CA), MBL International

30   Corporation (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal, Canada; 1-888-DNA-KITS).

- 13 -

Identification of Species Homologs

Species homologs of human serine/threonine protein kinase polypeptide can be obtained using serine/threonine protein kinase polypeptide polynucleotides (described below) to make suitable probes or primers for screening cDNA expression libraries from other species, such as mice, monkeys, or yeast, identifying cDNAs which encode homologs of serine/threonine protein kinase polypeptide, and expressing the cDNAs as is known in the art.

Polynucleotides

A serine/threonine protein kinase polynucleotide can be single- or double-stranded and comprises a coding sequence or the complement of a coding sequence for a serine/threonine protein kinase polypeptide. A coding sequence for human serine/threonine protein kinase is shown in SEQ ID NO:1 and 4.

Degenerate nucleotide sequences encoding human serine/threonine protein kinase polypeptides, as well as homologous nucleotide sequences which are at least about 50, 55, 60, 65, 70, preferably about 75, 90, 96, 98, or 99% identical to the nucleotide sequence shown in SEQ ID NO:1 or 4 or its complement also are serine/threonine protein kinase polynucleotides. Percent sequence identity between the sequences of two polynucleotides is determined using computer programs such as ALIGN which employ the FASTA algorithm, using an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2. Complementary DNA (cDNA) molecules, species homologs, and variants of serine/threonine protein kinase polynucleotides that encode biologically active serine/threonine protein kinase polypeptides also are serine/threonine protein kinase polynucleotides. Polynucleotide fragments comprising at least 8, 9, 10, 11, 12, 15, 20, or 25 contiguous nucleotides of SEQ ID NO:1 or 4 or its complement also are serine/threonine protein kinase polynucleotides.

- 14 -

These fragments can be used, for example, as hybridization probes or as antisense oligonucleotides.

Identification of Polynucleotide Variants and Homologs

5

Variants and homologs of the serine/threonine protein kinase polynucleotides described above also are serine/threonine protein kinase polynucleotides. Typically, homologous serine/threonine protein kinase polynucleotide sequences can be identified by hybridization of candidate polynucleotides to known serine/threonine

10   protein kinase polynucleotides under stringent conditions, as is known in the art. For example, using the following wash conditions--2X SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2X SSC, 0.1% SDS, 50 °C once, 30 minutes; then 2X SSC, room temperature twice, 10 minutes each--homologous sequences can be identified which contain at most about

15   25-30% basepair mismatches. More preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

Species homologs of the serine/threonine protein kinase polynucleotides disclosed

20   herein also can be identified by making suitable probes or primers and screening cDNA expression libraries from other species, such as mice, monkeys, or yeast. Human variants of serine/threonine protein kinase polynucleotides can be identified, for example, by screening human cDNA expression libraries. It is well known that the T_m of a double-stranded DNA decreases by 1-1.5 °C with every 1% decrease in

25   homology (Bonner *et al.*, *J. Mol. Biol. 81*, 123 (1973). Variants of human serine/threonine protein kinase polynucleotides or serine/threonine protein kinase polynucleotides of other species can therefore be identified by hybridizing a putative homologous serine/threonine protein kinase polynucleotide with a polynucleotide having a nucleotide sequence of SEQ ID NO:1 or 4 or the complement thereof to

30   form a test hybrid. The melting temperature of the test hybrid is compared with the melting temperature of a hybrid comprising polynucleotides having perfectly

- 15 -

complementary nucleotide sequences, and the number or percent of basepair mismatches within the test hybrid is calculated.

Nucleotide sequences which hybridize to serine/threonine protein kinase polynucleotides or their complements following stringent hybridization and/or wash conditions also are serine/threonine protein kinase polynucleotides. Stringent wash conditions are well known and understood in the art and are disclosed, for example, in Sambrook *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, 2d ed., 1989, at pages 9.50-9.51.

Typically, for stringent hybridization conditions a combination of temperature and salt concentration should be chosen that is approximately 12-20 °C below the calculated T_m of the hybrid under study. The T_m of a hybrid between a serine/threonine protein kinase polynucleotide having a nucleotide sequence shown in SEQ ID NO:1 or 4 or the complement thereof and a polynucleotide sequence which is at least about 50, preferably about 75, 90, 96, or 98% identical to one of those nucleotide sequences can be calculated, for example, using the equation of Bolton and McCarthy, *Proc. Natl. Acad. Sci. U.S.A. 48*, 1390 (1962):

$$T_m = 81.5\ ^{\circ}C - 16.6(\log_{10}[Na^+]) + 0.41(\%G + C) - 0.63(\%formamide) - 600/l,$$
where l = the length of the hybrid in basepairs.

Stringent wash conditions include, for example, 4X SSC at 65 °C, or 50% formamide, 4X SSC at 42 °C, or 0.5X SSC, 0.1% SDS at 65 °C. Highly stringent wash conditions include, for example, 0.2X SSC at 65 °C.

Preparation of Polynucleotides

A serine/threonine protein kinase polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides can be made by a cell and isolated using standard nucleic acid purification

techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated serine/threonine protein kinase polynucleotides. For example, restriction enzymes and probes can be used to isolate polynucleotide fragments, which comprise serine/threonine protein kinase nucleotide sequences. Isolated polynucleotides are in preparations that are free or at least 70, 80, or 90% free of other molecules.

Human serine/threonine protein kinase cDNA molecules can be made with standard molecular biology techniques, using serine/threonine protein kinase mRNA as a template. Human serine/threonine protein kinase cDNA molecules can thereafter be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook *et al.* (1989). An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or cDNA as a template.

Alternatively, synthetic chemistry techniques can be used to synthesize serine/threonine protein kinase polynucleotides. The degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode a serine/threonine protein kinase polypeptide having, for example, an amino acid sequence shown in SEQ ID NO:2 or a biologically active variant thereof.

Extending Polynucleotides

Various PCR-based methods can be used to extend the nucleic acid sequences disclosed herein to detect upstream sequences such as promoters and regulatory elements. For example, restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, *PCR Methods Applic. 2*, 318-322, 1993). Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences

- 17 -

are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region (Triglia *et al.*, *Nucleic Acids Res. 16*, 8186, 1988). Primers can be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72 °C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which can be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom *et al.*, *PCR Methods Applic. 1*, 111-119, 1991). In this method, multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

Another method which can be used to retrieve unknown sequences is that of Parker *et al.*, *Nucleic Acids Res. 19*, 3055-3060, 1991). Additionally, PCR, nested primers, and PROMOTERFINDER libraries (CLONTECH, Palo Alto, Calif.) can be used to walk genomic DNA (CLONTECH, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an

oligo d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

Commercially available capillary electrophoresis systems can be used to analyze the
5   size or confirm the nucleotide sequence of PCR or sequencing products. For example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) that are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity can be converted to electrical signal using appropriate
10   software (e.g. GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA that might be present in limited amounts in a particular sample.

15

Obtaining Polypeptides

Human serine/threonine protein kinase polypeptides can be obtained, for example, by purification from human cells, by expression of serine/threonine protein kinase
20   polynucleotides, or by direct chemical synthesis.

Protein Purification

Human serine/threonine protein kinase polypeptides can be purified from any cell
25   that expresses the polypeptide, including host cells that have been transfected with serine/threonine protein kinase expression constructs. A purified serine/threonine protein kinase polypeptide is separated from other compounds that normally associate with the serine/threonine protein kinase polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such
30   methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and

- 19 -

preparative gel electrophoresis. A preparation of purified serine/threonine protein kinase polypeptides is at least 80% pure; preferably, the preparations are 90%, 95%, or 99% pure. Purity of the preparations can be assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis.

5

Expression of Polynucleotides

To express a serine/threonine protein kinase polynucleotide, the polynucleotide can be inserted into an expression vector that contains the necessary elements for the

10   transcription and translation of the inserted coding sequence. Methods that are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding serine/threonine protein kinase polypeptides and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo*

15   genetic recombination. Such techniques are described, for example, in Sambrook *et al.* (1989) and in Ausubel *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1989.

A variety of expression vector/host systems can be utilized to contain and express

20   sequences encoding a serine/threonine protein kinase polypeptide. These include, but are not limited to, microorganisms, such as bacteria transformed with re-combinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast trans-formed with yeast expression vectors, insect cell systems infected with virus expression vectors (*e.g.*, baculovirus), plant cell systems transformed with virus

25   expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids), or animal cell systems.

The control elements or regulatory sequences are those non-translated regions of the

30   vector -- enhancers, promoters, 5' and 3' untranslated regions -- which interact with host cellular proteins to carry out transcription and translation. Such elements can

vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO, and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) can be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding a serine/threonine protein kinase polypeptide, vectors based on SV40 or EBV can be used with an appropriate selectable marker.

Bacterial and Yeast Expression Systems

In bacterial systems, a number of expression vectors can be selected depending upon the use intended for the serine/threonine protein kinase polypeptide. For example, when a large quantity of a serine/threonine protein kinase polypeptide is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional E. coli cloning and expression vectors such as BLUE-SCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding the serine/threonine protein kinase polypeptide can be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β-galactosidase so that a hybrid protein is produced. pIN vectors (Van Heeke & Schuster, J. Biol. Chem. 264, 5503-5509, 1989) or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose

- 21 -

beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

5

In the yeast *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used. For reviews, see Ausubel *et al.* (1989) and Grant *et al.*, *Methods Enzymol. 153*, 516-544, 1987.

10

Plant and Insect Expression Systems

If plant expression vectors are used, the expression of sequences encoding serine/threonine protein kinase polypeptides can be driven by any of a number of 15 promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV (Takamatsu, *EMBO J. 6*, 307-311, 1987). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used (Coruzzi *et al.*, *EMBO J. 3*, 1671-1680, 1984; Broglie *et al.*, *Science 224*, 838-843, 1984; Winter 20 *et al.*, *Results Probl. Cell Differ. 17*, 85-105, 1991). These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (*e.g.*, Hobbs or Murray, in McGRAW HILL YEARBOOK OF SCIENCE AND TECHNOLOGY, McGraw Hill, New York, N.Y., pp. 191-196, 1992).

25

An insect system also can be used to express a serine/threonine protein kinase polypeptide. For example, in one such system *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. Sequences encoding serine/threonine 30 protein kinase polypeptides can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter.

Successful insertion of serine/threonine protein kinase polypeptides will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect *S. frugiperda cells* or *Trichoplusia* larvae in which serine/threonine protein kinase polypeptides can be expressed (Engelhard *et al.*, *Proc. Nat. Acad. Sci. 91*, 3224-3227, 1994).

Mammalian Expression Systems

A number of viral-based expression systems can be used to express serine/threonine protein kinase polypeptides in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding serine/threonine protein kinase polypeptides can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus that is capable of expressing a serine/threonine protein kinase polypeptide in infected host cells (Logan & Shenk, *Proc. Natl. Acad. Sci. 81*, 3655-3659, 1984). If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) also can be used to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (*e.g.*, liposomes, polycationic amino polymers, or vesicles).

Specific initiation signals also can be used to achieve more efficient translation of sequences encoding serine/threonine protein kinase polypeptides. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding a serine/threonine protein kinase polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous

- 23 -

translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be

5   enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used (see Scharf *et al.*, *Results Probl. Cell Differ. 20*, 125-162, 1994).

Host Cells

10

A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed serine/threonine protein kinase polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation,

15   lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function. Different host cells that have specific cellular machinery and characteristic mechanisms for post-translational activities (*e.g.*, CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801

20   University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.

Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express serine/threonine protein kinase

25   polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer

30   resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced serine/threonine protein kinase sequences.

- 24 -

Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, ANIMAL CELL CULTURE, R.I. Freshney, ed., 1986.

5   Any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler *et al.*, *Cell 11*, 223-32, 1977) and adenine phosphoribosyltransferase (Lowy *et al.*, *Cell 22*, 817-23, 1980) genes which can be employed in *tk⁻* or *aprt⁻* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as

10   the basis for selection. For example, *dhfr* confers resistance to methotrexate (Wigler *et al.*, *Proc. Natl. Acad. Sci. 77*, 3567-70, 1980), *npt* confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin *et al.*, *J. Mol. Biol. 150*, 1-14, 1981), and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murray, 1992, *supra*). Additional selectable genes

15   have been described. For example, *trpB* allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, *Proc. Natl. Acad. Sci. 85*, 8047-51, 1988). Visible markers such as anthocyanins, β-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount

20   of transient or stable protein expression attributable to a specific vector system (Rhodes *et al.*, *Methods Mol. Biol. 55*, 121-131, 1995).

Detecting Expression

25   Although the presence of marker gene expression suggests that the serine/threonine protein kinase polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a serine/threonine protein kinase polypeptide is inserted within a marker gene sequence, transformed cells containing sequences that encode a serine/threonine protein kinase polypeptide can be identified

30   by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a serine/threonine protein kinase polypeptide

under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the serine/threonine protein kinase polynucleotide.

5 Alternatively, host cells which contain a serine/threonine protein kinase polynucleotide and which express a serine/threonine protein kinase polypeptide can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques that include membrane, solution, or chip-based
10 technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a polynucleotide sequence encoding a serine/threonine protein kinase polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding a serine/threonine protein kinase polypeptide. Nucleic acid ampli-
15 fication-based assays involve the use of oligonucleotides selected from sequences encoding a serine/threonine protein kinase polypeptide to detect transformants that contain a serine/threonine protein kinase polynucleotide.

A variety of protocols for detecting and measuring the expression of a
20 serine/threonine protein kinase polypeptide, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immuno-assay using monoclonal antibodies reactive to two non-interfering epitopes on a
25 serine/threonine protein kinase polypeptide can be used, or a competitive binding assay can be employed. These and other assays are described in Hampton *et al.*, SEROLOGICAL METHODS: A LABORATORY MANUAL, APS Press, St. Paul, Minn., 1990) and Maddox *et al.*, *J. Exp. Med. 158*, 1211-1216, 1983).

30 A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for

producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding serine/threonine protein kinase polypeptides include oligo-labeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding a serine/threonine protein kinase polypeptide can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes *in vitro* by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Expression and Purification of Polypeptides

Host cells transformed with nucleotide sequences encoding a serine/threonine protein kinase polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode serine/threonine protein kinase poly-peptides can be designed to contain signal sequences which direct secretion of soluble serine/threonine protein kinase polypeptides through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound serine/threonine protein kinase polypeptide.

As discussed above, other constructions can be used to join a sequence encoding a serine/threonine protein kinase polypeptide to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such puri-fication facilitating domains include, but are not limited to, metal chelating peptides

- 27 -

such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Inclusion of cleavable linker sequences such as those specific for Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the serine/threonine protein kinase polypeptide also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a serine/threonine protein kinase polypeptide and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilized metal ion affinity chromatography, as described in Porath *et al.*, *Prot. Exp. Purif.* 3, 263-281, 1992), while the enterokinase cleavage site provides a means for purifying the serine/threonine protein kinase polypeptide from the fusion protein. Vectors that contain fusion proteins are disclosed in Kroll *et al.*, *DNA Cell Biol.* 12, 441-453, 1993.

Chemical Synthesis

Sequences encoding a serine/threonine protein kinase polypeptide can be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers *et al.*, *Nucl. Acids Res. Symp. Ser.* 215-223, 1980; Horn *et al. Nucl. Acids Res. Symp. Ser.* 225-232, 1980). Alternatively, a serine/threonine protein kinase polypeptide itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques (Merrifield, *J. Am. Chem. Soc. 85*, 2149-2154, 1963; Roberge *et al.*, *Science 269*, 202-204, 1995). Protein synthesis can be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Optionally, fragments of serine/threonine protein kinase polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.

- 28 -

The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography (*e.g.*, Creighton, PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES, WH Freeman and Co., New York, N.Y., 1983). The composition of a synthetic serine/threonine protein kinase polypeptide can be
5   confirmed by amino acid analysis or sequencing (*e.g.*, the Edman degradation procedure; *see* Creighton, *supra*). Additionally, any portion of the amino acid sequence of the serine/threonine protein kinase polypeptide can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.
10

Production of Altered Polypeptides

As will be understood by those of skill in the art, it may be advantageous to produce serine/threonine protein kinase polypeptide-encoding nucleotide sequences
15   possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life that is longer than that of a transcript generated from the naturally occurring sequence.
20

The nucleotide sequences disclosed herein can be engineered using methods generally known in the art to alter serine/threonine protein kinase polypeptide-encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or
25   mRNA product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.
30

Antibodies

Any type of antibody known in the art can be generated to bind specifically to an epitope of a serine/threonine protein kinase polypeptide. "Antibody" as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab,

5 F(ab')$_2$, and Fv, which are capable of binding an epitope of a serine/threonine protein kinase polypeptide. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, e.g., at least 15, 25, or 50 amino acids.

10 An antibody which specifically binds to an epitope of a serine/threonine protein kinase polypeptide can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies having the desired specificity.

15 Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody that specifically binds to the immunogen.

20 Typically, an antibody which specifically binds to a serine/threonine protein kinase polypeptide provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay. Preferably, antibodies which specifically bind to serine/threonine protein kinase polypeptides do not detect other proteins in immunochemical assays and can

25 immunoprecipitate a serine/threonine protein kinase polypeptide from solution.

Human serine/threonine protein kinase polypeptides can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, a serine/threonine protein kinase polypeptide can

30 be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending on the host species, various adjuvants can

- 30 -

be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (*e.g.*, aluminum hydroxide), and surface active substances (*e.g.* lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol). Among adjuvants used
5   in humans, BCG (*bacilli Calmette-Guerin*) and *Corynebacterium parvum* are especially useful.

Monoclonal antibodies that specifically bind to a serine/threonine protein kinase polypeptide can be prepared using any technique which provides for the production
10   of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler *et al.*, *Nature 256*, 495-497, 1985; Kozbor *et al.*, *J. Immunol. Methods 81*, 31-42, 1985; Cote *et al.*, *Proc. Natl. Acad. Sci. 80*, 2026-2030, 1983; Cole *et al.*, *Mol. Cell Biol. 62*, 109-120, 1984).
15

In addition, techniques developed for the production of "chimeric antibodies," the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison *et al.*, *Proc. Natl. Acad. Sci. 81*, 6851-6855, 1984; Neuberger *et al.*, *Nature 312*, 604-608,
20   1984; Takeda *et al.*, *Nature 314*, 452-454, 1985). Monoclonal and other antibodies also can be "humanized" to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues. Sequence differences between rodent
25   antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grating of entire complementarity determining regions. Alternatively, humanized antibodies can be produced using recombinant methods, as described in GB2188638B. Antibodies that specifically bind to a serine/threonine protein kinase
30   polypeptide can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.

- 31 -

Alternatively, techniques described for the production of single chain antibodies can be adapted using methods known in the art to produce single chain antibodies that specifically bind to serine/threonine protein kinase polypeptides. Antibodies with

5   related specificity, but of distinct idiotypic composition, can be generated by chain shuffling from random combinatorial immunoglobin libraries (Burton, *Proc. Natl. Acad. Sci. 88*, 11120-23, 1991).

Single-chain antibodies also can be constructed using a DNA amplification method,

10   such as PCR, using hybridoma cDNA as a template (Thirion *et al.*, 1996, *Eur. J. Cancer Prev. 5*, 507-11). Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught, for example, in Coloma & Morrison, 1997, *Nat. Biotechnol. 15*, 159-63. Construction of bivalent, bispecific single-chain antibodies is taught in

15   Mallender & Voss, 1994, *J. Biol. Chem. 269*, 199-206.

A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding

20   sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology (Verhaar *et al.*, 1995, *Int. J. Cancer 61*, 497-501; Nicholls *et al.*, 1993, *J. Immunol. Meth. 165*, 81-91).

25   Antibodies which specifically bind to serine/threonine protein kinase polypeptides also can be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi *et al.*, *Proc. Natl. Acad. Sci. 86*, 3833-3837, 1989; Winter *et al.*, *Nature 349*, 293-299, 1991).

30

Other types of antibodies can be constructed and used therapeutically in methods of the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.

Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which a serine/threonine protein kinase polypeptide is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.

Antisense Oligonucleotides

Antisense oligonucleotides are nucleotide sequences that are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of serine/threonine protein kinase gene products in the cell.

Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. *See* Brown, *Meth. Mol.*

- 33 -

Biol. 20, 1-8, 1994; Sonveaux, *Meth. Mol. Biol. 26*, 1-72, 1994; Uhlmann *et al.*, *Chem. Rev. 90*, 543-583, 1990.

Modifications of serine/threonine protein kinase gene expression can be obtained by designing antisense oligonucleotides that will form duplexes to the control, 5', or regulatory regions of the serine/threonine protein kinase gene. Oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex DNA have been described in the literature (*e.g.*, Gee *et al.*, in Huber & Carr, MOLECULAR AND IMMUNOLOGIC APPROACHES, Futura Publishing Co., Mt. Kisco, N.Y., 1994). An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a serine/threonine protein kinase polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a serine/threonine protein kinase polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent serine/threonine protein kinase nucleotides, can provide sufficient targeting specificity for serine/threonine protein kinase mRNA. Preferably, each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length. One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular serine/threonine protein kinase polynucleotide sequence.

- 34 -

Antisense oligonucleotides can be modified without affecting their ability to hybridize to a serine/threonine protein kinase polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule. For example, internucleoside phosphate linkages can be modified by adding cholesteryl or diamine

5   moieties with varying numbers of carbon residues between the amino groups and terminal ribose. Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well

10   known in the art. *See, e.g.,* Agrawal *et al., Trends Biotechnol. 10,* 152-158, 1992; Uhlmann *et al., Chem. Rev. 90,* 543-584, 1990; Uhlmann *et al., Tetrahedron. Lett. 215,* 3539-3542, 1987.

Ribozymes

15

Ribozymes are RNA molecules with catalytic activity. *See, e.g.,* Cech, *Science 236,* 1532-1539; 1987; Cech, *Ann. Rev. Biochem. 59,* 543-568; 1990, Cech, *Curr. Opin. Struct. Biol. 2,* 605-609; 1992, Couture & Stinchcomb, *Trends Genet. 12,* 510-515, 1996. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence,

20   as is known in the art (*e.g.,* Haseloff *et al.,* U.S. Patent 5,641,673). The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide

25   sequences.

The coding sequence of a serine/threonine protein kinase polynucleotide can be used to generate ribozymes that will specifically bind to mRNA transcribed from the serine/threonine protein kinase polynucleotide. Methods of designing and con-

30   structing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art (*see* Haseloff

- 35 -

et al. Nature 334, 585-591, 1988). For example, the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target (see, for example,

5   Gerlach *et al.*, EP 321,201).

Specific ribozyme cleavage sites within a serine/threonine protein kinase RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short

10   RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate serine/threonine protein kinase RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribo-

15   nuclease protection assays. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

20

Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease serine/threonine protein

25   kinase expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. A ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator

30   signal, for controlling transcription of ribozymes in the cells.

As taught in Haseloff *et al.*, U.S. Patent 5,641,673, ribozymes can be engineered so that ribozyme expression will occur in response to factors that induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

Differentially Expressed Genes

Described herein are methods for the identification of genes whose products interact with human serine/threonine protein kinase. Such genes may represent genes that are differentially expressed in disorders including, but not limited to, cancer, COPD, cardiovascular disorders, urinary disorders, obesity, diabetes, and peripheral and central nervous system disorders. Further, such genes may represent genes that are differentially regulated in response to manipulations relevant to the progression or treatment of such diseases. Additionally, such genes may have a temporally modulated expression, increased or decreased at different stages of tissue or organism development. A differentially expressed gene may also have its expression modulated under control versus experimental conditions. In addition, the human serine/threonine protein kinase gene or gene product may itself be tested for differential expression.

The degree to which expression differs in a normal versus a diseased state need only be large enough to be visualized via standard characterization techniques such as differential display techniques. Other such standard characterization techniques by which expression differences may be visualized include but are not limited to, quantitative RT (reverse transcriptase), PCR, and Northern analysis.

Identification of Differentially Expressed Genes

To identify differentially expressed genes total RNA or, preferably, mRNA is isolated from tissues of interest. For example, RNA samples are obtained from

- 37 -

tissues of experimental subjects and from corresponding tissues of control subjects. Any RNA isolation technique that does not select against the isolation of mRNA may be utilized for the purification of such RNA samples. See, for example, Ausubel *et al.*, ed., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, Inc. New York, 1987-1993. Large numbers of tissue samples may readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski, U.S. Patent 4,843,155.

Transcripts within the collected RNA samples that represent RNA produced by differentially expressed genes are identified by methods well known to those of skill in the art. They include, for example, differential screening (Tedder *et al.*, *Proc. Natl. Acad. Sci. U.S.A. 85*, 208-12, 1988), subtractive hybridization (Hedrick *et al.*, *Nature 308*, 149-53; Lee *et al.*, *Proc. Natl. Acad. Sci. U.S.A. 88*, 2825, 1984), and, preferably, differential display (Liang & Pardee, *Science 257*, 967-71, 1992; U.S. Patent 5,262,311).

The differential expression information may itself suggest relevant methods for the treatment of disorders involving the human serine/threonine protein kinase. For example, treatment may include a modulation of expression of the differentially expressed genes and/or the gene encoding the human serine/threonine protein kinase. The differential expression information may indicate whether the expression or activity of the differentially expressed gene or gene product or the human serine/threonine protein kinase gene or gene product are up-regulated or down-regulated.

Screening Methods

The invention provides assays for screening test compounds that bind to or modulate the activity of a serine/threonine protein kinase polypeptide or a serine/threonine protein kinase polynucleotide. A test compound preferably binds to a serine/threo-nine protein kinase polypeptide or polynucleotide. More preferably, a test compound

decreases or increases serine/threonine protein kinase activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the test compound.

5   *Test Compounds*

Test compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity. The compounds can be naturally occurring or designed in the laboratory. They can be

10   isolated from microorganisms, animals, or plants, and can be produced recombinantly, or synthesized by chemical methods known in the art. If desired, test compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods

15   requiring deconvolution, the "one-bead one-compound" library method, and synthetic library methods using affinity chromatography selection. The biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of compounds. *See* Lam, *Anticancer Drug Des. 12*, 145, 1997.

20

Methods for the synthesis of molecular libraries are well known in the art (*see*, for example, DeWitt *et al.*, *Proc. Natl. Acad. Sci. U.S.A. 90*, 6909, 1993; Erb *et al. Proc. Natl. Acad. Sci. U.S.A. 91*, 11422, 1994; Zuckermann *et al.*, *J. Med. Chem. 37*, 2678, 1994; Cho *et al.*, *Science 261*, 1303, 1993; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.*

25   *33*, 2059, 1994; Carell *et al.*, *Angew. Chem. Int. Ed. Engl. 33*, 2061; Gallop *et al.*, *J. Med. Chem. 37*, 1233, 1994). Libraries of compounds can be presented in solution (*see, e.g.*, Houghten, *BioTechniques 13*, 412-421, 1992), or on beads (Lam, *Nature 354*, 82-84, 1991), chips (Fodor, *Nature 364*, 555-556, 1993), bacteria or spores (Ladner, U.S. Patent 5,223,409), plasmids (Cull *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*

30   *89*, 1865-1869, 1992), or phage (Scott & Smith, *Science 249*, 386-390, 1990; Devlin,

- 39 -

Science 249, 404-406, 1990); Cwirla *et al., Proc. Natl. Acad. Sci. 97*, 6378-6382, 1990; Felici, *J. Mol. Biol. 222*, 301-310, 1991; and Ladner, U.S. Patent 5,223,409).

<u>High Throughput Screening</u>

5

Test compounds can be screened for the ability to bind to serine/threonine protein kinase polypeptides or polynucleotides or to affect serine/threonine protein kinase activity or serine/threonine protein kinase gene expression using high throughput screening. Using high throughput screening, many discrete compounds can be tested

10   in parallel so that large numbers of test compounds can be quickly screened. The most widely established techniques utilize 96-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 50 to 500 μl. In addition to the plates, many instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the 96-well format.

15

Alternatively, "free format assays," or assays that have no physical barrier between samples, can be used. For example, an assay using pigment cells (melanocytes) in a simple homogeneous assay for combinatorial peptide libraries is described by Jayawickreme *et al., Proc. Natl. Acad. Sci. U.S.A. 19*, 1614-18 (1994). The cells are

20   placed under agarose in petri dishes, then beads that carry combinatorial compounds are placed on the surface of the agarose. The combinatorial compounds are partially released the compounds from the beads. Active compounds can be visualized as dark pigment areas because, as the compounds diffuse locally into the gel matrix, the active compounds cause the cells to change colors.

25

Another example of a free format assay is described by Chelsky, "Strategies for Screening Combinatorial Libraries: Novel and Traditional Approaches," reported at the First Annual Conference of The Society for Biomolecular Screening in Philadelphia, Pa. (Nov. 7-10, 1995). Chelsky placed a simple homogenous enzyme

30   assay for carbonic anhydrase inside an agarose gel such that the enzyme in the gel would cause a color change throughout the gel. Thereafter, beads carrying

combinatorial compounds via a photolinker were placed inside the gel and the compounds were partially released by UV-light. Compounds that inhibited the enzyme were observed as local zones of inhibition having less color change.

5   Yet another example is described by Salmon *et al.*, *Molecular Diversity 2*, 57-63 (1996). In this example, combinatorial libraries were screened for compounds that had cytotoxic effects on cancer cells growing in agar.

Another high throughput screening method is described in Beutel *et al.*, U.S. Patent
10   5,976,813. In this method, test samples are placed in a porous matrix. One or more assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support. When samples are introduced to the porous matrix they diffuse sufficiently slowly, such that the assays can be performed without the test samples running together.

15

Binding Assays

For binding assays, the test compound is preferably a small molecule that binds to and occupies, for example, the active site of the serine/threonine protein kinase
20   polypeptide, such that normal biological activity is prevented. Examples of such small molecules include, but are not limited to, small peptides or peptide-like molecules.

In binding assays, either the test compound or the serine/threonine protein kinase
25   polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase. Detection of a test compound that is bound to the serine/threonine protein kinase polypeptide can then be accomplished, for example, by direct counting of radioemmission, by scintillation counting, or by determining
30   conversion of an appropriate substrate to a detectable product.

- 41 -

Alternatively, binding of a test compound to a serine/threonine protein kinase poly-peptide can be determined without labeling either of the interactants. For example, a microphysiometer can be used to detect binding of a test compound with a serine/threonine protein kinase polypeptide. A microphysiometer (*e.g.*, Cyto-sensor™) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and a serine/threonine protein kinase polypeptide (McConnell *et al.*, *Science 257*, 1906-1912, 1992).

Determining the ability of a test compound to bind to a serine/threonine protein kinase polypeptide also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) (Sjolander & Urbaniczky, *Anal. Chem. 63*, 2338-2345, 1991, and Szabo *et al.*, *Curr. Opin. Struct. Biol. 5*, 699-705, 1995). BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore™). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In yet another aspect of the invention, a serine/threonine protein kinase polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay (see, *e.g.*, U.S. Patent 5,283,317; Zervos *et al.*, *Cell 72*, 223-232, 1993; Madura *et al.*, *J. Biol. Chem. 268*, 12046-12054, 1993; Bartel *et al.*, *BioTechniques 14*, 920-924, 1993; Iwabuchi *et al.*, *Oncogene 8*, 1693-1696, 1993; and Brent WO94/10300), to identify other proteins which bind to or interact with the serine/threonine protein kinase poly-peptide and modulate its activity.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. For example, in one construct, polynucleotide encoding a serine/threonine protein kinase polypeptide can be fused to a polynucleo-

tide encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct a DNA sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact *in vivo* to form an protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein that interacts with the serine/threonine protein kinase polypeptide.

It may be desirable to immobilize either the serine/threonine protein kinase polypeptide (or polynucleotide) or the test compound to facilitate separation of bound from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either the serine/threonine protein kinase polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach the enzyme polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to a serine/threonine protein kinase polypeptide (or polynucleotide) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.

In one embodiment, the serine/threonine protein kinase polypeptide is a fusion protein comprising a domain that allows the serine/threonine protein kinase polypeptide to be bound to a solid support. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the non-adsorbed serine/threonine protein kinase polypeptide; the mixture is then incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solid support also can be used in the screening assays of the invention. For example, either a serine/threonine protein kinase polypeptide (or polynucleotide) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated serine/threonine protein kinase polypeptides (or polynucleotides) or test compounds can be prepared from biotin-NHS(N-hydroxysuccinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies which specifically bind to a serine/threonine protein kinase polypeptide, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the active site of the serine/threonine protein kinase polypeptide, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.

Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to the serine/threonine protein kinase polypeptide or test compound, enzyme-linked assays which rely on detecting an activity of the

- 44 -

serine/threonine protein kinase polypeptide, and SDS gel electrophoresis under non-reducing conditions.

Screening for test compounds which bind to a serine/threonine protein kinase polypeptide or polynucleotide also can be carried out in an intact cell. Any cell which comprises a serine/threonine protein kinase polypeptide or polynucleotide can be used in a cell-based assay system. A serine/threonine protein kinase polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Binding of the test compound to a serine/threonine protein kinase polypeptide or polynucleotide is determined as described above.

Enzyme Assays

Test compounds can be tested for the ability to increase or decrease the serine/threonine protein kinase activity of a human serine/threonine protein kinase polypeptide. Serine/threonine protein kinase activity can be measured, for example, as described in Example 4.

Enzyme assays can be carried out after contacting either a purified serine/threonine protein kinase polypeptide, a cell membrane preparation, or an intact cell with a test compound. A test compound that decreases a serine/threonine protein kinase activity of a serine/threonine protein kinase polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for decreasing serine/threonine protein kinase activity. A test compound which increases a serine/threonine protein kinase activity of a human serine/threonine protein kinase polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for increasing human serine/threonine protein kinase activity.

Gene Expression

In another embodiment, test compounds that increase or decrease serine/threonine protein kinase gene expression are identified. A serine/threonine protein kinase polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of the serine/threonine protein kinase polynucleotide is determined. The level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound. The test compound can then be identified as a modulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.

The level of serine/threonine protein kinase mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or polypeptide. Either qualitative or quantitative methods can be used. The presence of polypeptide products of a serine/threonine protein kinase polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry. Alternatively, polypeptide synthesis can be determined *in vivo*, in a cell culture, or in an *in vitro* translation system by detecting incorporation of labeled amino acids into a serine/threonine protein kinase polypeptide.

Such screening can be carried out either in a cell-free assay system or in an intact cell. Any cell that expresses a serine/threonine protein kinase polynucleotide can be used in a cell-based assay system. The serine/threonine protein kinase polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Either a primary culture or an established cell line, such as CHO or human embryonic kidney 293 cells, can be used.

- 46 -

Pharmaceutical Compositions

The invention also provides pharmaceutical compositions that can be administered to a patient to achieve a therapeutic effect. Pharmaceutical compositions of the invention can comprise, for example, a serine/threonine protein kinase polypeptide, serine/threonine protein kinase polynucleotide, ribozymes or antisense oligonucleotides, antibodies which specifically bind to a serine/threonine protein kinase polypeptide, or mimetics, activators, or inhibitors of a serine/threonine protein kinase polypeptide activity. The compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.

In addition to the active ingredients, these pharmaceutical compositions can contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations which can be used pharmaceutically. Pharmaceutical compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means. Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to

obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxy-propylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid poly-ethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous in-jection suspensions can contain substances that increase the viscosity of the sus-pension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.

- 48 -

Non-lipid polycationic amino polymers also can be used for delivery. Optionally, the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For topical or nasal administration, penetrants appropriate to the particular barrier to be

5 permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, *e.g.*, by means of conventional mixing, dissolving,

10 granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. The pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In

15 other cases, the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

Further details on techniques for formulation and administration can be found in the

20 latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (Maack Publishing Co., Easton, Pa.). After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of ad-ministration.

25

Therapeutic Indications and Methods

Human serine/threonine protein kinase can be regulated to treat cancer, COPD, cardiovascular disorders, urinary disorders, obesity, diabetes, and peripheral and

30 central nervous system disorders.

Cancer

Cancer is a disease fundamentally caused by oncogenic cellular transformation. There are several hallmarks of transformed cells that distinguish them from their normal counterparts and underlie the pathophysiology of cancer. These include un-controlled cellular proliferation, unresponsiveness to normal death-inducing signals (immortalization), increased cellular motility and invasiveness, increased ability to recruit blood supply through induction of new blood vessel formation (angiogenesis), genetic instability, and dysregulated gene expression. Various combinations of these aberrant physiologies, along with the acquisition of drug-resistance frequently lead to an intractable disease state in which organ failure and patient death ultimately ensue.

Most standard cancer therapies target cellular proliferation and rely on the differential proliferative capacities between transformed and normal cells for their efficacy. This approach is hindered by the facts that several important normal cell types are also highly proliferative and that cancer cells frequently become resistant to these agents. Thus, the therapeutic indices for traditional anti-cancer therapies rarely exceed 2.0.

The advent of genomics-driven molecular target identification has opened up the possibility of identifying new cancer-specific targets for therapeutic intervention that will provide safer, more effective treatments for cancer patients. Thus, newly dis-covered tumor-associated genes and their products can be tested for their role(s) in disease and used as tools to discover and develop innovative therapies. Genes play-ing important roles in any of the physiological processes outlined above can be characterized as cancer targets.

Genes or gene fragments identified through genomics can readily be expressed in one or more heterologous expression systems to produce functional recombinant proteins. These proteins are characterized _in vitro_ for their biochemical properties and then used as tools in high-throughput molecular screening programs to identify chemical

- 50 -

modulators of their biochemical activities. Agonists and/or antagonists of target protein activity can be identified in this manner and subsequently tested in cellular and *in vivo* disease models for anti-cancer activity. Optimization of lead compounds with iterative testing in biological models and detailed pharmacokinetic and toxicological analyses form the basis for drug development and subsequent testing in humans.

COPD.

Chronic obstructive pulmonary (or airways) disease (COPD) is a condition defined physiologically as airflow obstruction that generally results from a mixture of emphysema and peripheral airway obstruction due to chronic bronchitis (Senior & Shapiro, *Pulmonary Diseases and Disorders*, 3d ed., New York, McGraw-Hill, 1998, pp. 659-681, 1998; Barnes, *Chest 117*, 10S-14S, 2000). Emphysema is characterized by destruction of alveolar walls leading to abnormal enlargement of the air spaces of the lung. Chronic bronchitis is defined clinically as the presence of chronic productive cough for three months in each of two successive years. In COPD, air-flow obstruction is usually progressive and is only partially reversible. By far the most important risk factor for development of COPD is cigarette smoking, although the disease does occur in non-smokers.

Chronic inflammation of the airways is a key pathological feature of COPD (Senior & Shapiro, 1998). The inflammatory cell population comprises increased numbers of macrophages, neutrophils, and CD8[+] lymphocytes. Inhaled irritants, such as cigarette smoke, activate macrophages which are resident in the respiratory tract, as well as epithelial cells leading to release of chemokines (*e.g.*, interleukin-8) and other chemotactic factors. These chemotactic factors act to increase the neutrophil/mono-cyte trafficking from the blood into the lung tissue and airways. Neutrophils and monocytes recruited into the airways can release a variety of potentially damaging mediators such as proteolytic enzymes and reactive oxygen species. Matrix degradation and emphysema, along with airway wall thickening, surfactant dys-

function, and mucus hypersecretion, all are potential sequelae of this inflammatory response that lead to impaired airflow and gas exchange.

COPD is characterized by damage to the lung extracellular matrix and emphysema can be viewed as the pathologic process that affects the lung parenchyma. This process eventually leads to the destruction of the airway walls resulting in permanent airspace enlargement (Senior and Shapiro, in PULMONARY DISEASES AND DISORDERS, 3rd ed., New York, McGraw-Hill, 1998, pp. 659 – 681, 1998). The observation that inherited deficiency of a1-antitrypsin (a1-AT), the primary inhibitor of neutrophil elastase, predisposes individuals to early onset emphysema, and that intrapulmonary instillation of elastolytic enzymes in experimental animals causes emphysema, led to the elastase:antielastase hypothesis for the pathogenesis of emphysema (Eriksson, *Acta Med. Scand. 177(Suppl.)*, 432, 1965, Gross, *J. Occup. Med.* 6, 481-84, 1964). This in turn led to the concept that destruction of elastin in the lung parenchyma is the basis of the development of emphysema.

A broad range of immune and inflammatory cells including neutrophils, macrophages, T lymphocytes and eosinophils contain proteolytic enzymes that could contribute to the destruction of lung extracellular matrix (Shapiro, 1999). In addition, a number of different classes of proteases have been identified that have the potential to contribute to lung matrix destruction. These include serine proteases, matrix metalloproteinases and cysteine proteases. Of these classes of enzymes, a number can hydrolyze elastin and have been shown to be elevated in COPD patients (neutrophil elastase, MMP-2, 9, 12) (Culpitt *et al.*, *Am. J. Respir. Crit. Care Med. 160*, 1635-39, 1999, Shapiro, *Am. J. Crit. Care Med. 160 (5)*, S29 – S32,1999).

It is expected that in the future novel members of the existing classes of proteases and new classes of proteases will be identified that play a significant role in the damage of the extracellular lung matrix including elastin proteolysis. Novel protease targets therefore remain very attractive therapeutic targets.

Cardiovascular disorders

Cardiovascular diseases include the following disorders of the heart and the vascular system: congestive heart failure, myocardial infarction, ischemic diseases of the heart, all kinds of atrial and ventricular arrhythmias, hypertensive vascular diseases, and peripheral vascular diseases.

Heart failure is defined as a pathophysiologic state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failure, such as high-output and low-output, acute and chronic, right-sided or left-sided, systolic or diastolic, independent of the underlying cause.

Myocardial infarction (MI) is generally caused by an abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously narrowed by arteriosclerosis. MI prophylaxis (primary and secondary prevention) is included, as well as the acute treatment of MI and the prevention of complications.

Ischemic diseases are conditions in which the coronary flow is restricted resulting in a perfusion which is inadequate to meet the myocardial requirement for oxygen. This group of diseases includes stable angina, unstable angina, and asymptomatic ischemia.

Arrhythmias include all forms of atrial and ventricular tachyarrhythmias (atrial tachycardia, atrial flutter, atrial fibrillation, atrio-ventricular reentrant tachycardia, preexcitation syndrome, ventricular tachycardia, ventricular flutter, and ventricular fibrillation), as well as bradycardic forms of arrhythmias.

Vascular diseases include primary as well as all kinds of secondary arterial hypertension (renal, endocrine, neurogenic, others). The disclosed gene and its product

- 53 -

may be used as drug targets for the treatment of hypertension as well as for the prevention of all complications.

5   Peripheral vascular diseases are defined as vascular diseases in which arterial and/or venous flow is reduced resulting in an imbalance between blood supply and tissue oxygen demand. It includes chronic peripheral arterial occlusive disease (PAOD), acute arterial thrombosis and embolism, inflammatory vascular disorders, Raynaud's phenomenon, and venous disorders.

10   _Obesity_

Obesity and overweight are defined as an excess of body fat relative to lean body mass. An increase in caloric intake or a decrease in energy expenditure or both can bring about this imbalance leading to surplus energy being stored as fat. Obesity is

15   associated with important medical morbidities and an increase in mortality. The causes of obesity are poorly understood and may be due to genetic factors, environmental factors or a combination of the two to cause a positive energy balance. In contrast, anorexia and cachexia are characterized by an imbalance in energy intake versus energy expenditure leading to a negative energy balance and weight loss.

20   Agents that either increase energy expenditure and/or decrease energy intake, absorption or storage would be useful for treating obesity, overweight, and associated comorbidities. Agents that either increase energy intake and/or decrease energy expenditure or increase the amount of lean tissue would be useful for treating cachexia, anorexia and wasting disorders.

25

This gene, translated proteins and agents which modulate this gene or portions of the gene or its products are useful for treating obesity, overweight, anorexia, cachexia, wasting disorders, appetite suppression, appetite enhancement, increases or decreases in satiety, modulation of body weight, and/or other eating disorders such as bulimia.

30   Also this gene, translated proteins and agents which modulate this gene or portions of the gene or its products are useful for treating obesity/overweight-associated

comorbidities including hypertension, type 2 diabetes, coronary artery disease, hyperlipidemia, stroke, gallbladder disease, gout, osteoarthritis, sleep apnea and respiratory problems, some types of cancer including endometrial, breast, prostate, and colon cancer, thrombolic disease, polycystic ovarian syndrome, reduced fertility, complications of pregnancy, menstrual irregularities, hirsutism, stress incontinence, and depression.

Diabetes

Diabetes mellitus is a common metabolic disorder characterized by an abnormal elevation in blood glucose, alterations in lipids and abnormalities (complications) in the cardiovascular system, eye, kidney and nervous system. Diabetes is divided into two separate diseases: type 1 diabetes (juvenile onset), which results from a loss of cells which make and secrete insulin, and type 2 diabetes (adult onset), which is caused by a defect in insulin secretion and a defect in insulin action.

Type 1 diabetes is initiated by an autoimuune reaction that attacks the insulin secreting cells (beta cells) in the pancreatic islets. Agents that prevent this reaction from occurring or that stop the reaction before destruction of the beta cells has been accomplished are potential therapies for this disease. Other agents that induce beta cell proliferation and regeneration also are potential therapies.

Type II diabetes is the most common of the two diabetic conditions (6% of the population). The defect in insulin secretion is an important cause of the diabetic condition and results from an inability of the beta cell to properly detect and respond to rises in blood glucose levels with insulin release. Therapies that increase the response by the beta cell to glucose would offer an important new treatment for this disease.

The defect in insulin action in Type II diabetic subjects is another target for therapeutic intervention. Agents that increase the activity of the insulin receptor in

- 55 -

muscle, liver, and fat will cause a decrease in blood glucose and a normalization of plasma lipids. The receptor activity can be increased by agents that directly stimulate the receptor or that increase the intracellular signals from the receptor. Other therapies can directly activate the cellular end process, *i.e.* glucose transport or various enzyme systems, to generate an insulin-like effect and therefore a produce beneficial outcome. Because overweight subjects have a greater susceptibility to Type II diabetes, any agent that reduces body weight is a possible therapy.

Both Type I and Type diabetes can be treated with agents that mimic insulin action or that treat diabetic complications by reducing blood glucose levels. Likewise, agents that reduces new blood vessel growth can be used to treat the eye complications that develop in both diseases.

Peripheral and central nervous system disorders

Peripheral or central nervous system disorders which may be treated include brain injuries, cerebrovascular diseases and their consequences, Parkinson's disease, corticobasal degeneration, motor neuron disease, dementia, including ALS, multiple sclerosis, traumatic brain injury, stroke, post-stroke, post-traumatic brain injury, and small-vessel cerebrovascular disease. Dementias, such as Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia and Parkinsonism linked to chromosome 17, frontotemporal dementias, including Pick's disease, progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, and Korsakoff's psychosis also can be treated. Similarly, it may be possible to treat cognitive-related disorders, such as mild cognitive impairment, age-associated memory impairment, age-related cognitive decline, vascular cognitive impairment, attention deficit disorders, attention deficit hyperactivity disorders, and memory disturbances in children with learning disabilities, by regulating the activity of human serine/threonine protein kinase.

Pain that is associated with peripheral or central nervous system disorders also can be treated by regulating the activity of human serine/threonine protein kinase. Pain which can be treated includes that associated with central nervous system disorders, such as multiple sclerosis, spinal cord injury, sciatica, failed back surgery syndrome,

5   traumatic brain injury, epilepsy, Parkinson's disease, post-stroke, and vascular lesions in the brain and spinal cord (*e.g.*, infarct, hemorrhage, vascular malformation). Non-central neuropathic pain includes that associated with post mastectomy pain, reflex sympathetic dystrophy (RSD), trigeminal neuralgiaradio- culopathy, post-surgical pain, HIV/AIDS related pain, cancer pain, metabolic neuro-

10   pathies (*e.g.*, diabetic neuropathy, vasculitic neuropathy secondary to connective tissue disease), paraneoplastic polyneuropathy associated, for example, with carcinoma of lung, or leukemia, or lymphoma, or carcinoma of prostate, colon or stomach, trigeminal neuralgia, cranial neuralgias, and post-herpetic neuralgia. Pain associated with cancer and cancer treatment also can be treated, as can headache pain

15   (for example, migraine with aura, migraine without aura, and other migraine disorders), episodic and chronic tension-type headache, tension-type like headache, cluster headache, and chronic paroxysmal hemicrania.

This invention further pertains to the use of novel agents identified by the screening

20   assays described above. Accordingly, it is within the scope of this invention to use a test compound identified as described herein in an appropriate animal model. For example, an agent identified as described herein (*e.g.*, a modulating agent, an antisense nucleic acid molecule, a specific antibody, ribozyme, or a serine/threonine protein kinase polypeptide binding molecule) can be used in an animal model to

25   determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

30

- 57 -

A reagent which affects serine/threonine protein kinase activity can be administered to a human cell, either *in vitro* or *in vivo*, to reduce serine/threonine protein kinase activity. The reagent preferably binds to an expression product of a human serine/threonine protein kinase gene. If the expression product is a protein, the

5 reagent is preferably an antibody. For treatment of human cells *ex vivo*, an antibody can be added to a preparation of stem cells that have been removed from the body. The cells can then be replaced in the same or another human body, with or without clonal propagation, as is known in the art.

10 In one embodiment, the reagent is delivered using a liposome. Preferably, the liposome is stable in the animal into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour, and even more preferably for at least about 24 hours. A liposome comprises a lipid composition that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal,

15 such as a human. Preferably, the lipid composition of the liposome is capable of targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph nodes, and skin.

A liposome useful in the present invention comprises a lipid composition that is

20 capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell. Preferably, the transfection efficiency of a liposome is about 0.5 µg of DNA per 16 nmole of liposome delivered to about 10^6 cells, more preferably about 1.0 µg of DNA per 16 nmole of liposome delivered to about 10^6 cells, and even more preferably about 2.0 µg of DNA per 16 nmol of liposome delivered to about

25 10^6 cells. Preferably, a liposome is between about 100 and 500 nm, more preferably between about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter.

Suitable liposomes for use in the present invention include those liposomes

30 standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes include liposomes having a polycationic lipid

- 58 -

composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol. Optionally, a liposome comprises a compound capable of targeting the liposome to a particular cell type, such as a cell-specific ligand exposed on the outer surface of the liposome.

5

Complexing a liposome with a reagent such as an antisense oligonucleotide or ribozyme can be achieved using methods that are standard in the art (see, for example, U.S. Patent 5,705,151). Preferably, from about 0.1 µg to about 10 µg of polynucleotide is combined with about 8 nmol of liposomes, more preferably from

10   about 0.5 µg to about 5 µg of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0 µg of polynucleotides is combined with about 8 nmol liposomes.

In another embodiment, antibodies can be delivered to specific tissues *in vivo* using

15   receptor-mediated targeted delivery. Receptor-mediated DNA delivery techniques are taught in, for example, Findeis *et al. Trends in Biotechnol. 11*, 202-05 (1993); Chiou *et al.*, GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER (J.A. Wolff, ed.) (1994); Wu & Wu, *J. Biol. Chem. 263*, 621-24 (1988); Wu *et al., J. Biol. Chem. 269*, 542-46 (1994); Zenke *et al., Proc. Natl. Acad. Sci.*

20   *U.S.A. 87*, 3655-59 (1990); Wu *et al., J. Biol. Chem. 266*, 338-42 (1991).

Determination of a Therapeutically Effective Dose

The determination of a therapeutically effective dose is well within the capability of

25   those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which increases or decreases serine/threonine protein kinase activity relative to the serine/threonine protein kinase activity which occurs in the absence of the therapeutically effective dose.

30   For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The

animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

5   Therapeutic efficacy and toxicity, e.g., ED_{50} (the dose therapeutically effective in 50% of the population) and LD_{50} (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD_{50}/ED_{50}.

10

Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED_{50} with

15   little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to

20   provide sufficient levels of the active ingredient or to maintain the desired effect. Factors that can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be

25   administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular

30   dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations

- 60 -

for nucleotides than for proteins or their inhibitors. Similarly, delivery of poly-nucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

5   If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either *ex vivo* or *in vivo* using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads,
10   protoplast fusion, viral infection, electroporation, "gene gun," and DEAE- or calcium phosphate-mediated transfection.

Effective *in vivo* dosages of an antibody are in the range of about 5 μg to about 50 μg/kg, about 50 μg to about 5 mg/kg, about 100 μg to about 500 μg/kg of patient
15   body weight, and about 200 to about 250 μg/kg of patient body weight. For administration of polynucleotides encoding single-chain antibodies, effective *in vivo* dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1 μg to about 2 mg, about 5 μg to about 500 μg, and about 20 μg to about 100 μg of DNA.

20

If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides that express antisense oligonucleo-tides or ribozymes can be introduced into cells by a variety of methods, as described above.

25

Preferably, a reagent reduces expression of a serine/threonine protein kinase gene or the activity of a serine/threonine protein kinase polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of
30   expression of a serine/threonine protein kinase gene or the activity of a serine/threo-nine protein kinase polypeptide can be assessed using methods well known in the art,

- 61 -

such as hybridization of nucleotide probes to serine/threonine protein kinase-specific mRNA, quantitative RT-PCR, immunologic detection of a serine/threonine protein kinase polypeptide, or measurement of serine/threonine protein kinase activity.

In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

Diagnostic Methods

Human serine/threonine protein kinase also can be used in diagnostic assays for detecting diseases and abnormalities or susceptibility to diseases and abnormalities related to the presence of mutations in the nucleic acid sequences that encode the enzyme. For example, differences can be determined between the cDNA or genomic sequence encoding serine/threonine protein kinase in individuals afflicted with a disease and in normal individuals. If a mutation is observed in some or all of the afflicted individuals but not in normal individuals, then the mutation is likely to be the causative agent of the disease.

Sequence differences between a reference gene and a gene having mutations can be revealed by the direct DNA sequencing method. In addition, cloned DNA segments can be employed as probes to detect specific DNA segments. The sensitivity of this

- 62 -

method is greatly enhanced when combined with PCR. For example, a sequencing primer can be used with a double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures using radiolabeled nucleotides or by automatic sequencing procedures using fluorescent tags.

Genetic testing based on DNA sequence differences can be carried out by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized, for example, by high resolution gel electrophoresis. DNA fragments of different sequences can be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (see, e.g., Myers et al., Science 230, 1242, 1985). Sequence changes at specific locations can also be revealed by nuclease protection assays, such as RNase and S 1 protection or the chemical cleavage method (e.g., Cotton et al., Proc. Natl. Acad. Sci. USA 85, 4397-4401, 1985). Thus, the detection of a specific DNA sequence can be performed by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes and Southern blotting of genomic DNA. In addition to direct methods such as gel-electrophoresis and DNA sequencing, mutations can also be detected by in situ analysis.

Altered levels of serine/threonine protein kinase also can be detected in various tissues. Assays used to detect levels of the receptor polypeptides in a body sample, such as blood or a tissue biopsy, derived from a host are well known to those of skill in the art and include radioimmunoassays, competitive binding assays, Western blot analysis, and ELISA assays.

All patents and patent applications cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following

specific examples, which are provided for purposes of illustration only and are not intended to limit the scope of the invention.

- 64 -

EXAMPLE 1

Detection of serine/threonine kinase activity

5   For high level expression of a FLAG-tagged serine/threonine kinase polypeptide, COS-1 cells are transfected with the expression vector pC- serine/threonine kinase polypeptide (expressing the DNA-sequence of ID NO: 1) using the calcium phosphate method. After 5h, the cells are infected with recombinant vaccinia virus vTF7-3 (10 plaque-forming units/cell). The cells are harvested 20h after infection

10   and lysed in 50 mM Tris, pH 7,5, 5 mM MgCl2, 0,1% Nonidet P-40, 0,5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin. serine/threo-nine kinase polypeptide is immunoprecipitated from the lysate using anti-FLAG antibodies. In vitro kinase assay and phosphoamino acid analysis are performed in a volume of 40 μl with immunoprecipitated FLAG serine/threonine kinase polypeptide

15   in 50 mM Tris-HCl, pH 8,0, 50 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol. The reaction is started by the addition of 4 μl of 1 mM ATP supplemented with 5 μCi of (-32P)ATP and incubated for 30 min at 37°C. Afterward, the samples are subjected to SDS-PAGE and phosphorylated proteins are detected by autoradiography. Histone type III-S, casein, bovine serum albumin, or myelin basic proteins are used as

20   substrates. It is shown that the polypeptide with the amino acid sequence of SEQ ID NO.: 2 has serine/threonine kinase activity.

EXAMPLE 2

25   *Expression of recombinant human serine/threonine protein kinase*

The *Pichia pastoris* expression vector pPICZB (Invitrogen, San Diego, CA) is used to produce large quantities of recombinant human serine/threonine protein kinase polypeptides in yeast. The serine/threonine protein kinase-encoding DNA sequence

30   is derived from SEQ ID NO:1. Before insertion into vector pPICZB, the DNA sequence is modified by well known methods in such a way that it contains at its

5'-end an initiation codon and at its 3'-end an enterokinase cleavage site, a His6 reporter tag and a termination codon. Moreover, at both termini recognition sequences for restriction endonucleases are added and after digestion of the multiple cloning site of pPICZ B with the corresponding restriction enzymes the modified DNA sequence is ligated into pPICZB. This expression vector is designed for inducible expression in *Pichia pastoris*, driven by a yeast promoter. The resulting pPICZ/md-His6 vector is used to transform the yeast.

The yeast is cultivated under usual conditions in 5 liter shake flasks and the recombinantly produced protein isolated from the culture by affinity chromatography (Ni-NTA-Resin) in the presence of 8 M urea. The bound polypeptide is eluted with buffer, pH 3.5, and neutralized. Separation of the polypeptide from the His6 reporter tag is accomplished by site-specific proteolysis using enterokinase (Invitrogen, San Diego, CA) according to manufacturer's instructions. Purified human serine/threonine protein kinase polypeptide is obtained.

EXAMPLE 3

Identification of test compounds that bind to serine/threonine protein kinase polypeptides

Purified serine/threonine protein kinase polypeptides comprising a glutathione-S-transferase protein and absorbed onto glutathione-derivatized wells of 96-well microtiter plates are contacted with test compounds from a small molecule library at pH 7.0 in a physiological buffer solution. Human serine/threonine protein kinase polypeptides comprise the amino acid sequence shown in SEQ ID NO:2. The test compounds comprise a fluorescent tag. The samples are incubated for 5 minutes to one hour. Control samples are incubated in the absence of a test compound.

The buffer solution containing the test compounds is washed from the wells. Binding of a test compound to a serine/threonine protein kinase polypeptide is

- 66 -

detected by fluorescence measurements of the contents of the wells. A test compound that increases the fluorescence in a well by at least 15% relative to fluorescence of a well in which a test compound is not incubated is identified as a compound which binds to a serine/threonine protein kinase polypeptide.

EXAMPLE 4

Identification of a test compound which decreases serine/threonine protein kinase gene expression

A test compound is administered to a culture of human cells transfected with a serine/threonine protein kinase expression construct and incubated at 37 °C for 10 to 45 minutes. A culture of the same type of cells that have not been transfected is incubated for the same time without the test compound to provide a negative control.

RNA is isolated from the two cultures as described in Chirgwin *et al., Biochem. 18,* 5294-99, 1979). Northern blots are prepared using 20 to 30 μg total RNA and hybridized with a ^{32}P-labeled serine/threonine protein kinase-specific probe at 65 ° C in Express-hyb (CLONTECH). The probe comprises at least 11 contiguous nucleotides selected from the complement of SEQ ID NO:1. A test compound that decreases the serine/threonine protein kinase-specific signal relative to the signal obtained in the absence of the test compound is identified as an inhibitor of serine/threonine protein kinase gene expression.

EXAMPLE 5

Identification of a test compound which decreases serine/threonine protein kinase activity

A test compound is administered to a culture of human cells transfected with a serine/threonine protein kinase expression construct and incubated at 37 °C for 10 to

- 67 -

45 minutes. A culture of the same type of cells that have not been transfected is incubated for the same time without the test compound to provide a negative control. Kinase activity can be measured, for example, as taught in Trost *et al., J. Biol. Chem.* *275*, 7373-77, 2000; Hayashi *et al., Biochem. Biophys. Res. Commun. 264*, 449-56, 1999; Masure *et al., Eur. J. Biochem. 265*, 353-60, 1999; and Mukhopadhyay *et al., J. Bacteriol. 181*, 6615-22, 1999.

A test compound which decreases the serine/threonine protein kinase activity of the serine/threonine protein kinase relative to the serine/threonine protein kinase activity in the absence of the test compound is identified as an inhibitor of serine/threonine protein kinase activity.

EXAMPLE 6

Tissue-specific expression of serine/threonine protein kinase

The qualitative expression pattern of serine/threonine protein kinase in various tissues is determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR).

To demonstrate that serine/threonine protein kinase is involved in cancer, expression is determined in the following tissues: adrenal gland, bone marrow, brain, cerebellum, colon, fetal brain, fetal liver, heart, kidney, liver, lung, mammary gland, pancreas, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thymus, thyroid, trachea, uterus, and peripheral blood lymphocytes. Expression in the following cancer cell lines also is determined: DU-145 (prostate), NCI-H125 (lung), HT-29 (colon), COLO-205 (colon), A-549 (lung), NCI-H460 (lung), HT-116 (colon), DLD-1 (colon), MDA-MD-231 (breast), LS174T (colon), ZF-75 (breast), MDA-MN-435 (breast), HT-1080, MCF-7 (breast), and U87. Matched pairs of malignant and normal tissue from the same patient also are tested.

To demonstrate that serine/threonine protein kinase is involved in the disease process of COPD, the initial expression panel consists of RNA samples from respiratory tissues and inflammatory cells relevant to COPD: lung (adult and fetal), trachea, freshly isolated alveolar type II cells, cultured human bronchial epithelial cells, cultured small airway epithelial cells, cultured bronchial sooth muscle cells, cultured H441 cells (Clara-like), freshly isolated neutrophils and monocytes, and cultured monocytes (macrophage-like). Body map profiling also is carried out, using total RNA panels purchased from Clontech. The tissues are adrenal gland, bone marrow, brain, colon, heart, kidney, liver, lung, mammary gland, pancreas, prostate, salivary gland, skeletal muscle, small intestine, spleen, stomach, testis, thymus, trachea, thyroid, and uterus.

To demonstrate that serine/threonine protein kinase is involved in the disease process of obesity, expression is determined in the following tissues: subcutaneous adipose tissue, mesenteric adipose tissue, adrenal gland, bone marrow, brain (cerebellum, spinal cord, cerebral cortex, caudate, medulla, substantia nigra, and putamen), colon, fetal brain, heart, kidney, liver, lung, mammary gland, pancreas, placenta, prostate, salivary gland, skeletal muscle small intestine, spleen, stomach, testes, thymus, thyroid trachea, and uterus. Neuroblastoma cell lines SK-Nr-Be (2), Hr, Sk-N-As, HTB-10, IMR-32, SNSY-5Y, T3, SK-N-D2, D283, DAOY, CHP-2, U87MG, BE(2)C, T986, KANTS, MO59K, CHP234, C6 (rat), SK-N-F1, SK-PU-DW, PFSK-1, BE(2)M17, and MCIXC also are tested for serine/threonine protein kinase expression. As a final step, the expression of serine/threonine protein kinase in cells derived from normal individuals with the expression of cells derived from obese individuals is compared.

To demonstrate that serine/threonine protein kinase is involved in the disease process of diabetes, the following whole body panel is screened to show predominant or relatively high expression: subcutaneous and mesenteric adipose tissue, adrenal gland, bone marrow, brain, colon, fetal brain, heart, hypothalamus, kidney, liver, lung, mammary gland, pancreas, placenta, prostate, salivary gland, skeletal muscle,

small intestine, spleen, stomach, testis, thymus, thyroid, trachea, and uterus. Human islet cells and an islet cell library also are tested. As a final step, the expression of serine/threonine protein kinase in cells derived from normal individuals with the expression of cells derived from diabetic individuals is compared.

5

To demonstrate that serine/threonine protein kinase is involved in peripheral or central nervous system disorders, the following tissues are screened: fetal and adult brain, muscle, heart, lung, kidney, liver, thymus, testis, colon, placenta, trachea, pancreas, kidney, gastric mucosa, colon, liver, cerebellum, skin, cortex (Alzheimer's and normal), hypothalamus, cortex, amygdala, cerebellum, hippocampus, choroid, plexus, thalamus, and spinal cord.

10

Quantitative expression profiling. Quantitative expression profiling is performed by the form of quantitative PCR analysis called "kinetic analysis" firstly described in Higuchi *et al., BioTechnology 10*, 413-17, 1992, and Higuchi *et al., BioTechnology 11*, 1026-30, 1993. The principle is that at any given cycle within the exponential phase of PCR, the amount of product is proportional to the initial number of template copies.

15

If the amplification is performed in the presence of an internally quenched fluorescent oligonucleotide (TaqMan probe) complementary to the target sequence, the probe is cleaved by the 5'-3' endonuclease activity of Taq DNA polymerase and a fluorescent dye released in the medium (Holland *et al., Proc. Natl. Acad. Sci. U.S.A. 88*, 7276-80, 1991). Because the fluorescence emission will increase in direct proportion to the amount of the specific amplified product, the exponential growth phase of PCR product can be detected and used to determine the initial template concentration (Heid *et al., Genome Res. 6*, 986-94, 1996, and Gibson *et al., Genome Res. 6*, 995-1001, 1996).

20

25

The amplification of an endogenous control can be performed to standardize the amount of sample RNA added to a reaction. In this kind of experiment, the control

30

- 70 -

of choice is the 18S ribosomal RNA. Because reporter dyes with differing emission spectra are available, the target and the endogenous control can be independently quantified in the same tube if probes labeled with different dyes are used.

5   All "real time PCR" measurements of fluorescence are made in the ABI Prism 7700.

RNA extraction and cDNA preparation. Total RNA from the tissues listed above are used for expression quantification. RNAs labeled "from autopsy" were extracted from autoptic tissues with the TRIzol reagent (Life Technologies, MD) according to

10   the manufacturer's protocol.

Fifty μg of each RNA were treated with DNase I for 1 hour at 37°C in the following reaction mix: 0.2 U/μl RNase-free DNase I (Roche Diagnostics, Germany); 0.4 U/μl RNase inhibitor (PE Applied Biosystems, CA); 10 mM Tris-HCl pH 7.9; 10mM

15      $MgCl_2$; 50 mM NaCl; and 1 mM DTT.

After incubation, RNA is extracted once with 1 volume of phenol:chloroform:iso-amyl alcohol (24:24:1) and once with chloroform, and precipitated with 1/10 volume of 3 M NaAcetate, pH5.2, and 2 volumes of ethanol.

20

Fifty μg of each RNA from the autoptic tissues are DNase treated with the DNA-free kit purchased from Ambion (Ambion, TX). After resuspension and spectrophoto-metric quantification, each sample is reverse transcribed with the TaqMan Reverse Transcription Reagents (PE Applied Biosystems, CA) according to the manu-

25   facturer's protocol. The final concentration of RNA in the reaction mix is 200ng/μL. Reverse transcription is carried out with 2.5μM of random hexamer primers.

TaqMan quantitative analysis. Specific primers and probe are designed according to the recommendations of PE Applied Biosystems; the probe can be labeled at the 5'

30   end FAM (6-carboxy-fluorescein) and at the 3' end with TAMRA (6-carboxy-tetra-

- 71 -

methyl-rhodamine). Quantification experiments are performed on 10 ng of reverse transcribed RNA from each sample. Each determination is done in triplicate.

Total cDNA content is normalized with the simultaneous quantification (multiplex PCR) of the 18S ribosomal RNA using the Pre-Developed TaqMan Assay Reagents (PDAR) Control Kit (PE Applied Biosystems, CA).

The assay reaction mix is as follows: 1X final TaqMan Universal PCR Master Mix (from 2X stock) (PE Applied Biosystems, CA); 1X PDAR control – 18S RNA (from 20X stock); 300 nM forward primer; 900 nM reverse primer; 200 nM probe; 10 ng cDNA; and water to 25 μl.

Each of the following steps are carried out once: pre PCR, 2 minutes at 50° C, and 10 minutes at 95°C. The following steps are carried out 40 times: denaturation, 15 seconds at 95°C, annealing/extension, 1 minute at 60°C.

The experiment is performed on an ABI Prism 7700 Sequence Detector (PE Applied Biosystems, CA). At the end of the run, fluorescence data acquired during PCR are processed as described in the ABI Prism 7700 user's manual in order to achieve better background subtraction as well as signal linearity with the starting target quantity.

EXAMPLE 7

In vivo testing of compounds/target validation

1. Pain:

Acute Pain

Acute pain is measured on a hot plate mainly in rats. Two variants of hot plate testing are used: In the classical variant animals are put on a hot surface (52 to 56 °C) and the latency time is measured until the animals show nocifensive behavior, such as

stepping or foot licking. The other variant is an increasing temperature hot plate where the experimental animals are put on a surface of neutral temperature. Subsequently this surface is slowly but constantly heated until the animals begin to lick a hind paw. The temperature which is reached when hind paw licking begins is a measure for pain threshold.

Compounds are tested against a vehicle treated control group. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.

Persistent Pain

Persistent pain is measured with the formalin or capsaicin test, mainly in rats. A solution of 1 to 5% formalin or 10 to 100 μg capsaicin is injected into one hind paw of the experimental animal. After formalin or capsaicin application the animals show nocifensive reactions like flinching, licking and biting of the affected paw. The number of nocifensive reactions within a time frame of up to 90 minutes is a measure for intensity of pain.

Compounds are tested against a vehicle treated control group. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to formalin or capsaicin administration.

Neuropathic Pain

Neuropathic pain is induced by different variants of unilateral sciatic nerve injury mainly in rats. The operation is performed under anesthesia. The first variant of sciatic nerve injury is produced by placing loosely constrictive ligatures around the common sciatic nerve. The second variant is the tight ligation of about the half of the diameter of the common sciatic nerve. In the next variant, a group of models is used in which tight ligations or transections are made of either the L5 and L6 spinal

- 73 -

nerves, or the L% spinal nerve only. The fourth variant involves an axotomy of two of the three terminal branches of the sciatic nerve (tibial and common peroneal nerves) leaving the remaining sural nerve intact whereas the last variant comprises the axotomy of only the tibial branch leaving the sural and common nerves uninjured. Control animals are treated with a sham operation.

Postoperatively, the nerve injured animals develop a chronic mechanical allodynia, cold allodynioa, as well as a thermal hyperalgesia. Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer, IITC Inc.-Life Science Instruments, Woodland Hills, SA, USA; Electronic von Frey System, Somedic Sales AB, Hörby, Sweden). Thermal hyperalgesia is measured by means of a radiant heat source (Plantar Test, Ugo Basile, Comerio, Italy), or by means of a cold plate of 5 to 10 °C where the nocifensive reactions of the affected hind paw are counted as a measure of pain intensity. A further test for cold induced pain is the counting of nocifensive reactions, or duration of nocifensive responses after plantar administration of acetone to the affected hind limb. Chronic pain in general is assessed by registering the circadanian rhythms in activity (Surjo and Arndt, Universität zu Köln, Cologne, Germany), and by scoring differences in gait (foot print patterns; FOOTPRINTS program, Klapdor et al., 1997. A low cost method to analyze footprint patterns. J. Neurosci. Methods 75, 49-54).

Compounds are tested against sham operated and vehicle treated control groups. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.

Inflammatory Pain

Inflammatory pain is induced mainly in rats by injection of 0.75 mg carrageenan or complete Freund's adjuvant into one hind paw. The animals develop an edema with mechanical allodynia as well as thermal hyperalgesia. Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer,

- 74 -

IITC Inc.-Life Science Instruments, Woodland Hills, SA, USA). Thermal hyperalgesia is measured by means of a radiant heat source (Plantar Test, Ugo Basile, Comerio, Italy, Paw thermal stimulator, G. Ozaki, University of California, USA). For edema measurement two methods are being used. In the first method, the animals are sacrificed and the affected hindpaws sectioned and weighed. The second method comprises differences in paw volume by measuring water displacement in a plethysmometer (Ugo Basile, Comerio, Italy).

Compounds are tested against uninflamed as well as vehicle treated control groups. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.

Diabetic Neuropathic Pain

Rats treated with a single intraperitoneal injection of 50 to 80 mg/kg streptozotocin develop a profound hyperglycemia and mechanical allodynia within 1 to 3 weeks. Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer, IITC Inc.-Life Science Instruments, Woodland Hills, SA, USA).

Compounds are tested against diabetic and non-diabetic vehicle treated control groups. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.

2. Parkinson's disease
6-Hydroxydopamine (6-OH-DA) Lesion

Degeneration of the dopaminergic nigrostriatal and striatopallidal pathways is the central pathological event in Parkinson's disease. This disorder has been mimicked

- 75 -

experimentally in rats using single/sequential unilateral stereotaxic injections of 6-OH-DA into the medium forebrain bundle (MFB).

5   Male Wistar rats (Harlan Winkelmann, Germany), weighing 200±250 g at the beginning of the experiment, are used. The rats are maintained in a temperature- and humidity-controlled environment under a 12 h light/dark cycle with free access to food and water when not in experimental sessions. The following in vivo protocols are approved by the governmental authorities. All efforts are made to minimize animal suffering, to reduce the number of animals used, and to utilize alternatives to
10   in vivo techniques.

Animals are administered pargyline on the day of surgery (Sigma, St. Louis, MO, USA; 50 mg/kg i.p.) in order to inhibit metabolism of 6-OHDA by monoamine oxidase and desmethylimipramine HCl (Sigma; 25 mg/kg i.p.) in order to prevent
15   uptake of 6-OHDA by noradrenergic terminals. Thirty minutes later the rats are anesthetized with sodium pentobarbital (50 mg/kg) and placed in a stereotaxic frame. In order to lesion the DA nigrostriatal pathway 4 μl of 0.01% ascorbic acid-saline containing 8 μg of 6-OHDA HBr (Sigma) are injected into the left medial fore-brain bundle at a rate of 1 μl/min (2.4 mm anterior, 1.49 mm lateral, -2.7 mm ventral to
20   Bregma and the skull surface). The needle is left in place an additional 5 min to allow diffusion to occur.

Stepping Test

25   Forelimb akinesia is assessed three weeks following lesion placement using a modified stepping test protocol. In brief, the animals are held by the experimenter with one hand fixing the hindlimbs and slightly raising the hind part above the surface. One paw is touching the table, and is then moved slowly sideways (5 s for 1 m), first in the forehand and then in the backhand direction. The number of adjusting
30   steps is counted for both paws in the backhand and forehand direction of movement. The sequence of testing is right paw forehand and backhand adjusting stepping,

followed by left paw forehand and backhand directions. The test is repeated three times on three consecutive days, after an initial training period of three days prior to the first testing. Forehand adjusted stepping reveals no consistent differences between lesioned and healthy control animals. Analysis is therefore restricted to backhand adjusted stepping.

Balance Test

Balance adjustments following postural challenge are also measured during the stepping test sessions. The rats are held in the same position as described in the stepping test and, instead of being moved sideways, tilted by the experimenter towards the side of the paw touching the table. This maneuver results in loss of balance and the ability of the rats to regain balance by forelimb movements is scored on a scale ranging from 0 to 3. Score 0 is given for a normal forelimb placement. When the forelimb movement is delayed but recovery of postural balance detected, score 1 is given. Score 2 represents a clear, yet insufficient, forelimb reaction, as evidenced by muscle contraction, but lack of success in recovering balance, and score 3 is given for no reaction of movement. The test is repeated three times a day on each side for three consecutive days after an initial training period of three days prior to the first testing.

Staircase Test (Paw Reaching)

A modified version of the staircase test is used for evaluation of paw reaching behavior three weeks following primary and secondary lesion placement. Plexiglass test boxes with a central platform and a removable staircase on each side are used. The apparatus is designed such that only the paw on the same side at each staircase can be used, thus providing a measure of independent forelimb use. For each test the animals are left in the test boxes for 15 min. The double staircase is filled with 7 x 3 chow pellets (Precision food pellets, formula: P, purified rodent diet, size 45 mg; Sandown Scientific) on each side. After each test the number of pellets eaten

- 77 -

(successfully retrieved pellets) and the number of pellets taken (touched but dropped) for each paw and the success rate (pellets eaten/pellets taken) are counted separately. After three days of food deprivation (12 g per animal per day) the animals are tested for 11 days. Full analysis is conducted only for the last five days.

MPTP treatment

The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) causes degeneration of mesencephalic dopaminergic (DAergic) neurons in rodents, non-human primates, and humans and, in so doing, reproduces many of the symptoms of Parkinson's disease. MPTP leads to a marked decrease in the levels of dopamine and its metabolites, and in the number of dopaminergic terminals in the striatum as well as severe loss of the tyrosine hydroxylase (TH)-immunoreactive cell bodies in the substantia nigra, pars compacta.

In order to obtain severe and long-lasting lesions, and to reduce mortality, animals receive single injections of MPTP, and are then tested for severity of lesion 7–10 days later. Successive MPTP injections are administered on days 1, 2 and 3. Animals receive application of 4 mg/kg MPTP hydrochloride (Sigma) in saline once daily. All injections are intraperitoneal (i.p.) and the MPTP stock solution is frozen between injections. Animals are decapitated on day 11.

Immunohistology

At the completion of behavioral experiments, all animals are anaesthetized with 3 ml thiopental (1 g/40 ml i.p., Tyrol Pharma). The mice are perfused transcardially with 0.01 M PBS (pH 7.4) for 2 min, followed by 4% paraformaldehyde (Merck) in PBS for 15 min. The brains are removed and placed in 4% paraformaldehyde for 24 h at 4°C. For dehydration they are then transferred to a 20% sucrose (Merck) solution in 0.1 M PBS at 4 °C until they sink. The brains are frozen in methylbutan at -20 °C for 2 min and stored at -70 °C. Using a sledge microtome (mod. 3800-Frigocut, Leica), 25 μm sections are taken from the genu of the corpus callosum (AP 1.7 mm) to the

- 78 -

hippocampus (AP 21.8 mm) and from AP 24.16 to AP 26.72. Forty-six sections are cut and stored in assorters in 0.25 M Tris buffer (pH 7.4) for immunohistochemistry.

5   A series of sections is processed for free-floating tyrosine hydroxylase (TH) immunohistochemistry. Following three rinses in 0.1 M PBS, endogenous peroxidase activity is quenched for 10 min in 0.3% H_2O_2 ±PBS. After rinsing in PBS, sections are preincubated in 10% normal bovine serum (Sigma) for 5 min as blocking agent and transferred to either primary anti-rat TH rabbit antiserum (dilution 1:2000).

10   Following overnight incubation at room temperature, sections for TH immunoreactivity are rinsed in PBS (2 x10 min) and incubated in biotinylated anti-rabbit immunoglobulin G raised in goat (dilution 1:200) (Vector) for 90 min, rinsed repeatedly and transferred to Vectastain ABC (Vector) solution for 1 h. 3,.3' -Diaminobenzidine tetrahydrochloride (DAB; Sigma) in 0.1 M PBS, supplemented
15   with 0.005% H_2O_2 , serves as chromogen in the subsequent visualization reaction. Sections are mounted on to gelatin-coated slides, left to dry overnight, counter-stained with hematoxylin dehydrated in ascending alcohol concentrations and cleared in butylacetate. Coverslips are mounted on entellan.

20   Rotarod Test

We use a modification of the procedure described by Rozas and Labandeira-Garcia (1997), with a CR-1 Rotamex system (Columbus Instruments, Columbus, OH) comprising an IBM-compatible personal computer, a CIO-24 data acquisition card, a
25   control unit, and a four-lane rotarod unit. The rotarod unit consists of a rotating spindle (diameter 7.3 cm) and individual compartments for each mouse. The system software allows preprogramming of session protocols with varying rotational speeds (0–80 rpm). Infrared beams are used to detect when a mouse has fallen onto the base grid beneath the rotarod. The system logs the fall as the end of the experiment for
30   that mouse, and the total time on the rotarod, as well as the time of the fall and all the

set-up parameters, are recorded. The system also allows a weak current to be passed through the base grid, to aid training.

3. Dementia

5   *The object recognition task*

The object recognition task has been designed to assess the effects of experimental manipulations on the cognitive performance of rodents. A rat is placed in an open field, in which two identical objects are present. The rats inspects both objects during

10   the first trial of the object recognition task. In a second trial, after a retention interval of for example 24 hours, one of the two objects used in the first trial, the 'familiar' object, and a novel object are placed in the open field. The inspection time at each of the objects is registered. The basic measures in the OR task is the time spent by a rat exploring the two object the second trial. Good retention is reflected by higher

15   exploration times towards the novel than the 'familiar' object.

Administration of the putative cognition enhancer prior to the first trial pre-dominantly allows assessment of the effects on acquisition, and eventually on consolidation processes. Administration of the testing compound after the first trial

20   allows to assess the effects on consolidation processes, whereas administration before the second trial allows to measure effects on retrieval processes.

The passive avoidance task

25   The passive avoidance task assesses memory performance in rats and mice. The inhibitory avoidance apparatus consists of a two-compartment box with a light compartment and a dark compartment. The two compartments are separated by a guillotine door that can be operated by the experimenter. A threshold of 2 cm separates the two compartments when the guillotine door is raised. When the door is

30   open, the illumination in the dark compartment is about 2 lux. The light intensity is about 500 lux at the center of the floor of the light compartment.

Two habituation sessions, one shock session, and a retention session are given, separated by inter-session intervals of 24 hours. In the habituation sessions and the retention session the rat is allowed to explore the apparatus for 300 sec. The rat is placed in the light compartment, facing the wall opposite to the guillotine door. After an accommodation period of 15 sec. the guillotine door is opened so that all parts of the apparatus can be visited freely. Rats normally avoid brightly lit areas and will enter the dark compartment within a few seconds.

In the shock session the guillotine door between the compartments is lowered as soon as the rat has entered the dark compartment with its four paws, and a scrambled 1 mA footshock is administered for 2 sec. The rat is removed from the apparatus and put back into its home cage. The procedure during the retention session is identical to that of the habituation sessions.

The step-through latency, that is the first latency of entering the dark compartment (in sec.) during the retention session is an index of the memory performance of the animal; the longer the latency to enter the dark compartment, the better the retention is. A testing compound in given half an hour before the shock session, together with 1 mg*kg^{-1} scopolamine. Scopolamine impairs the memory performance during the retention session 24 hours later. If the test compound increases the enter latency compared with the scopolamine-treated controls, is likely to possess cognition enhancing potential.

The Morris water escape task

The Morris water escape task measures spatial orientation learning in rodents. It is a test system that has extensively been used to investigate the effects of putative therapeutic on the cognitive functions of rats and mice. The performance of an animal is assessed in a circular water tank with an escape platform that is submerged about 1 cm below the surface of the water. The escape platform is not visible for an

- 81 -

animal swimming in the water tank. Abundant extra-maze cues are provided by the furniture in the room, including desks, computer equipment, a second water tank, the presence of the experimenter, and by a radio on a shelf that is playing softly.

5   The animals receive four trials during five daily acquisition sessions. A trial is started by placing an animal into the pool, facing the wall of the tank. Each of four starting positions in the quadrants north, east, south, and west is used once in a series of four trials; their order is randomized. The escape platform is always in the same position. A trial is terminated as soon as the animal had climbs onto the escape platform or

10   when 90 seconds have elapsed, whichever event occurs first. The animal is allowed to stay on the platform for 30 seconds. Then it is taken from the platform and the next trial is started. If an animal did not find the platform within 90 seconds it is put on the platform by the experimenter and is allowed to stay there for 30 seconds. After the fourth trial of the fifth daily session, an additional trial is given as a probe trial:

15   the platform is removed, and the time the animal spends in the four quadrants is measured for 30 or 60 seconds. In the probe trial, all animals start from the same start position, opposite to the quadrant where the escape platform had been positioned during acquisition.

20   Four different measures are taken to evaluate the performance of an animal during acquisition training: escape latency, traveled distance, distance to platform, and swimming speed. The following measures are evaluated for the probe trial: time (s) in quadrants and traveled distance (cm) in the four quadrants. The probe trial provides additional information about how well an animal learned the position of the

25   escape platform. If an animal spends more time and swims a longer distance in the quadrant where the platform had been positioned during the acquisition sessions than in any other quadrant, one concludes that the platform position has been learned well.

In order to assess the effects of putative cognition enhancing compounds, rats or

30   mice with specific brain lesions which impair cognitive functions, or animals treated

with compounds such as scopolamine or MK-801, which interfere with normal learning, or aged animals which suffer from cognitive deficits, are used.

The T-maze spontaneous alternation task

The T-maze spontaneous alternation task (TeMCAT) assesses the spatial memory performance in mice. The start arm and the two goal arms of the T-maze are provided with guillotine doors which can be operated manually by the experimenter. A mouse is put into the start arm at the beginning of training. The guillotine door is closed. In the first trial, the 'forced trial', either the left or right goal arm is blocked by lowering the guillotine door. After the mouse has been released from the start arm, it will negotiate the maze, eventually enter the open goal arm, and return to the start position, where it will be confined for 5 seconds, by lowering the guillotine door. Then, the animal can choose freely between the left and right goal arm (all guillotine-doors opened) during 14 'free choice' trials. As soon a the mouse has entered one goal arm, the other one is closed. The mouse eventually returns to the start arm and is free to visit whichever go alarm it wants after having been confined to the start arm for 5 seconds. After completion of 14 free choice trials in one session, the animal is removed from the maze. During training, the animal is never handled.

The percent alternations out of 14 trials is calculated. This percentage and the total time needed to complete the first forced trial and the subsequent 14 free choice trials (in s) is analyzed. Cognitive deficits are usually induced by an injection of scopolamine, 30 min before the start of the training session. Scopolamine reduced the per-cent alternations to chance level, or below. A cognition enhancer, which is always administered before the training session, will at least partially, antagonize the scopolamine-induced reduction in the spontaneous alternation rate.

EXAMPLE 8

- 83 -

Proliferation inhibition assay: Antisense oligonucleotides suppress the growth of cancer cell lines

5   The cell line used for testing is the human colon cancer cell line HCT116. Cells are cultured in RPMI-1640 with 10-15% fetal calf serum at a concentration of 10,000 cells per milliliter in a volume of 0.5 ml and kept at 37 °C in a 95% air/5%CO_2 atmosphere.

10 Phosphorothioate oligoribonucleotides are synthesized on an Applied Biosystems Model 380B DNA synthesizer using phosphoroamidite chemistry. A sequence of 24 bases complementary to the nucleotides at position 1 to 24 of SEQ ID NO:1 is used as the test oligonucleotide. As a control, another (random) sequence is used: 5'-TCA ACT GAC TAG ATG TAC ATG GAC-3'. Following assembly and deprotection, oligonucleotides are ethanol-precipitated twice, dried, and suspended in phosphate

15 buffered saline at the desired concentration. Purity of the oligonucleotides is tested by capillary gel electrophoresis and ion exchange HPLC. The purified oligonucleotides are added to the culture medium at a concentration of 10 μM once per day for seven days.

20 The addition of the test oligonucleotide for seven days results in significantly reduced expression of human serine/threonine protein kinase as determined by Western blotting. This effect is not observed with the control oligonucleotide. After 3 to 7 days, the number of cells in the cultures is counted using an automatic cell counter. The number of cells in cultures treated with the test oligonucleotide (expressed as

25 100%) is compared with the number of cells in cultures treated with the control oligonucleotide. The number of cells in cultures treated with the test oligonucleotide is not more than 30% of control, indicating that the inhibition of human serine/threonine protein kinase has an anti-proliferative effect on cancer cells.

30 **EXAMPLE 9**

In vivo testing of compounds/target validation

- 84 -

1.   Acute Mechanistic Assays

1.1.   *Reduction in Mitogenic Plasma Hormone Levels*

This non-tumor assay measures the ability of a compound to reduce either the endogenous level of a circulating hormone or the level of hormone produced in response to a biologic stimulus. Rodents are administered test compound (p.o., i.p., i.v., i.m., or s.c.). At a predetermined time after administration of test compound, blood plasma is collected. Plasma is assayed for levels of the hormone of interest. If the normal circulating levels of the hormone are too low and/or variable to provide consistent results, the level of the hormone may be elevated by a pre-treatment with a biologic stimulus (i.e., LHRH may be injected i.m. into mice at a dosage of 30 ng/mouse to induce a burst of testosterone synthesis). The timing of plasma collection would be adjusted to coincide with the peak of the induced hormone response. Compound effects are compared to a vehicle-treated control group. An F-test is preformed to determine if the variance is equal or unequal followed by a Student's t-test. Significance is p value ≤ 0.05 compared to the vehicle control group.

1.2.   *Hollow Fiber Mechanism of Action Assay*

Hollow fibers are prepared with desired cell line(s) and implanted intraperitoneally and/or subcutaneously in rodents. Compounds are administered p.o., i.p., i.v., i.m., or s.c. Fibers are harvested in accordance with specific readout assay protocol, these may include assays for gene expression (bDNA, PCR, or Taqman), or a specific biochemical activity (i.e., cAMP levels. Results are analyzed by Student's t-test or Rank Sum test after the variance between groups is compared by an F-test, with significance at $p \leq 0.05$ as compared to the vehicle control group.

2.   Subacute Functional *In Vivo* Assays

2.1.   *Reduction in Mass of Hormone Dependent Tissues*

This is another non-tumor assay that measures the ability of a compound to reduce the mass of a hormone dependent tissue (i.e., seminal vesicles in males and uteri in females). Rodents are administered test compound (p.o., i.p., i.v., i.m., or s.c.) according to a predetermined schedule and for a predetermined duration (i.e., 1

5   week). At termination of the study, animals are weighed, the target organ is excised, any fluid is expressed, and the weight of the organ is recorded. Blood plasma may also be collected. Plasma may be assayed for levels of a hormone of interest or for levels of test agent. Organ weights may be directly compared or they may be normalized for the body weight of the animal. Compound effects are compared to a

10   vehicle-treated control group. An F-test is preformed to determine if the variance is equal or unequal followed by a Student's t-test. Significance is p value $\leq$ 0.05 compared to the vehicle control group.

2.2.   Hollow Fiber Proliferation Assay

15

Hollow fibers are prepared with desired cell line(s) and implanted intraperitoneally and/or subcutaneously in rodents. Compounds are administered p.o., i.p., i.v., i.m., or s.c. Fibers are harvested in accordance with specific readout assay protocol. Cell proliferation is determined by measuring a marker of cell number (i.e., MTT or

20   LDH). The cell number and change in cell number from the starting inoculum are analyzed by Student's t-test or Rank Sum test after the variance between groups is compared by an F-test, with significance at $p \leq 0.05$ as compared to the vehicle control group.

25   ### 2.3.   Anti-angiogenesis Models
2.3.1.   Corneal Angiogenesis

Hydron pellets with or without growth factors or cells are implanted into a micropocket surgically created in the rodent cornea. Compound administration may

30   be systemic or local (compound mixed with growth factors in the hydron pellet). Corneas are harvested at 7 days post implantation immediately following intracardiac

infusion of colloidal carbon and are fixed in 10% formalin. Readout is qualitative scoring and/or image analysis. Qualitative scores are compared by Rank Sum test. Image analysis data is evaluated by measuring the area of neovascularization (in pixels) and group averages are compared by Student's t-test (2 tail). Significance is p ≤ 0.05 as compared to the growth factor or cells only group.

2.3.2. Matrigel Angiogenesis

Matrigel, containing cells or growth factors, is injected subcutaneously. Compounds are administered p.o., i.p., i.v., i.m., or s.c. Matrigel plugs are harvested at predetermined time point(s) and prepared for readout. Readout is an ELISA-based assay for hemoglobin concentration and/or histological examination (i.e. vessel count, special staining for endothelial surface markers: CD31, factor-8). Readouts are analyzed by Student's t-test, after the variance between groups is compared by an F-test, with significance determined at $p \leq 0.05$ as compared to the vehicle control group.

3. Primary Antitumor Efficacy
3.1. Early Therapy Models
3.1.1. Subcutaneous Tumor

Tumor cells or fragments are implanted subcutaneously on Day 0. Vehicle and/or compounds are administered p.o., i.p., i.v., i.m., or s.c. according to a predetermined schedule starting at a time, usually on Day 1, prior to the ability to measure the tumor burden. Body weights and tumor measurements are recorded 2-3 times weekly. Mean net body and tumor weights are calculated for each data collection day. Antitumor efficacy may be initially determined by comparing the size of treated (T) and control (C) tumors on a given day by a Student's t-test, after the variance between groups is compared by an F-test, with significance determined at $p \leq 0.05$. The experiment may also be continued past the end of dosing in which case tumor measurements would continue to be recorded to monitor tumor growth delay. Tumor growth delays are expressed as the difference in the median time for the treated and

control groups to attain a predetermined size divided by the median time for the control group to attain that size. Growth delays are compared by generating Kaplan-Meier curves from the times for individual tumors to attain the evaluation size. Significance is $p \leq 0.05$.

3.1.2. Intraperitoneal/Intracranial Tumor Models

Tumor cells are injected intraperitoneally or intracranially on Day 0. Compounds are administered p.o., i.p., i.v., i.m., or s.c. according to a predetermined schedule starting on Day 1. Observations of morbidity and/or mortality are recorded twice daily. Body weights are measured and recorded twice weekly. Morbidity/mortality data is expressed in terms of the median time of survival and the number of long-term survivors is indicated separately. Survival times are used to generate Kaplan-Meier curves. Significance is $p \leq 0.05$ by a log-rank test compared to the control group in the experiment.

3.2.   Established Disease Model

Tumor cells or fragments are implanted subcutaneously and grown to the desired size for treatment to begin. Once at the predetermined size range, mice are randomized into treatment groups.   Compounds are administered p.o., i.p., i.v., i.m., or s.c. according to a predetermined schedule. Tumor and body weights are measured and recorded 2-3 times weekly. Mean tumor weights of all groups over days post inoculation are graphed for comparison. An F-test is preformed to determine if the variance is equal or unequal followed by a Student's t-test to compare tumor sizes in the treated and control groups at the end of treatment. Significance is $p \leq 0.05$ as compared to the control group. Tumor measurements may be recorded after dosing has stopped to monitor tumor growth delay. Tumor growth delays are expressed as the difference in the median time for the treated and control groups to attain a predetermined size divided by the median time for the control group to attain that size. Growth delays are compared by generating Kaplan-Meier curves from the

- 88 -

times for individual tumors to attain the evaluation size. Significance is p value$\leq$ 0.05 compared to the vehicle control group.

3.3.   Orthotopic Disease Models

3.3.1. Mammary Fat Pad Assay

Tumor cells or fragments, of mammary adenocarcinoma origin, are implanted directly into a surgically exposed and reflected mammary fat pad in rodents. The fat pad is placed back in its original position and the surgical site is closed. Hormones may also be administered to the rodents to support the growth of the tumors. Compounds are administered p.o., i.p., i.v., i.m., or s.c. according to a predetermined schedule. Tumor and body weights are measured and recorded 2-3 times weekly. Mean tumor weights of all groups over days post inoculation are graphed for comparison. An F-test is preformed to determine if the variance is equal or unequal followed by a Student's t-test to compare tumor sizes in the treated and control groups at the end of treatment. Significance is $p \leq 0.05$ as compared to the control group.

Tumor measurements may be recorded after dosing has stopped to monitor tumor growth delay. Tumor growth delays are expressed as the difference in the median time for the treated and control groups to attain a predetermined size divided by the median time for the control group to attain that size. Growth delays are compared by generating Kaplan-Meier curves from the times for individual tumors to attain the evaluation size. Significance is p value$\leq$ 0.05 compared to the vehicle control group. In addition, this model provides an opportunity to increase the rate of spontaneous metastasis of this type of tumor. Metastasis can be assessed at termination of the study by counting the number of visible foci per target organ, or measuring the target organ weight. The means of these endpoints are compared by Student's t-test after conducting an F-test, with significance determined at $p \leq 0.05$ compared to the control group in the experiment.

- 89 -

3.3.2. Intraprostatic Assay

Tumor cells or fragments, of prostatic adenocarcinoma origin, are implanted directly into a surgically exposed dorsal lobe of the prostate in rodents. The prostate is externalized through an abdominal incision so that the tumor can be implanted specifically in the dorsal lobe while verifying that the implant does not enter the seminal vesicles. The successfully inoculated prostate is replaced in the abdomen and the incisions through the abdomen and skin are closed. Hormones may also be administered to the rodents to support the growth of the tumors. Compounds are administered p.o., i.p., i.v., i.m., or s.c. according to a predetermined schedule. Body weights are measured and recorded 2-3 times weekly. At a predetermined time, the experiment is terminated and the animal is dissected. The size of the primary tumor is measured in three dimensions using either a caliper or an ocular micrometer attached to a dissecting scope. An F-test is preformed to determine if the variance is equal or unequal followed by a Student's t-test to compare tumor sizes in the treated and control groups at the end of treatment. Significance is $p \leq 0.05$ as compared to the control group. This model provides an opportunity to increase the rate of spontaneous metastasis of this type of tumor. Metastasis can be assessed at termination of the study by counting the number of visible foci per target organ (i.e., the lungs), or measuring the target organ weight (i.e., the regional lymph nodes). The means of these endpoints are compared by Student's t-test after conducting an F-test, with significance determined at $p \leq 0.05$ compared to the control group in the experiment.

3.3.3. Intrabronchial Assay

Tumor cells of pulmonary origin may be implanted intrabronchially by making an incision through the skin and exposing the trachea. The trachea is pierced with the beveled end of a 25 gauge needle and the tumor cells are inoculated into the main bronchus using a flat-ended 27 gauge needle with a 90° bend. Compounds are administered p.o., i.p., i.v., i.m., or s.c. according to a predetermined schedule. Body

weights are measured and recorded 2-3 times weekly. At a predetermined time, the experiment is terminated and the animal is dissected. The size of the primary tumor is measured in three dimensions using either a caliper or an ocular micrometer attached to a dissecting scope. An F-test is preformed to determine if the variance is equal or unequal followed by a Student's t-test to compare tumor sizes in the treated and control groups at the end of treatment. Significance is $p \leq 0.05$ as compared to the control group. This model provides an opportunity to increase the rate of spontaneous metastasis of this type of tumor. Metastasis can be assessed at termination of the study by counting the number of visible foci per target organ (i.e., the contralateral lung), or measuring the target organ weight. The means of these endpoints are compared by Student's t-test after conducting an F-test, with significance determined at $p \leq 0.05$ compared to the control group in the experiment.

3.3.4. Intracecal Assay

Tumor cells of gastrointestinal origin may be implanted intracecally by making an abdominal incision through the skin and externalizing the intestine. Tumor cells are inoculated into the cecal wall without penetrating the lumen of the intestine using a 27 or 30 gauge needle. Compounds are administered p.o., i.p., i.v., i.m., or s.c. according to a predetermined schedule. Body weights are measured and recorded 2-3 times weekly. At a predetermined time, the experiment is terminated and the animal is dissected. The size of the primary tumor is measured in three dimensions using either a caliper or an ocular micrometer attached to a dissecting scope. An F-test is preformed to determine if the variance is equal or unequal followed by a Student's t-test to compare tumor sizes in the treated and control groups at the end of treatment. Significance is $p \leq 0.05$ as compared to the control group. This model provides an opportunity to increase the rate of spontaneous metastasis of this type of tumor. Metastasis can be assessed at termination of the study by counting the number of visible foci per target organ (i.e., the liver), or measuring the target organ weight. The means of these endpoints are compared by Student's t-test after conducting an F-test,

with significance determined at $p \leq 0.05$ compared to the control group in the experiment.

4.   Secondary (Metastatic) Antitumor Efficacy

4.1.   Spontaneous Metastasis

Tumor cells are inoculated s.c. and the tumors allowed to grow to a predetermined range for spontaneous metastasis studies to the lung or liver. These primary tumors are then excised. Compounds are administered p.o., i.p., i.v., i.m., or s.c. according to a predetermined schedule which may include the period leading up to the excision of the primary tumor to evaluate therapies directed at inhibiting the early stages of tumor metastasis. Observations of morbidity and/or mortality are recorded daily. Body weights are measured and recorded twice weekly. Potential endpoints include survival time, numbers of visible foci per target organ, or target organ weight. When survival time is used as the endpoint the other values are not determined. Survival data is used to generate Kaplan-Meier curves. Significance is $p \leq 0.05$ by a log-rank test compared to the control group in the experiment. The mean number of visible tumor foci, as determined under a dissecting microscope, and the mean target organ weights are compared by Student's t-test after conducting an F-test, with significance determined at $p \leq 0.05$ compared to the control group in the experiment for both of these endpoints.

4.2.   Forced Metastasis

Tumor cells are injected into the tail vein, portal vein, or the left ventricle of the heart in experimental (forced) lung, liver, and bone metastasis studies, respectively. Compounds are administered p.o., i.p., i.v., i.m., or s.c. according to a predetermined schedule. Observations of morbidity and/or mortality are recorded daily. Body weights are measured and recorded twice weekly. Potential endpoints include survival time, numbers of visible foci per target organ, or target organ weight. When survival time is used as the endpoint the other values are not determined. Survival

- 92 -

data is used to generate Kaplan-Meier curves. Significance is $p \leq 0.05$ by a log-rank test compared to the control group in the experiment. The mean number of visible tumor foci, as determined under a dissecting microscope, and the mean target organ weights are compared by Student's t-test after conducting an F-test, with significance at $p \leq 0.05$ compared to the vehicle control group in the experiment for both endpoints.

EXAMPLE 10

Diabetes: In vivo testing of compounds/target validation

1.   Glucose Production:

Over-production of glucose by the liver, due to an enhanced rate of gluconeogenesis, is the major cause of fasting hyperglycemia in diabetes. Overnight fasted normal rats or mice have elevated rates of gluconeogenesis as do streptozotocin-induced diabetic rats or mice fed ad libitum. Rats are made diabetic with a single intravenous injection of 40 mg/kg of streptozotocin while C57BL/KsJ mice are given 40-60 mg/kg i.p. for 5 consecutive days. Blood glucose is measured from tail-tip blood and then compounds are administered via different routes (p.o., i.p., i.v., s.c.). Blood is collected at various times thereafter and glucose measured. Alternatively, compounds are administered for several days, then the animals are fasted overnight, blood is collected and plasma glucose measured. Compounds that inhibit glucose production will decrease plasma glucose levels compared to the vehicle-treated control group.

2.   Insulin Sensitivity:

Both ob/ob and db/db mice as well as diabetic Zucker rats are hyperglycemic, hyperinsulinemic and insulin resistant. The animals are pre-bled, their glucose levels measured, and then they are grouped so that the mean glucose level is the same for each group. Compounds are administered daily either q.d. or b.i.d. by different routes (p.o., i.p., s.c.) for 7-28 days. Blood is collected at various times and plasma

glucose and insulin levels determined. Compounds that improve insulin sensitivity in these models will decrease both plasma glucose and insulin levels when compared to the vehicle-treated control group.

5   3.   Insulin Secretion:

Compounds that enhance insulin secretion from the pancreas will increase plasma insulin levels and improve the disappearance of plasma glucose following the administration of a glucose load. When measuring insulin levels, compounds are

10   administered by different routes (p.o., i.p., s.c. or i.v.) to overnight fasted normal rats or mice. At the appropriate time an intravenous glucose load (0.4g/kg) is given, blood is collected one minute later. Plasma insulin levels are determined. Compounds that enhance insulin secretion will increase plasma insulin levels compared to animals given only glucose. When measuring glucose disappearance,

15   animals are bled at the appropriate time after compound administration, then given either an oral or intraperitoneal glucose load (1g/kg), bled again after 15, 30, 60 and 90 minutes and plasma glucose levels determined. Compounds that increase insulin levels will decrease glucose levels and the area-under-the glucose curve when compared to the vehicle-treated group given only glucose.

20

Compounds that enhance insulin secretion from the pancreas will increase plasma insulin levels and improve the disappearance of plasma glucose following the administration of a glucose load. When measuring insulin levels, test compounds which regulate serine/threonine protein kinase are administered by different routes

25   (p.o., i.p., s.c., or i.v.) to overnight fasted normal rats or mice. At the appropriate time an intravenous glucose load (0.4g/kg) is given, blood is collected one minute later. Plasma insulin levels are determined. Test compounds that enhance insulin secretion will increase plasma insulin levels compared to animals given only glucose. When measuring glucose disappearance, animals are bled at the appropriate time

30   after compound administration, then given either an oral or intraperitoneal glucose load (1g/kg), bled again after 15, 30, 60, and 90 minutes and plasma glucose levels

determined. Test compounds that increase insulin levels will decrease glucose levels and the area-under-the glucose curve when compared to the vehicle-treated group given only glucose.

5   4.   Glucose Production:

Over-production of glucose by the liver, due to an enhanced rate of gluconeogenesis, is the major cause of fasting hyperglycemia in diabetes. Overnight fasted normal rats or mice have elevated rates of gluconeogenesis as do streptozotocin-induced diabetic

10   rats or mice fed ad libitum. Rats are made diabetic with a single intravenous injection of 40 mg/kg of streptozotocin while C57BL/KsJ mice are given 40-60 mg/kg i.p. for 5 consecutive days. Blood glucose is measured from tail-tip blood and then compounds are administered via different routes (p.o., i.p., i.v., s.c.). Blood is collected at various times thereafter and glucose measured. Alternatively,

15   compounds are administered for several days, then the animals are fasted overnight, blood is collected and plasma glucose measured. Compounds that inhibit glucose production will decrease plasma glucose levels compared to the vehicle-treated control group.

20   5.   Insulin Sensitivity:

Both ob/ob and db/db mice as well as diabetic Zucker rats are hyperglycemic, hyperinsulinemic and insulin resistant. The animals are pre-bled, their glucose levels measured, and then they are grouped so that the mean glucose level is the same for

25   each group. Compounds are administered daily either q.d. or b.i.d. by different routes (p.o., i.p., s.c.) for 7-28 days. Blood is collected at various times and plasma glucose and insulin levels determined. Compounds that improve insulin sensitivity in these models will decrease both plasma glucose and insulin levels when compared to the vehicle-treated control group.

30

- 95 -

6.   Insulin Secretion:

Compounds that enhance insulin secretion from the pancreas will increase plasma insulin levels and improve the disappearance of plasma glucose following the administration of a glucose load. When measuring insulin levels, compounds are administered by different routes (p.o., i.p., s.c. or i.v.) to overnight fasted normal rats or mice. At the appropriate time an intravenous glucose load (0.4g/kg) is given, blood is collected one minute later. Plasma insulin levels are determined. Compounds that enhance insulin secretion will increase plasma insulin levels compared to animals given only glucose. When measuring glucose disappearance, animals are bled at the appropriate time after compound administration, then given either an oral or intraperitoneal glucose load (1g/kg), bled again after 15, 30, 60 and 90 minutes and plasma glucose levels determined. Compounds that increase insulin levels will decrease glucose levels and the area-under-the glucose curve when compared to the vehicle-treated group given only glucose.

EXAMPLE 11

Quantitative RT-PCR analysis of cancer tissues and obesity and diabetes tissues.
RNA extraction and cDNA preparation

Total RNA used for Taqman quantitative analysis were either purchased (Clontech, CA) or extracted from tissues using TRIzol reagent (Life Technologies, MD) according to a modified vendor protocol that utilizes the Rneasy protocol (Qiagen, CA).

One hundred µg of each RNA were treated with DNase I using RNase free- DNase (Qiagen, CA) for use with RNeasy or QiaAmp columns.

After elution and quantitation with Ribogreen (Molecular Probes Inc., OR) each sample was reverse transcribed using the GibcoBRL Superscript II First Strand

Synthesis System for RT-PCR according to vendor protocol (Life Technologies, MD). The final concentration of RNA in the reaction mix was 50ng/µL. Reverse transcription was performed with 0.5µg of Oligo dT primer for the cancer panel and 50ng of Random Hexamers for the obesity and diabetes panel.

TaqMan quantitative analysis

Specific primers and probe were designed according to PE Applied Biosystems recommendations and are listed below:

forward primer: 5'-(CAACATCGTGAAATTGCATGAA)-3' (SEQ ID NO:12)
reverse primer: 5'-(TTTCTATGATGGCGTCAAAAAGG)-3' (SEQ ID NO:13)
probe: SYBR Green

The expected length of the PCR product was 100 bp.

Quantitation experiments were performed on 25 ng of reverse transcribed RNA from each sample. Each determination was done in duplicate. 18S ribosomal RNA was measured as a control using the Pre-Developed TaqMan Assay Reagents (PDAR)(PE Applied Biosystems, CA). Assay reaction mix was as follows:

	final
TaqMan SYBR Green PCR Master Mix (2x)	1x
(PE Applied Biosystems, CA)	
Forward primer	
CAACATCGTGAAATTGCATGAA	300nM
Reverse primer	
TTTCTATGATGGCGTCAAAAAGG	300nM
cDNA	25ng
Water to 25µL	

18s control:

Taqman Universal PCR Master Mix (2x)		1x
(PE Applied Biosystems, CA)		
PDAR control – 18S RNA (20x)		1x
18S ribosomal forward primer		300nM
18S ribosomal reverse primer		300nM
cDNA		25ng
Water to 25µl		

PCR conditions:

Once: 2 minutes at 50 °C

            10 minutes at 95 °C

40cycles: 15 sec. at 95 °C

                1 minute at 60 °C

The experiment was performed on an ABI Prism 7700 Sequence Detector (PE Applied Biosystems, CA). At the end of the run, fluorescence data acquired during PCR were processed as described in the ABI Prism 7700 user's manual.

For cancer tissues, fold change was calculated using the delta-delta C_T method with normalization to the 18S RNA values. Results are shown in FIG. 19.

For obesity and diabetes tissues, relative expression was determined as follows. Ct values were normalized to 18S RNA values. The highest expressing tissue was then assigned a value of 100. Expression levels for the remaining tissues were then expressed as percentages of the highest expressing tissue ($[\Delta C_T$ of tissue x/ΔC_T of highest expresser] X100). Results are shown in FIG. 20

REFERENCES

1. Protein kinase catalytic domain sequence database: identification of con-
    served features of primary structure and classification of family members.
    Methods Enzymol 1991;200:38-62

2. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase
    (catalytic) domain structure and classification. FASEB J 1995 May;9(8):576-
    96

3. DCAMKL1, a brain-specific transmembrane protein on 13q12.3 that is
    similar to doublecortin (DCX).Genomics 1999 Feb 15;56(1):121-6

4. Doublecortin mutations cluster in evolutionarily conserved functional
    domains. Hum Mol Genet 2000 Mar 22;9(5):703-12

5. Human doublecortin (DCX) and the homologous gene in mouse encode a
    putative Ca2+-dependent signaling protein which is mutated in human X-
    linked neuronal migration defects. Hum Mol Genet 1998 Aug;7(8):1327-32

6. Doublecortin, a brain-specific gene mutated in human X-linked lissencephaly
    and double cortex syndrome, encodes a putative signaling protein. Cell 1998
    Jan 9;92(1):63-72

7. Doublecortin is the major gene causing X-linked subcortical laminar
    heterotopia (SCLH).Hum Mol Genet 1998 Jul;7(7):1063-70

8. A novel CNS gene required for neuronal migration and involved in X-linked
    subcortical laminar heterotopia and lissencephaly syndrome. Cell 1998 Jan
    9;92(1):51-61

CLAIMS

1. An isolated polynucleotide being selected from the group consisting of:

    a) a polynucleotide encoding a serine/threonine protein kinase polypeptide comprising an amino acid sequence selected form the group consisting of:

    amino acid sequences which are at least about 75% identical to

    the amino acid sequence shown in SEQ ID NO: 2; and

    the amino acid sequence shown in SEQ ID NO: 2.

    b) a polynucleotide comprising the sequence of SEQ ID NO: 1 or 4;

    c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b) and encodes a serine/threonine protein kinase polypeptide;

    d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code and encodes a serine/threonine protein kinase polypeptide; and

    e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d) and encodes a serine/threonine protein kinase polypeptide.

2. An expression vector containing any polynucleotide of claim 1.

3. A host cell containing the expression vector of claim 2.

4. A substantially purified serine/threonine protein kinase polypeptide encoded by a polynucleotide of claim 1.

5. A method for producing a serine/threonine protein kinase polypeptide, where-in the method comprises the following steps:

a)   culturing the host cell of claim 3 under conditions suitable for the expression of the serine/threonine protein kinase polypeptide; and

b)   recovering the serine/threonine protein kinase polypeptide from the host cell culture.

6.   A method for detection of a polynucleotide encoding a serine/threonine protein kinase polypeptide in a biological sample comprising the following steps:

a)   hybridizing any polynucleotide of claim 1 to a nucleic acid material of a biological sample, thereby forming a hybridization complex; and

b)   detecting said hybridization complex.

7.   The method of claim 6, wherein before hybridization, the nucleic acid material of the biological sample is amplified.

8.   A method for the detection of a polynucleotide of claim 1 or a serine/threonine protein kinase polypeptide of claim 4 comprising the steps of:
contacting a biological sample with a reagent which specifically interacts with the polynucleotide or the serine/threonine protein kinase polypeptide.

9.   A diagnostic kit for conducting the method of any one of claims 6 to 8.

10.   A method of screening for agents which decrease the activity of a serine/threonine protein kinase, comprising the steps of:
contacting a test compound with any serine/threonine protein kinase polypeptide encoded by any polynucleotide of claim1;
detecting binding of the test compound to the serine/threonine protein kinase polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential therapeutic agent for decreasing the activity of a serine/threonine protein kinase.

11. A method of screening for agents which regulate the activity of a serine/threonine protein kinase, comprising the steps of:

contacting a test compound with a serine/threonine protein kinase polypeptide encoded by any polynucleotide of claim 1; and

detecting a serine/threonine protein kinase activity of the polypeptide, wherein a test compound which increases the serine/threonine protein kinase activity is identified as a potential therapeutic agent for increasing the activity of the serine/threonine protein kinase, and wherein a test compound which decreases the serine/threonine protein kinase activity of the polypeptide is identified as a potential therapeutic agent for decreasing the activity of the serine/threonine protein kinase.

12. A method of screening for agents which decrease the activity of a serine/threonine protein kinase, comprising the steps of:

contacting a test compound with any polynucleotide of claim 1 and detecting binding of the test compound to the polynucleotide, wherein a test compound which binds to the polynucleotide is identified as a potential therapeutic agent for decreasing the activity of serine/threonine protein kinase.

13. A method of reducing the activity of serine/threonine protein kinase, comprising the steps of:

contacting a cell with a reagent which specifically binds to any polynucleotide of claim 1 or any serine/threonine protein kinase polypeptide of claim 4, whereby the activity of serine/threonine protein kinase is reduced.

14. A reagent that modulates the activity of a serine/threonine protein kinase polypeptide or a polynucleotide wherein said reagent is identified by the method of any of the claim 10 to 12.

15. A pharmaceutical composition, comprising:

the expression vector of claim 2 or the reagent of claim 14 and a pharmaceutically acceptable carrier.

16.   Use of the expression vector of claim 2 or the reagent of claim 14 in the preparation of a medicament for modulating the activity of a serine/threonine protein kinase in a disease.

17.   Use of claim 16 wherein the disease is cancer, COPD, a cardiovascular disorder, a urinary disorder, obesity, diabetes; or a peripheral or central nervous system disorder.

18.   A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.

19.   The cDNA of claim 18 which comprises SEQ ID NO:1 or 4.

20.   The cDNA of claim 18 which consists of SEQ ID NO:1 or 4.

21.   An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.

22.   The expression vector of claim 21 wherein the polynucleotide consists of SEQ ID NO:1 or 4.

23.   A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.

24.   The host cell of claim 23 wherein the polynucleotide consists of SEQ ID NO:1 or 4.

25.   A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.

26.   The purified polypeptide of claim 25 which consists of the amino acid sequence shown in SEQ ID NO:2.

27.   A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO:2.

28.   A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed; and
isolating the polypeptide.

29.   The method of claim 28 wherein the expression vector comprises SEQ ID NO:1 or 4.

30.   A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO:1 or 4 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
detecting the hybridization complex.

31.   The method of claim 30 further comprising the step of amplifying the nucleic acid material before the step of hybridizing.

32.   A kit for detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising:

a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO:1 or 4; and

instructions for the method of claim 30.

5   33.   A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:

contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex; and

detecting the reagent-polypeptide complex.

10

34.   The method of claim 33 wherein the reagent is an antibody.

35.   A kit for detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising:

15   an antibody which specifically binds to the polypeptide; and

instructions for the method of claim 33.

36.   A method of screening for agents which can modulate the activity of a human serine/threonine protein kinase, comprising the steps of:

20   contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 75% identical to the amino acid sequence shown in SEQ ID NO:2 and (2) the amino acid sequence shown in SEQ ID NO:2; and

detecting binding of the test compound to the polypeptide, wherein a test

25   compound which binds to the polypeptide is identified as a potential agent for regulating activity of the human serine/threonine protein kinase.

37.   The method of claim 36 wherein the step of contacting is in a cell.

30   38.   The method of claim 36 wherein the cell is *in vitro*.

39.   The method of claim 36 wherein the step of contacting is in a cell-free system.

40.   The method of claim 36 wherein the polypeptide comprises a detectable label.

41.   The method of claim 36 wherein the test compound comprises a detectable label.

42.   The method of claim 36 wherein the test compound displaces a labeled ligand which is bound to the polypeptide.

43.   The method of claim 36 wherein the polypeptide is bound to a solid support.

44.   The method of claim 36 wherein the test compound is bound to a solid support.

45.   A method of screening for agents which modulate an activity of a human serine/threonine protein kinase, comprising the steps of:
       contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 75% identical to the amino acid sequence shown in SEQ ID NO:2 and (2) the amino acid sequence shown in SEQ ID NO:2; and detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human serine/threonine protein kinase, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human serine/threonine protein kinase.

46.   The method of claim 45 wherein the step of contacting is in a cell.

- 106 -

47.   The method of claim 45 wherein the cell is *in vitro*.

48.   The method of claim 45 wherein the step of contacting is in a cell-free system.

49.   A method of screening for agents which modulate an activity of a human serine/threonine protein kinase, comprising the steps of:
contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO:1 or 4; and detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human serine/threonine protein kinase.

50.   The method of claim 49 wherein the product is a polypeptide.

51.   The method of claim 49 wherein the product is RNA.

52.   A method of reducing activity of a human serine/threonine protein kinase, comprising the step of:
contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:1 or 4, whereby the activity of a human serine/threonine protein kinase is reduced.

53.   The method of claim 52 wherein the product is a polypeptide.

54.   The method of claim 53 wherein the reagent is an antibody.

55.   The method of claim 52 wherein the product is RNA.

56.   The method of claim 55 wherein the reagent is an antisense oligonucleotide.

57.　　The method of claim 56 wherein the reagent is a ribozyme.

58.　　The method of claim 52 wherein the cell is *in vitro*.

5

59.　　The method of claim 52 wherein the cell is *in vivo*.

60.　　A pharmaceutical composition, comprising:

a reagent which specifically binds to a polypeptide comprising the amino acid

10　　sequence shown in SEQ ID NO:2; and

a pharmaceutically acceptable carrier.

61.　　The pharmaceutical composition of claim 60 wherein the reagent is an antibody.

15

62.　　A pharmaceutical composition, comprising:

a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:1 or 4; and

a pharmaceutically acceptable carrier.

20

63.　　The pharmaceutical composition of claim 62 wherein the reagent is a ribozyme.

64.　　The pharmaceutical composition of claim 62 wherein the reagent is an

25　　antisense oligonucleotide.

65.　　The pharmaceutical composition of claim 62 wherein the reagent is an antibody.

30　　66.　　A pharmaceutical composition, comprising:

- 108 -

an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2; and

a pharmaceutically acceptable carrier.

5   67.   The pharmaceutical composition of claim 66 wherein the expression vector comprises SEQ ID NO:1 or 4.

     68.   A method of treating a serine/threonine protein kinase dysfunction related disease, wherein the disease is selected from cancer, COPD, a cardiovascular

10   disorder, a urinary disorder, obesity, diabetes, or a peripheral or central nervous system disorder comprising the step of: administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human serine/threonine protein kinase, whereby symptoms of the serine/threonine protein kinase dysfunction related disease are

15   ameliorated.

     69.   The method of claim 68 wherein the reagent is identified by the method of claim 36.

20   70.   The method of claim 68 wherein the reagent is identified by the method of claim 45.

     71.   The method of claim 68 wherein the reagent is identified by the method of claim 49.

Fig. 1

```
gacagcaaggcgtatgtgaccattctctagaatatttaagctcgagaatctca
gagcggaagctgcaaggctcctggctgcctgccagccgagggaatctggagaa
accattcctgggggccgcgtggccccgtcgtgcccttgttctgccctcggaatg
gccttcactcagcacatcctgagaacagccctctgaagcccagggtcgtgacc
gtagtgaagctgggtgggcagcgcccccgaaagatcactctgctcctcaacag
gcgatcagtgcagacgttcgagcagctcttagctgacatctcagaagccttgg
gctctcccagatggaagaatgaccgtgtgaggaaactgtttaacctcaagggc
agggaaatcaggagcgtctctgatttcttcagggaaggggatgctttcatagc
tatgggcaaagaaccactgacactgaagagcattcaggtggctgtagaagaac
tgtaccccaacaaagcccgggccctgacactggcccagcacagccgtgccct
tctccaaggctgaggagcaggctgtttagcaaggctctgaaaggagaccaccg
ctgtggggagaccgagacccccaagagctgcagcgaagttgcaggatgcaagg
cagccatgaggcaccaggggaagatccccgaggagctttcactagatgacaga
gcgaggacccagaagaagtgggggaggggaaatgggagccagaacccagtag
caagcccccagggaagccactctggaagagaggcacgcaagggggagagaagc
atcttggggtggagattgaaaagacctcgggtgaaattatcagatgcgagaag
tgcaagagagagagggagctccagcagagcctggagcgtgagaggctttctct
ggggaccagtgagctggatatggggaagggcccaatgtatgatgtggagaagc
tggtgaggaccagaagctgcaggaggtctcccgaggcaaatcctgcaagtggg
gaggaagggtggaagggtgacagccacaggagcagccccaggaatcccactca
agagctgaggagacccagcaagagcatggacaagaaagaggacagaggcccag
aggatcaagaaagccatgctcagggagcagccaaggccaagaaggaccttgtg
gaagttcttcctgtcacagaggaggggctgagggaggtgaagaaggacaccag
gcccatgagcaggagcaaacatggtggctggctcctgagagagcaccaggcgg
gctttgagaagctccgcaggacccgaggagaagagaaggaggcagagaaggag
aaaaagccatgtatgtctggaggcagaaggatgactctcagagatgaccaacc
tgcaaagctagaaaaggagcccaagacgaggccagaagagaacaagccagagc
ggcccagcggtcggaagccacggcccatgggcatcattgccgccaatgtggaa
aagcattatgagactggccgggtcattggggatgggaactttgctgtcgtgaa
ggagtgcagacaccgcgagaccaggcaggcctatgcgatgaagatcattgaca
agtccagactcaagggcaaggaggacatggtggacagtgagatcttgatcatc
cagagcctctctcaccccaacatcgtgaaattgcatgaagtctacgaaacaga
catggaaatctacctgatcctggagtacgtgcaggaggagacctttttgacg
ccatcatagaaagtgtgaagttcccggagcccgatgctgccctcatgatcatg
gacttatgcaaagccctcgtccacatgcacgacaagagcattgtccaccggga
cctcaagccggaaaaccttttg
```

Fig. 2

```
MAEGKEGQVPSYMDGSRQRENEEDAKAETPDVTIRSYEIYSLPWNRQQGVCDH
SLEYLSSRISERKLQGSWLPASRGNLEKPFLGPRGPVVPLFCPRNGLHSAHPE
NSPLKPRVVTVVKLGGQRPRKITLLLNRRSVQTFEQLLADISEALGSPRWKND
RVRKLFNLKGREIRSVSDFFREGDAFIAMGKEPLTLKSIQVAVEELYPNKARA
LTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGK
IPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEK
TSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCR
RSPEANPASGEEGWKGDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQ
GAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRT
RGEEKEAEKEKKPCMSGGRRMTLRDDQPAKLEKEPKTRPEENKPERPSGRKPR
PMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKE
DMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKF
PEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGL
AKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPPFRS
PERDQDELFNIIQLGHFEFLPPYWDNISDAAKDLVSRLLVVDPKKRYTAHQVL
QHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHKRVVEQVS
```

Fig. 3

```
MSFGRDMELEHFDERDKAQRYSRGSRVNGLPSPTHSAHCSFYRTRTLQTLSSE
KKAKKVRFYRNGDRYFKGIVYAISPDRFRSFEALLADLTRTLSDNVNLPQGVR
TIYTIDGLKKISSLDQLVEGESYVCGSIEPFKKLEYTKNVPNWSVNVKTTSA
SRAVSSLATAKGSPSEVRENKDFIRPKLVTIIRSGVKPRKAVRILLNKKTAHS
FEQVLTDITDAIKLDSGVVKRLYTLDGKQVMCLQDFFGDDDIFIACGPEKFRY
QDDFLLDESECRVVKSTSYTKIASSSRRSTTKSPGPSRRSKSPASTSSVNGTP
GSQLSTPRSGKSPSPSPTSPGSLRKQRSSQHGGSSTSLASTKVCSSMDENDGP
GEEVSEEGFQIPATITERYKVGRTIGDGNFAVVKECVERSTAREYALKIIKKS
KCRGKEHMIQNEVSILRRVKHPNIVLLIEEMDVPTELYLVMELVKGGDLFDAI
TSTNKYTERDASGMLYNLASAIKYLHSLNIVHRDIKPENLLVYEHQDGSKSLK
LGDFGLATIVDGPLYTVCGTPTYVAPEIIAETGYGLKVDIWAAGVITYILLCG
FPPFRGSGDDQEVLFDQILMGQVDFPSPYWDNVSDSAKELITMMLLVDVDQRF
SAVQVLEHPWVNDDGLPENEHQLSVAGKIKKHFNTGPKPNSTAAGVSVIATTA
LDKERQVFRRRRNQDVRSRYKAQPAPPELNSESEDYSPSSSETVRSPNSPF
```

Fig. 4

```
atggcggaaggcaaggaagggcaagtcccatcttacatggatggcagcaggca
aagagagaatgaggaagatgcaaaagcggaaacccctgatgtaaccatcagat
cttatgagatttattcactaccatggaacagacagcaaggcgtatgtgaccat
tctctagaatatttaagctcgagaatctcagagcggaagctgcaaggctcctg
gctgcctgccagccgagggaatctggagaaaccattcctggggccgcgtggcc
ccgtcgtgcccttgttctgccctcggaatggccttcactcagcacatcctgag
aacagccctctgaagcccagggtcgtgaccgtagtgaagctgggtgggcagcg
cccccgaaagatcactctgctcctcaacaggcgatcagtgcagacgttcgagc
agctcttagctgacatctcagaagccttgggctctcccagatggaagaatgac
cgtgtgaggaaactgtttaacctcaagggcagggaaatcaggagcgtctctga
tttcttcagggaaggggatgctttcatagctatgggcaaagaaccactgacac
tgaagagcattcaggtggctgtagaagaactgtaccccaacaaagcccgggcc
ctgacactggcccagcacagccgtgccccttctccaaggctgaggagcaggct
gtttagcaaggctctgaaaggagaccaccgctgtggggagaccgagaccccca
agagctgcagcgaagttgcaggatgcaaggcagccatgaggcaccaggggaag
atccccgaggagctttcactagatgacagagcgaggacccagaagaagtgggg
gaggggaaatgggagccagaacccagtagcaagcccccaggaagccactc
tggaagagaggcacgcaaggggagagaagcatcttggggtggagattgaaaag
acctcgggtgaaattatcagatgcgagaagtgcaagagagagagggagctcca
gcagagcctggagcgtgagaggctttctctggggaccagtgagctggatatgg
ggaagggcccaatgtatgatgtggagaagctggtgaggaccagaagctgcagg
aggtctcccgaggcaaatcctgcaagtggggaggaagggtggaagggtgacag
ccacaggagcagcccccaggaatcccactcaagagctgaggagacccagcaaga
gcatggacaagaaagaggacagaggcccagaggatcaagaaagccatgctcag
ggagcagccaaggccaagaaggaccttgtggaagttcttcctgtcacagagga
ggggctgagggaggtgaagaaggacaccaggcccatgagcaggagcaaacatg
gtggctggctcctgagagagcaccaggcgggctttgagaagctccgcaggacc
cgaggagaagagaaggaggcagagaaggagaaaaagccatgtatgtctggagg
cagaaggatgactctcagagatgaccaacctgcaaagctagaaaaggagccca
agacgaggccagaagagaacaagccagagcggcccagcggtcggaagccacgg
cccatgggcatcattgccgccaatgtggaaaagcattatgagactggccgggt
cattggggatgggaactttgctgtcgtgaaggagtgcagacaccgcgagacca
ggcaggcctatgcgatgaagatcattgacaagtccagactcaagggcaaggag
gacatggtggacagtgagatcttgatcatccagagcctctctcaccccaacat
cgtgaaattgcatgaagtctacgaaacagacatggaaatctacctgatcctgg
agtacgtgcagggaggagaccttttttgacgccatcatagaaagtgtgaagttc
ccggagcccgatgctgccctcatgatcatggacttatgcaaagccctcgtcca
catgcacgacaagagcattgtccaccgggacctcaagccggaaaacctttttgg
ttcagcgaaatgaggacaaatctactaccttgaaattggctgattttggactt
gcaaagcatgtggtgagacctatatttactgtgtgtgggacccaacttacgt
agctcccgaaattctttctgagaaaggttatggactggaggtggacatgtggg
ctgctggcgtgatcctctatatcctgctgtgtggctttcccccattccgcagc
cctgagagggaccaggacgagctctttaacatcatccagctgggccactttga
gttcctcccccttactgggacaatatctctgatgctgctaaagatctggtga
gccggttgctggtggtagaccccaaaaagcgctacacagctcatcaggttctt
cagcacccctggatcgaaacagctggcaagaccaatacagtgaaacgacagaa
gcaggtgtcccccagcagcgagggtcacttccggagccagcacaagagggttg
tggagcaggtatca
```

Fig. 5

LQVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVD
MWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDAAKD
LVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHK
RVVEQVS

Fig. 6

TTACAGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTT
TGGACTTGCAAAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAA
CTTACGTAGCTCCCGAAATTCTTTCTGAGAAAGGTTATGGACTGGAGGTGGAC
ATGTGGGCTGCTGGCGTGATCCTCTATATCCTGCTGTGTGGCTTTCCCCCATT
CCGCAGCCCTGAGAGGGACCAGGACGAGCTCTTTAACATCATCCAGCTGGGCC
ACTTTGAGTTCCTCCCCCCTTACTGGGACAATATCTCTGATGCTGCTAAAGAT
CTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTACACAGCTCATCA
GGTTCTTCAGCACCCCTGGATCGAAACAGCTGGCAAGACCAATACAGTGAAAC
GACAGAAGCAGGTGTCCCCCAGCAGCGAGGGTCACTTCCGGAGCCAGCACAAG
AGGGTTGTGGAGCAGGTATCA

Fig. 7

MAEGKEGQVPSYMDGSRQRENEEDAKAETPDVTIRSYEIYSLPWNRQQGVCDH
SLEYLSSRISERKLQGSWLPASRGNLEKPFLGPRGPVVPLFCPRNGLHSAHPE
NSPLKPRVVTVVKLGGQRPRKITLLLNRRSVQTFEQLLADISEALGSPRWKND
RVRKLFNLKGREIRSVSDFFREGDAFIAMGKEPLTLKSIQVAVEELYPNKARA
LTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGK
IPEELSLDDRARTQKKWGRGKWEPEPSSKPPREATLEERHARGEKHLGVEIEK
TSGEIIRCEKCKRERELQQSLERERLSLGTSELDMGKGPMYDVEKLVRTRSCR
RSPEANPASGEEGWKGDSHRSSPRNPTQELRRPSKSMDKKEDRGPEDQESHAQ
GAAKAKKDLVEVLPVTEEGLREVKKDTRPMSRSKHGGWLLREHQAGFEKLRRT
RGEEKEAEKEKKPCMSGGRRMTLRDDQPAKLEKEPKTRPEENKPERPSGRKPR
PMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKE
DMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKF
PEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLGCEPAMKAQPGKTEPWKT
TLSHSEIMEGKKSVLGSLVKEKTLRSSKCGTKCPMVLLFIFKGVDKAEKQSDV
QPFNDFYEG

Fig. 8

```
atggcggaaggcaaggaagggcaagtcccatcttacatggatggcagcaggca
aagagagaatgaggaagatgcaaaagcggaaacccctgatgtaaccatcagat
cttatgagatttattcactaccatggaacagacagcaaggcgtatgtgaccat
tctctagaatatttaagctcgagaatctcagagcggaagctgcaaggctcctg
gctgcctgccagccgagggaatctggagaaaccattcctggggccgcgtggcc
ccgtcgtgcccttgttctgccctcggaatggccttcactcagcacatcctgag
aacagccctctgaagcccagggtcgtgaccgtagtgaagctgggtgggcagcg
cccccgaaagatcactctgctcctcaacaggcgatcagtgcagacgttcgagc
agctcttagctgacatctcagaagccttgggctctcccagatggaagaatgac
cgtgtgaggaaactgtttaacctcaagggcagggaaatcaggagcgtctctga
tttcttcagggaaggggatgctttcatagctatgggcaaagaaccactgacac
tgaagagcattcaggtggctgtagaagaactgtaccccaacaaagcccgggcc
ctgacactggcccagcacagccgtgccccttctccaaggctgaggagcaggct
gtttagcaaggctctgaaaggagaccaccgctgtggggagaccgagaccccca
agagctgcagcgaagttgcaggatgcaaggcagccatgaggcaccaggggaag
atccccgaggagctttcactagatgacagagcgaggacccagaagaagtgggg
gaggggaaatgggagccagaacccagtagcaagcccccagggaagccactc
tggaagagaggcacgcaaggggagagaagcatcttggggtggagattgaaaag
acctcgggtgaaattatcagatgcgagaagtgcaagagagagagggagctcca
gcagagcctggagcgtgagaggctttctctggggaccagtgagctggatatgg
ggaagggcccaatgtatgatgtggagaagctggtgaggaccagaagctgcagg
aggtctcccgaggcaaatcctgcaagtggggaggaagggtggaagggtgacag
ccacaggagcagccccaggaatcccactcaagagctgaggagacccagcaaga
gcatggacaagaaagaggacagaggcccagaggatcaagaaagccatgctcag
ggagcagccaaggccaagaaggaccttgtggaagttcttcctgtcacagagga
ggggctgagggaggtgaagaaggacaccaggcccatgagcaggagcaaacatg
gtggctggctcctgagagagcaccaggcgggctttgagaagctccgcaggacc
cgaggagaagagaaggaggcagagaaggagaaaaagccatgtatgtctggagg
cagaaggatgactctcagagatgaccaacctgcaaagctagaaaaggagccca
agacgaggccagaagagaacaagccagagcggcccagcggtcggaagccacgg
cccatgggcatcattgccgccaatgtggaaaagcattatgagactggccgggt
cattggggatgggaactttgctgtcgtgaaggagtgcagacaccgcgagacca
ggcaggcctatgcgatgaagatcattgacaagtccagactcaagggcaaggag
gacatggtggacagtgagatcttgatcatccagagcctctctcaccccaacat
cgtgaaattgcatgaagtctacgaaacagacatggaaatctacctgatcctgg
agtacgtgcagggaggagacctttttgacgccatcatagaaagtgtgaagttc
ccggagcccgatgctgccctcatgatcatggacttatgcaaagccctcgtcca
catgcacgacaagagcattgtccaccgggacctcaagccggaaaaccttttgg
gatgtgagccagccatgaaagcacaacctgggaaaacagaaccatggaaaaca
acactcagtcactcagagattatggaagggaagaagtctgtgttgggaagcct
ggtaaaggaaaaaaccctcagaagcagcaaatgtgggacaaaatgtcccatgg
tgcttctgtttatttttcaagggagtagacaaagcggagaaacagagtgatgtt
cagcccttcaacgatttttatgagggctga
```

Fig. 9

CCGCCAATGTGGAAAAGCATTATGAGACTGGCCGGGTCATTGGGGATGGGAAC
TTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCGAT
GAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTG
AGATCTTGATCATCCAGAGCCTCTNTCACCCCAACATCGTGAAATTGCATGAA
GTCTACGAAACAGACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGG
AGACCTTTTTGACGCCATCATAGAAAGTGTGAAGTT

Fig. 10

ACAGCTGGCAAGACCAATACAGTGAAACGACAGAAGCAGGTGTCCCCCAGCAG
CGAGGGTCACTTCCGGAGCCAGCACAAGAGGGTTGTGGAGCAGGTATCATAGT
CACCACCTTGGGAATCTGTCCAGCCCCCAGTTCTGCTCAAGGACAGAGAAAAG
GATAGAAGTTTGAGAGAAAAACAATGAAAGAGGCTTCTTTCACATAATTGGTG
AATCAGAGGGAGAGACACTGAGTATATTTTAAAGCATATTAAAAAAATTAAGT
CAATGTTAAATGTCACAACATATTTTTAGATTTGTATATTTAAAGCCTTTAAT
ACATTTTTGGGGGGTAAGCATTGTCATCAGTGAGGAATTTTGGTAATAATGAT
GTGTTTTGCTTCCCCTTTGTAACCAAGTTTATTCTGTACTACAGGAGTGGTGC
TTACCAGGGTCTAAACTCCCCCTGTGAGATTAATAAGGTGCATTGTGGTCTTT
CTGTGTTAATAAAATGTGCTCTGAATAA

Fig. 11

TCTGTTATTCAGAGCACATTTTATTAACACAGAAAGACCACAATGCACCTTAT
TAATCTCACAGGGGGAGTTTAGACCCTGGTAAGCACCACTCCTGTAGTACAGA
ATAAACTTGGTTACAAAGGGGAAGCAAAACACATCATTATTACCAAAATTCCT
CACTGATGACAATGCTTACCCCCCAAAAATGTATTAAAGGCTTTAAATATACA
AATCTAAAAATATGTTGTGACATTTAACATTGACTTAATTTTTTTAATATGCT
TTAAAATATACTCAGTGTCTCTCCCTCTGATTCACCAATTATGTGAAGAAGCC
TCTTTCATTGTTTTTCTCTCAAACTTCTATCCTTTTCTCTGTCCTTGAGCAGA
ACTGGGGGCTGGACAGATTCCCAAGGTGGTGACTATGATACCTGCTCCACAAC
CCTCTTGTGCTGGCTCCGGAAGTGACCCTCGCTGCTGGGGGAC

Fig. 12

BLASTP - alignment of 411 against swissnew|O15075|DCK1_HUMANSERINE/THREONINE-
PROTEIN KINASE DCAMKL1 (EC 2.7.1.-) (DOUBLECORTIN- LIKE AND CAM KINASE-LIKE

1)./;:swiss|O15075|DCK1_HUMAN SERINE/THREONINE-PROTEIN KINASE DCAMKL1 (EC
2.7.1.-) (DOUBLECORTIN-LIKE

AND CAM KINASE-LIKE 1) (KIAA0369).

This hit is scoring at : 2e-87 (expectation value)
Alignment length (overlap) : 294
Identities : 52 %
Scoring matrix : BLOSUM62 (used to infer consensus pattern)
Database searched : nrdb_1_i

```
                        PROTEIN KINASE ATP
Q:   535 IAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYAMKIIDKSRLKGKEDMVDSEILIIQ
             I.A.:.:.:Y:.GR.IGDGNFAVVKEC .R.T:.:YA:KII.KS:..:GKE.M:.:E:.I::
H:   382 IPATITERYKVGRTIGDGNFAVVKECVERSTAREYALKIIKKSKCRGKEHMIQNEVSILR

         SLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVH
         .:.HPNIV L E .:.:E:YL::E.V:GGDLFDAI.:. K:.E DA: M:.:L.:A: :
         RVKHPNIVLLIEEMDVPTELYLVMELVKGGDLFDAITSTNKYTERDASGMLYNLASAIKY

                        PROTEIN KINASE ST
         MHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSE
         :H.:IVHRD:KPENLLV..:.:D S.:LKL.DFGLA. V P::TVCGTPTYVAPEI::E
         LHSLNIVHRDIKPENLLIVYEHQDGSKSLKLGDFGLATIVDGPLYTVCGTPTYVAPEIIAE
```

Fig. 12 (continued)

```
KGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDELFNIIQLGHFEFLPPYWDNISDAAK
.GYGL:VD:WAAGVI.YILLCGFPPFR..  DQ: LF: I :G...:F .PYWDN:SD:AK
TGYGLKVDIWAAGVITYILLCGFPPFRGSGDDQEVLFDQILMGQVDFPSPYWDNVSDSAK

DLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHK    828
:L::.:L:VD .:R::A QVL:HPW:.. G .:.. :.Q .V: . HF.: K
ELITMMLLVDVDQRFSAVQVLEHPWVNDDGLPEN-EHQLSVAGKIKKHFNTGPK    674
```

Fig. 13

BLASTP - alignment of 411 against swissnew|O15075|DCK1_HUMAN

SERINE/THREONINE-PROTEIN KINASE DCAMKL1 (EC 2.7.1.-) (DOUBLECORTIN- LIKE AND CAM KINASE-LIKE

1).//:swiss|O15075|DCK1_HUMAN SERINE/THREONINE-PROTEIN KINASE DCAMKL1 (EC 2.7.1.-) (DOUBLECORTIN-LIKE AND CAM KINASE-LIKE 1) (KIAA0369).

This hit is scoring at : 6e-09 (expectation value)
Alignment length (overlap) : 158
Identities : 24 %
Scoring matrix : BLOSUM62 (used to infer consensus pattern)
Database searched : nrdb_1_;

DOUBLECORTIN DOMAIN

Q: 110 LKPRVVTVVKLGGQRPRKITLLLNRRSVSVQTFEQLLADISEALGSPRWKNDRVRKLFNLKG
         ::P::VT:::G : :.:::LLN::.:::FEQ:L.DI::A: :.:::V::L::L.G
H: 183 IRPKLVTIIRSGVKPRKAVRILLNKKTAHSFEQVLTDITDAI---KLDSGVVKRLYTLDG

         REIRSVSDFFREGDAFIAMGKEPLTLKSIQVAVEELYPNKARALTLAQHSRAPSPRLRSR
         :::::.:DFF ::D.FIA.G.E:..::.: E ::.R:.:::::..S..:RS.
         KQVMCLQDFFGDDDIFIACGPEKFRYQDDFLLDE----SECRVVKSTSYTKIASSSRRST

         LFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIP   267
         :K: .:R..::.:S..::.G.::.::.GK P
         --TKSPGPSRRSKSPASTSSVNGTPGSQLSTPRSGKSP   331

Fig. 14

HMMPFAM - alignment of 411 against pfam|hmm|pkinase

Eukaryotic protein kinase domain

This hit is scoring at : 350.2
Scoring matrix : BLOSUM62 (used to infer consensus pattern)

```
Q:  543 YETGRVIGDGNFAVVKECRHReTRQAYAMKIIDKSRLKgkedmvDSEILIIQSLSHPNIV
        YE.:G:F. V .::H: T :.:A:KI:.K..L.           .EI I::.LSHPNIV
H:    1 yelleklGeGsfGkVykakhk.tgkivAvKiikkesls......lrEiqilkrlsHpNIv

        KLHEVYE-TDMEIYLILEYVQGGDLFDAIIESVKFPEPDAALMIMDLCKALVHMHDKSIV
        :L V:E TD .:YL::EY::GGDLFD : . ..:E.:A.::i::::L .::H...IV
        rllgvfedtddhlylvmEymegGdlfdylrrngplsekeakkialQilrGleYLHsngiv

        HRDLKPENLLVQRNedksTTLKLADFGLAKHVvRPIFTVCGTPTYV-APEI-LSEKGYGL
        HRDLKPEN:L:..N      T:K:ADFGLA: .::T.:GTP Y: APE: L. :GY.
        HRDLKpeNILlden.....gtvKiaDFGLArll.eklttfvGTpwYmmAPEvilegrgyss

        EVDMWAAGVILYILLCG----                      -----FPPFRS----PERDQD
        :VD:W:.GVILY LL.G                               PF.:
        kvDvwSlGvilyElltggplfpgadlpaftggdevdqliifvklPfsdelpktridple

        ELFNIIQLghfefLPPYWDNISDAAKDLVSRLLVVDPKKRY---TAHQVLQHPWI  800
        ELF.I :    P..N.S:.KDL:.::L DP.KR  TA.:L.HPW
        elfrikkr.....rlplpsncSeelkdLlkkcLnkDPskRpGsatakeilnhpwf  278
```

Fig. 15

Genscan analysis of target #411 using genomic sequence AC032001.2

   GENSCAN 1.0   Date run: 22-Jan-101   Time: 16:49:26

Sequence gi : 190827 bp : 41.86% C+G : Isochore 1 (0 - 43 C+G%)

Parameter matrix: HumanIso.smat

Predicted genes/exons:

Gn.Ex	Type	S	.Begin	...End	.Len	Fr	Ph	I/Ac	Do/T	CodRg	P....	Tscr..
3.00	Prom	+	29387	29426	40							-6.35
3.01	Init	+	34006	34141	136	0	1	98	17	124	0.854	6.65
3.02	Intr	+	34536	36412	1877	1	2	123	99	1835	0.995	174.47
3.03	Term	+	38194	38436	243	0	0	13	47	213	0.893	4.62
3.04	PlyA	+	38602	38607	6							1.05

Fig. 16

Genewise analysis of target #411 using genomic sequence AC032001.2 and the rat
protein as template(Y42696).genewise output

Score 333.62 bits over entire alignment

Scores as bits over a synchronous coding model

Warning: The bits scores is not probablistically correct for single seqs

See WWW help for more info

```
Y42696              568  llvqrnedksttlkladfglakhvvrpiftvcgtptyvapeiltek
                         + +++++++++++++++++++++++++++++++++++++++++++
                         LQVQRNEDKSTTLKLADFGLAKHVVRPIFTVCGTPTYVAPEILSEK

gi|7658410|gb-176116  tcgccaggataatatggtgcgacggacatagtgacatggcgactga
                      tatagaaaacccctatcatgtccatgttctggccatccattcaa
                      agtgatgatgcattcgagtttatagtgtggatattgtcatcatttga

Y42696              614                       yglevdmwaagvilyillcgfpp
                                              +++++++++++++++++++++++
                                              YGLEVDMWAAGVILYILLCGFPP

                         g:G[ggt]

gi|7658410|gb-175978  GGTAAGTG  Intron 1  CAGGTtgcgggatggggactacctgtcc
                                           agtatatgccgtttatttggtcc
                                           tagggcggttcgcctcggtctca

Y42696              638  frsperdqdelfniiqlgqfeflspywdnisd
                         + +++++++++++++++++  +++++ +++++
                         FRSPERDQDELFNIIQLGHFEFLPPYWDNISD
```

```
Fig. 16 (continued)

gi|7658410|gb-172557  tcacgagcggctaaaccgctgtcccttgaatg
                      tggcagaaattattatgatattccagaatca
                      ccctggcgcggctcccggcctgccctcgctctt

Y42696           670                          akdlvrnllvvdpkkrytahqvl
                                              +++++  ++++++++++++++++
                               a:A[gct]        AKDLVSRLLVVDPKKRYTAHQVL

gi|7658410|gb-172461  GGTGAGAT  Intron 2  CAGCTgagcgactcgggcaactagccgc
                                          caattggttttacaagaccaatt
                                          tatggcggggaccagccattgtt

Y42696           694  qhpwigmvghpstvnpqkeespssegrfqsqhkkvaehvs
                      +++++  +   +++  + ++++++++ + ++
                      QHPWIETAGKTNTVKRQKQVSPSSEGHFRSQHKRVVEQVS

gi|7658410|gb-169901  ccctagagaggaaaagagaccaccacgtcaaggctcaccaagggcgt
                      aacgtaccgacactagaaatccggagatggaaagttaatc
                      gccgcaatcgctagaaggggcccgtccgcgcggtgggaa
//
Gene 1
Gene 176116 1699782
Exon 176116 175978
Exon 172628 172461
Exon 169972 169782
//
```

Fig. 17

Genewise results.

```
gi|7658410|gb|AC032001.2|AC032001    GeneWise    match    169780    176116
333.62     -
gi|7658410|gb|AC032001.2|AC032001    GeneWise    cds      176115    175976
       -Y42696
0.00   -
gi|7658410|gb|AC032001.2|AC032001    GeneWise    intron   175977    172629
0
0.00   -
gi|7658410|gb|AC032001.2|AC032001    GeneWise    cds      172627    172459
       -Y42696
2
0.00   -
gi|7658410|gb|AC032001.2|AC032001    GeneWise    intron   172460    169973
0.00   -
gi|7658410|gb|AC032001.2|AC032001    GeneWise    cds      169971    169780
       -Y42696
2
0.00
```

Fig. 18

BLASTP - alignment of 411 against aageneseq|Y42696|Y42696

Rat serine-threonine protein kinase PK80 sequence.

This hit is scoring at : 0.0 (expectation value)
Alignment length (overlap) : 746
Identities : 74 %
Scoring matrix : BLOSUM62 (used to infer consensus pattern)
Database searched : aageneseq

```
Q:  91 VPLFCPRNGLHSAHPENSPLKPRVVTVVKLGGQRPRKITLLLNRRSVQTFEQLLADISEA
        :P:F.P::.LHS...E:SPLKPRVVTVVKLG Q RK.TLLLNRRSVQTFEQLL:DISEA
H:   1 MPMFSPQSSLHSVRAEHSPLKPRVVTVVKLGVQPFRKATLLLNRRSVQTFEQLLSDISEA

LGSPRWKNDRVRKLFNLKGREIRSVSDFFREGDAFIAMGKEPLTLKSIQVAVEELYPNKA
LG PRWKNDRVRKLF.LKGRE::SVSDFFREGDAFIAMGKEPLTLKSIQ:A:EELYP K
LGFPRWKNDRVRKLFTLKGREVKSVSDFFREGDAFIAMGKEPLTLKSIQLAMEELYP-KN

RALTLAQHSRAPSPRLRSRLFSKALKGDHRCGETETPKSCSEVAGCKAAMRHQGKIPEEL
RAL.LA.HSR.PSPRLRSRL SK.LKG.HRCGE.   S .EV.G KA.:RHQGK..:EL
RALALAPHSRVPSPRLRSRLPSKLLKGSHRCGEAG---SYGEVMGNKAVIRHQGKTSTEL

SLDDRARTQXXWGRGXWEPEPSSXP-PREATLEERHARGEXHLGVEIEXTSGEIIRCEXC
: :D:AR.Q..W  G. E.E ...P PREAT EE.HA.GE.HLGVEIE.TSGEI:RCE.C
APEDKARAQKKWVGGKQESENGGLPSPREATQEETHASGEKHLGVEIEKTSGEIVRCEKC

XRERELQQSLERERLSLGTSELDMGXGPMYDVEXLVRTRSCRRSPEANPASGEEGWXGDS
.RE.ELQ .L:R .:. GTSELD:G.G.. D E.LVRT:SCRR:.EA...GEEGW.GDS
KRETELQLGLQRGQCPPGTSELDLGRGQKRDSEKLVRTKSCRRASEAKSTDGEEGWKGDS
```

Fig. 18 (continued)

```
HRSSPRNPTQELRRPSXSMDXXEDRGPEDQESHAQGAAXAXXDLVEVLPVTEEGLREVXX
HR.SPR:P.QELRRP:..:D..E.RG.E QESH.QG.A.A..DL:E LP..EEG. .:..:
HRGSPRDPPQELRRPNNNSDKKESRGSEAQESHPQGVAKAQKDLMEGLPAVEEGAVDARR

DTRPMSRSXHGGWLLREHQAGFEXLRRTRGEEXEAEXEXXPCMSGGRRMTLRDDQPAXLE
D:R ..R .H..WL RE.QA    .L RTRGEE.EAE.E..   GGRRM         LE
DSRHTCRIKHAAWLRREQQAEPPQLPRTRGEEKEAEHEKKSGGLGGRRM------- -LE

XEPXTRPEENXPERPSGRXPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAY
.E..T:PEEN.PERPSGR. RP.GII:A:VEKHY:.GRVIGDGNFA:VKEC:HRETRQAY
KESKTKPEENRPERPSGRKLRPTGIISADVEKHYDIGRVIGDGNFAIVKECKHRETRQAY

AMKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDA
AMKIIDKS:LKGKED:VDSEILIIQSLSHPNIVKLHEVYET:.EIYLI:EYVQGGDLFDA
AMKIIDKSQLKGKEDIVDSEILIIQSLSHPNIVKLHEVYETEAEIYLIMEYVQGGDLFDA

IIESVKFPEPDAALMIMDLCKALVHMHDKSIVHRDLKPENLLVQRNEDKSTTLKLADFGL
IIESVKFPEPDAA:MI.DLCKALVHMHDK.IVHRDLKPENLLVQRNEDKSTTLKLADFGL
IIESVKFPEPDAAVMITDLCKALVHMHDKKIVHRDLKPENLLVQRNEDKSTTLKLADFGL

AKHVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDE
AKHVVRPIFTVCGTPTYVAPEIL:EKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDE
AKHVVRPIFTVCGTPTYVAPEILTEKGYGLEVDMWAAGVILYILLCGFPPFRSPERDQDE

LFNIIQLGHFEFLPPYWDNISDAAKDLVSRLLVVDPKKRYTAHQVLQHPWIETAGKTNTV     835
LFNIIQLG.FEFL.PYWDNISDAAKDLV..LLVVDPKKRYTAHQVLQHPWI  .G..:TV
LFNIIQLGQFEFLSPYWDNISDAAKDLVRNLLVVDPKKRYTAHQVLQHPWIGMVGHPSTV

KRQKQVSPSSEGHFRSQHKRVVEQVS     835
.QK: SPSSEG.F:SQHK:V.E.VS
NPQKEESPSSEGRFQSQHKKVAEHVS     733
```

Fig. 19

	Breast Cancer 5781	Breast Cancer 5922	Breast Cancer 5988	Colon Cancer 5255	Colon Cancer 5295	Colon Cancer 5298	Lung Cancer 5299 B	Lung Cancer 5662	Lung Cancer 5833	Prostate CAN 5917	Ovary CAN 6145
Fold Induction	0,13	0,27	0,19	0,76	0,88	2,64	0,77	1,43	0,97	2,35	12,21
411-Ct	35,19	36,58	34,25	34,85	33,87	32,29	33,21	35,14	33,02	36,16	32,13
18s-Ct	15,76	16,46	16,65	16,76	17,12	16,20	16,19	18,59	15,62	17,30	17,74

Fold Change

Fig. 20

Copy #	adipose mes	adipose subq	brain	islets	hypothalamus	liver	skeletal muscle	testes
411-Ct	37,795	35,905	35,14	35,52	33,465	38,005	34,16	33,21
18s-Ct	15,35	14,705	15,655	15	14,975	15,045	15,07	16,46
Copy Number	4,07890648	13,5584759	22,0476271	17,3171493	63,9272313	3,56928095	41,1013343	75,1743282

Fig. 21

Relative Expression

	adipose mes	adipose subq	brain	islets	hypothalamus	liver	skeletal muscle	testes
411-Ct	37,795	35,905	35,14	35,52	33,465	38,005	34,16	33,21
18s-Ct	15,35	14,705	15,655	15	14,975	15,045	15,07	16,46
Relative Expression	1,93034162	4,5752678	15,0204506	7,33021843	29,9369676	1,35083942	19,7510328	100

Relative Expression

SEQUENCE LISTING

<110>   Bayer AG

<120>   REGULATION OF HUMAN SERINE/THREONINE PROTEIN KINASE

<130>   LIO289 Foreign Countries

<150>   US 60/265,903

<151>   2001-02-05

<150>   US 60/308,104

<151>   2001-07-30

<160>   13

<170>   PatentIn version 3.1

<210>   1

<211>   2505

<212>   DNA

<213>   Homo sapiens

<400>   1
atggcggaag gcaaggaagg gcaagtccca tcttacatgg atggcagcag gcaaagagag   60

aatgaggaag atgcaaaagc ggaaacccct gatgtaacca tcagatctta tgagatttat   120

tcactaccat ggaacagaca gcaaggcgta tgtgaccatt ctctagaata tttaagctcg   180

agaatctcag agcggaagct gcaaggctcc tggctgcctg ccagccgagg gaatctggag   240

aaaccattcc tggggccgcg tggccccgtc gtgcccttgt tctgccctcg gaatggcctt   300

cactcagcac atcctgagaa cagccctctg aagcccaggg tcgtgaccgt agtgaagctg   360

```
ggtgggcagc gcccccgaaa gatcactctg ctcctcaaca ggcgatcagt gcagacgttc    420

gagcagctct tagctgacat ctcagaagcc ttgggctctc ccagatggaa gaatgaccgt    480

gtgaggaaac tgtttaacct caagggcagg gaaatcagga gcgtctctga tttcttcagg    540

gaaggggatg ctttcatagc tatgggcaaa gaaccactga cactgaagag cattcaggtg    600

gctgtagaag aactgtaccc caacaaagcc cgggccctga cactggccca gcacagccgt    660

gccccttctc caaggctgag gagcaggctg tttagcaagg ctctgaaagg agaccaccgc    720

tgtggggaga ccgagacccc caagagctgc agcgaagttg caggatgcaa ggcagccatg    780

aggcaccagg ggaagatccc cgaggagctt tcactagatg acagagcgag gacccagaag    840

aagtggggga gggggaaatg ggagccagaa cccagtagca agcccccccag ggaagccact    900

ctggaagaga ggcacgcaag gggagagaag catcttgggg tggagattga aaagacctcg    960

ggtgaaatta tcagatgcga gaagtgcaag agagagaggg agctccagca gagcctggag   1020

cgtgagaggc tttctctggg gaccagtgag ctggatatgg ggaagggccc aatgtatgat   1080

gtggagaagc tggtgaggac cagaagctgc aggaggtctc ccgaggcaaa tcctgcaagt   1140

ggggaggaag ggtggaaggg tgacagccac aggagcagcc ccaggaatcc cactcaagag   1200

ctgaggagac ccagcaagag catggacaag aaagaggaca gaggcccaga ggatcaagaa   1260

agccatgctc agggagcagc caaggccaag aaggaccttg tggaagttct tcctgtcaca   1320

gaggaggggc tgagggaggt gaagaaggac accaggccca tgagcaggag caaacatggt   1380

ggctggctcc tgagagagca ccaggcgggc tttgagaagc tccgcaggac ccgaggagaa   1440

gagaaggagg cagagaagga gaaaaagcca tgtatgtctg gaggcagaag gatgactctc   1500

agagatgacc aacctgcaaa gctagaaaag gagcccaaga cgaggccaga agagaacaag   1560

ccagagcggc ccagcggtcg gaagccacgg cccatgggca tcattgccgc caatgtggaa   1620

aagcattatg agactggccg ggtcattggg gatgggaact ttgctgtcgt gaaggagtgc   1680

agacaccgcg agaccaggca ggcctatgcg atgaagatca ttgacaagtc cagactcaag   1740

ggcaaggagg acatggtgga cagtgagatc ttgatcatcc agagcctctc tcaccccaac   1800

atcgtgaaat tgcatgaagt ctacgaaaca gacatggaaa tctacctgat cctggagtac   1860

gtgcagggag agacctttt tgacgccatc atagaaagtg tgaagttccc ggagcccgat   1920

gctgccctca tgatcatgga cttatgcaaa gccctcgtcc acatgcacga caagagcatt   1980

gtccaccggg acctcaagcc ggaaaacctt ttggttcagc gaaatgagga caaatctact   2040

accttgaaat tggctgattt tggacttgca aagcatgtgg tgagacctat atttactgtg   2100

tgtgggaccc caacttacgt agctcccgaa attctttctg agaaaggtta tggactggag   2160
```

```
gtggacatgt gggctgctgg cgtgatcctc tatatcctgc tgtgtggctt tcccccattc    2220

cgcagccctg agagggacca ggacgagctc tttaacatca tccagctggg ccactttgag    2280

ttcctcccccc cttactggga caatatctct gatgctgcta aagatctggt gagccggttg    2340

ctggtggtag accccaaaaa gcgctacaca gctcatcagg ttcttcagca cccctggatc    2400

gaaacagctg gcaagaccaa tacagtgaaa cgacagaagc aggtgtcccc cagcagcgag    2460

ggtcacttcc ggagccagca caagagggtt gtggagcagg tatca                    2505
```

<210> 2

<211> 835

<212> PRT

<213> Homo sapiens

<400> 2

```
Met Ala Glu Gly Lys Glu Gly Gln Val Pro Ser Tyr Met Asp Gly Ser
1               5                   10                  15


Arg Gln Arg Glu Asn Glu Glu Asp Ala Lys Ala Glu Thr Pro Asp Val
            20                  25                  30


Thr Ile Arg Ser Tyr Glu Ile Tyr Ser Leu Pro Trp Asn Arg Gln Gln
        35                  40                  45


Gly Val Cys Asp His Ser Leu Glu Tyr Leu Ser Ser Arg Ile Ser Glu
    50                  55                  60


Arg Lys Leu Gln Gly Ser Trp Leu Pro Ala Ser Arg Gly Asn Leu Glu
65                  70                  75                  80


Lys Pro Phe Leu Gly Pro Arg Gly Pro Val Val Pro Leu Phe Cys Pro
                85                  90                  95


Arg Asn Gly Leu His Ser Ala His Pro Glu Asn Ser Pro Leu Lys Pro
                100                 105                 110


Arg Val Val Thr Val Val Lys Leu Gly Gly Gln Arg Pro Arg Lys Ile
            115                 120                 125


Thr Leu Leu Leu Asn Arg Arg Ser Val Gln Thr Phe Glu Gln Leu Leu
```

```
            130                   135                   140
```

Ala Asp Ile Ser Glu Ala Leu Gly Ser Pro Arg Trp Lys Asn Asp Arg
145   150   155   160

Val Arg Lys Leu Phe Asn Leu Lys Gly Arg Glu Ile Arg Ser Val Ser
              165   170   175

Asp Phe Phe Arg Glu Gly Asp Ala Phe Ile Ala Met Gly Lys Glu Pro
          180   185   190

Leu Thr Leu Lys Ser Ile Gln Val Ala Val Glu Glu Leu Tyr Pro Asn
          195   200   205

Lys Ala Arg Ala Leu Thr Leu Ala Gln His Ser Arg Ala Pro Ser Pro
      210   215   220

Arg Leu Arg Ser Arg Leu Phe Ser Lys Ala Leu Lys Gly Asp His Arg
225   230   235   240

Cys Gly Glu Thr Glu Thr Pro Lys Ser Cys Ser Glu Val Ala Gly Cys
              245   250   255

Lys Ala Ala Met Arg His Gln Gly Lys Ile Pro Glu Glu Leu Ser Leu
              260   265   270

Asp Asp Arg Ala Arg Thr Gln Lys Lys Trp Gly Arg Gly Lys Trp Glu
          275   280   285

Pro Glu Pro Ser Ser Lys Pro Pro Arg Glu Ala Thr Leu Glu Glu Arg
      290   295   300

His Ala Arg Gly Glu Lys His Leu Gly Val Glu Ile Glu Lys Thr Ser
305   310   315   320

Gly Glu Ile Ile Arg Cys Glu Lys Cys Lys Arg Glu Arg Glu Leu Gln
              325   330   335

Gln Ser Leu Glu Arg Glu Arg Leu Ser Leu Gly Thr Ser Glu Leu Asp
          340   345   350

Met Gly Lys Gly Pro Met Tyr Asp Val Glu Lys Leu Val Arg Thr Arg
          355   360   365

Ser Cys Arg Arg Ser Pro Glu Ala Asn Pro Ala Ser Gly Glu Glu Gly
    370   375   380

Trp Lys Gly Asp Ser His Arg Ser Ser Pro Arg Asn Pro Thr Gln Glu
385   390   395   400

Leu Arg Arg Pro Ser Lys Ser Met Asp Lys Lys Glu Asp Arg Gly Pro
                405   410   415

Glu Asp Gln Glu Ser His Ala Gln Gly Ala Ala Lys Ala Lys Lys Asp
            420   425   430

Leu Val Glu Val Leu Pro Val Thr Glu Glu Gly Leu Arg Glu Val Lys
        435   440   445

Lys Asp Thr Arg Pro Met Ser Arg Ser Lys His Gly Gly Trp Leu Leu
    450   455   460

Arg Glu His Gln Ala Gly Phe Glu Lys Leu Arg Arg Thr Arg Gly Glu
465   470   475   480

Glu Lys Glu Ala Glu Lys Glu Lys Lys Pro Cys Met Ser Gly Gly Arg
            485   490   495

Arg Met Thr Leu Arg Asp Asp Gln Pro Ala Lys Leu Glu Lys Glu Pro
            500   505   510

Lys Thr Arg Pro Glu Glu Asn Lys Pro Glu Arg Pro Ser Gly Arg Lys
        515   520   525

Pro Arg Pro Met Gly Ile Ile Ala Ala Asn Val Glu Lys His Tyr Glu
    530   535   540

Thr Gly Arg Val Ile Gly Asp Gly Asn Phe Ala Val Val Lys Glu Cys
545   550   555   560

Arg His Arg Glu Thr Arg Gln Ala Tyr Ala Met Lys Ile Ile Asp Lys
            565   570   575

Ser Arg Leu Lys Gly Lys Glu Asp Met Val Asp Ser Glu Ile Leu Ile
        580   585   590

Ile Gln Ser Leu Ser His Pro Asn Ile Val Lys Leu His Glu Val Tyr
    595   600   605

Glu Thr Asp Met Glu Ile Tyr Leu Ile Leu Glu Tyr Val Gln Gly Gly
    610   615   620

Asp Leu Phe Asp Ala Ile Ile Glu Ser Val Lys Phe Pro Glu Pro Asp
625   630   635   640

Ala Ala Leu Met Ile Met Asp Leu Cys Lys Ala Leu Val His Met His
            645   650   655

Asp Lys Ser Ile Val His Arg Asp Leu Lys Pro Glu Asn Leu Leu Val
            660   665   670

Gln Arg Asn Glu Asp Lys Ser Thr Thr Leu Lys Leu Ala Asp Phe Gly
        675   680   685

Leu Ala Lys His Val Val Arg Pro Ile Phe Thr Val Cys Gly Thr Pro
    690   695   700

Thr Tyr Val Ala Pro Glu Ile Leu Ser Glu Lys Gly Tyr Gly Leu Glu
705   710   715   720

Val Asp Met Trp Ala Ala Gly Val Ile Leu Tyr Ile Leu Leu Cys Gly
            725   730   735

Phe Pro Pro Phe Arg Ser Pro Glu Arg Asp Gln Asp Glu Leu Phe Asn
            740   745   750

Ile Ile Gln Leu Gly His Phe Glu Phe Leu Pro Pro Tyr Trp Asp Asn
        755   760   765

Ile Ser Asp Ala Ala Lys Asp Leu Val Ser Arg Leu Leu Val Val Asp
    770   775   780

Pro Lys Lys Arg Tyr Thr Ala His Gln Val Leu Gln His Pro Trp Ile
785   790   795   800

Glu Thr Ala Gly Lys Thr Asn Thr Val Lys Arg Gln Lys Gln Val Ser
            805   810   815

Pro Ser Ser Glu Gly His Phe Arg Ser Gln His Lys Arg Val Val Glu
            820   825   830

Gln Val Ser
        835

<210> 3

<211> 740

<212> PRT

<213> Homo sapiens

<400> 3

Met Ser Phe Gly Arg Asp Met Glu Leu Glu His Phe Asp Glu Arg Asp
1   5   10   15

Lys Ala Gln Arg Tyr Ser Arg Gly Ser Arg Val Asn Gly Leu Pro Ser
                20   25   30

Pro Thr His Ser Ala His Cys Ser Phe Tyr Arg Thr Arg Thr Leu Gln
            35   40   45

Thr Leu Ser Ser Glu Lys Lys Ala Lys Lys Val Arg Phe Tyr Arg Asn
        50   55   60

Gly Asp Arg Tyr Phe Lys Gly Ile Val Tyr Ala Ile Ser Pro Asp Arg
65   70   75   80

Phe Arg Ser Phe Glu Ala Leu Leu Ala Asp Leu Thr Arg Thr Leu Ser
                85   90   95

Asp Asn Val Asn Leu Pro Gln Gly Val Arg Thr Ile Tyr Thr Ile Asp
                100   105   110

Gly Leu Lys Lys Ile Ser Ser Leu Asp Gln Leu Val Glu Gly Glu Ser
        115   120   125

Tyr Val Cys Gly Ser Ile Glu Pro Phe Lys Lys Leu Glu Tyr Thr Lys
        130   135   140

Asn Val Asn Pro Asn Trp Ser Val Asn Val Lys Thr Thr Ser Ala Ser
145   150   155   160

Arg Ala Val Ser Ser Leu Ala Thr Ala Lys Gly Ser Pro Ser Glu Val
                165   170   175

Arg Glu Asn Lys Asp Phe Ile Arg Pro Lys Leu Val Thr Ile Ile Arg

                    180   185   190

Ser Gly Val Lys Pro Arg Lys Ala Val Arg Ile Leu Leu Asn Lys Lys
        195   200   205

Thr Ala His Ser Phe Glu Gln Val Leu Thr Asp Ile Thr Asp Ala Ile
        210   215   220

Lys Leu Asp Ser Gly Val Val Lys Arg Leu Tyr Thr Leu Asp Gly Lys
225   230   235   240

Gln Val Met Cys Leu Gln Asp Phe Phe Gly Asp Asp Asp Ile Phe Ile
                245   250   255

Ala Cys Gly Pro Glu Lys Phe Arg Tyr Gln Asp Asp Phe Leu Leu Asp
                260   265   270

Glu Ser Glu Cys Arg Val Val Lys Ser Thr Ser Tyr Thr Lys Ile Ala
        275   280   285

Ser Ser Ser Arg Arg Ser Thr Thr Lys Ser Pro Gly Pro Ser Arg Arg
        290   295   300

Ser Lys Ser Pro Ala Ser Thr Ser Ser Val Asn Gly Thr Pro Gly Ser
305   310   315   320

Gln Leu Ser Thr Pro Arg Ser Gly Lys Ser Pro Ser Pro Ser Pro Thr
                325   330   335

Ser Pro Gly Ser Leu Arg Lys Gln Arg Ser Ser Gln His Gly Gly Ser
                340   345   350

Ser Thr Ser Leu Ala Ser Thr Lys Val Cys Ser Ser Met Asp Glu Asn
        355   360   365

Asp Gly Pro Gly Glu Glu Val Ser Glu Glu Gly Phe Gln Ile Pro Ala
        370   375   380

Thr Ile Thr Glu Arg Tyr Lys Val Gly Arg Thr Ile Gly Asp Gly Asn
385   390   395   400

Phe Ala Val Val Lys Glu Cys Val Glu Arg Ser Thr Ala Arg Glu Tyr
                405   410   415

Ala Leu Lys Ile Ile Lys Lys Ser Lys Cys Arg Gly Lys Glu His Met
            420   425   430

Ile Gln Asn Glu Val Ser Ile Leu Arg Arg Val Lys His Pro Asn Ile
            435   440   445

Val Leu Leu Ile Glu Glu Met Asp Val Pro Thr Glu Leu Tyr Leu Val
            450   455   460

Met Glu Leu Val Lys Gly Gly Asp Leu Phe Asp Ala Ile Thr Ser Thr
465   470   475   480

Asn Lys Tyr Thr Glu Arg Asp Ala Ser Gly Met Leu Tyr Asn Leu Ala
            485   490   495

Ser Ala Ile Lys Tyr Leu His Ser Leu Asn Ile Val His Arg Asp Ile
            500   505   510

Lys Pro Glu Asn Leu Leu Val Tyr Glu His Gln Asp Gly Ser Lys Ser
            515   520   525

Leu Lys Leu Gly Asp Phe Gly Leu Ala Thr Ile Val Asp Gly Pro Leu
            530   535   540

Tyr Thr Val Cys Gly Thr Pro Thr Tyr Val Ala Pro Glu Ile Ile Ala
545   550   555   560

Glu Thr Gly Tyr Gly Leu Lys Val Asp Ile Trp Ala Ala Gly Val Ile
            565   570   575

Thr Tyr Ile Leu Leu Cys Gly Phe Pro Pro Phe Arg Gly Ser Gly Asp
            580   585   590

Asp Gln Glu Val Leu Phe Asp Gln Ile Leu Met Gly Gln Val Asp Phe
            595   600   605

Pro Ser Pro Tyr Trp Asp Asn Val Ser Asp Ser Ala Lys Glu Leu Ile
            610   615   620

Thr Met Met Leu Leu Val Asp Val Asp Gln Arg Phe Ser Ala Val Gln
625   630   635   640

Val Leu Glu His Pro Trp Val Asn Asp Asp Gly Leu Pro Glu Asn Glu
            645   650   655

```
His Gln Leu Ser Val Ala Gly Lys Ile Lys Lys His Phe Asn Thr Gly
            660             665             670


Pro Lys Pro Asn Ser Thr Ala Ala Gly Val Ser Val Ile Ala Thr Thr
        675              .       680             685


Ala Leu Asp Lys Glu Arg Gln Val Phe Arg Arg Arg Arg Asn Gln Asp  .
    690                 695             700


Val Arg Ser Arg Tyr Lys Ala Gln Pro Ala Pro Pro Glu Leu Asn Ser
705                 710             715                 720


Glu Ser Glu Asp Tyr Ser Pro Ser Ser Ser Glu Thr Val Arg Ser Pro
                725             730                 735


Asn Ser Pro Phe
            740
```

```
<210>   4

<211>   1877

<212>   DNA

<213>   Homo sapiens


<400>   4
gacagcaagg cgtatgtgac cattctctag aatatttaag ctcgagaatc tcagagcgga        60

agctgcaagg ctcctggctg cctgccagcc gagggaatct ggagaaacca ttcctggggc       120

cgcgtggccc cgtcgtgccc ttgttctgcc ctcggaatgg ccttcactca gcacatcctg       180

agaacagccc tctgaagccc agggtcgtga ccgtagtgaa gctgggtggg cagcgccccc       240

gaaagatcac tctgctcctc aacaggcgat cagtgcagac gttcgagcag ctcttagctg       300

acatctcaga agccttgggc tctcccagat ggaagaatga ccgtgtgagg aaactgttta       360

acctcaaggg cagggaaatc aggagcgtct ctgatttctt cagggaaggg gatgctttca       420

tagctatggg caaagaacca ctgacactga agagcattca ggtggctgta gaagaactgt       480

accccaacaa agcccgggcc ctgacactgg cccagcacag ccgtgcccct tctccaaggc       540

tgaggagcag gctgtttagc aaggctctga aaggagacca ccgctgtggg gagaccgaga       600

cccccaagag ctgcagcgaa gttgcaggat gcaaggcagc catgaggcac caggggaaga       660

tccccgagga gctttcacta gatgacagag cgaggaccca gaagaagtgg gggaggggga       720
```

```
aatgggagcc agaacccagt agcaagcccc ccagggaagc cactctggaa gagaggcacg    780

caaggggaga gaagcatctt ggggtggaga ttgaaaagac ctcgggtgaa attatcagat    840

gcgagaagtg caagagagag agggagctcc agcagagcct ggagcgtgag aggctttctc    900

tggggaccag tgagctggat atggggaagg gcccaatgta tgatgtggag aagctggtga    960

ggaccagaag ctgcaggagg tctcccgagg caaatcctgc aagtggggag gaagggtgga   1020

agggtgacag ccacaggagc agccccagga atcccactca agagctgagg agacccagca   1080

agagcatgga caagaaagag gacagaggcc cagaggatca agaaagccat gctcagggag   1140

cagccaaggc caagaaggac cttgtggaag ttcttcctgt cacagaggag gggctgaggg   1200

aggtgaagaa ggacaccagg cccatgagca ggagcaaaca tggtggctgg ctcctgagag   1260

agcaccaggc gggctttgag aagctccgca ggacccgagg agaagagaag gaggcagaga   1320

aggagaaaaa gccatgtatg tctggaggca gaaggatgac tctcagagat gaccaacctg   1380

caaagctaga aaaggagccc aagacgaggc cagaagagaa caagccagag cggcccagcg   1440

gtcggaagcc acggcccatg ggcatcattg ccgccaatgt ggaaaagcat tatgagactg   1500

gccgggtcat tggggatggg aactttgctg tcgtgaagga gtgcagacac cgcgagacca   1560

ggcaggccta tgcgatgaag atcattgaca agtccagact caagggcaag gaggacatgg   1620

tggacagtga gatcttgatc atccagagcc tctctcaccc caacatcgtg aaattgcatg   1680

aagtctacga aacagacatg gaaatctacc tgatcctgga gtacgtgcag ggaggagacc   1740

tttttgacgc catcatagaa agtgtgaagt ccccggagcc cgatgctgcc ctcatgatca   1800

tggacttatg caaagccctc gtccacatgc acgacaagag cattgtccac cgggacctca   1860

agccggaaaa cctttttg                                                 1877
```

<210> 5

<211> 166

<212> PRT

<213> Homo sapiens

<400> 5

```
Leu Gln Val Gln Arg Asn Glu Asp Lys Ser Thr Thr Leu Lys Leu Ala
1               5                   10                  15


Asp Phe Gly Leu Ala Lys His Val Val Arg Pro Ile Phe Thr Val Cys
```

```
                    20                    25                    30

Gly Thr Pro Thr Tyr Val Ala Pro Glu Ile Leu Ser Glu Lys Gly Tyr
        35                  40                  45

Gly Leu Glu Val Asp Met Trp Ala Ala Gly Val Ile Leu Tyr Ile Leu
        50                  55                  60

Leu Cys Gly Phe Pro Pro Phe Arg Ser Pro Glu Arg Asp Gln Asp Glu
65                      70                  75                  80

Leu Phe Asn Ile Ile Gln Leu Gly His Phe Glu Phe Leu Pro Pro Tyr
            85                  90                  95

Trp Asp Asn Ile Ser Asp Ala Ala Lys Asp Leu Val Ser Arg Leu Leu
            100                 105                 110

Val Val Asp Pro Lys Lys Arg Tyr Thr Ala His Gln Val Leu Gln His
        115                 120                 125

Pro Trp Ile Glu Thr Ala Gly Lys Thr Asn Thr Val Lys Arg Gln Lys
        130                 135                 140

Gln Val Ser Pro Ser Ser Glu Gly His Phe Arg Ser Gln His Lys Arg
145                 150                 155                 160

Val Val Glu Gln Val Ser
                165
```

<210>   6

<211>   498

<212>   DNA

<213>   Homo sapiens

<400>   6
```
ttacaggttc agcgaaatga ggacaaatct actaccttga aattggctga ttttggactt      60

gcaaagcatg tggtgagacc tatatttact gtgtgtggga ccccaactta cgtagctccc     120

gaaattcttt ctgagaaagg ttatggactg gaggtggaca tgtgggctgc tggcgtgatc     180

ctctatatcc tgctgtgtgg ctttcccccca ttccgcagcc ctgagaggga ccaggacgag     240

ctctttaaca tcatccagct gggccacttt gagttcctcc cccttactg ggacaatatc     300
```

tctgatgctg ctaaagatct ggtgagccgg ttgctggtgg tagaccccaa aaagcgctac   360

acagctcatc aggttcttca gcacccctgg atcgaaacag ctggcaagac caatacagtg   420

aaacgacaga agcaggtgtc ccccagcagc gagggtcact tccggagcca gcacaagagg   480

gttgtggagc aggtatca   498

<210>   7

<211>   751

<212>   PRT

<213>   Homo sapiens

<400>   7

Met Ala Glu Gly Lys Glu Gly Gln Val Pro Ser Tyr Met Asp Gly Ser
1   5   10   15

Arg Gln Arg Glu Asn Glu Glu Asp Ala Lys Ala Glu Thr Pro Asp Val
            20   25   30

Thr Ile Arg Ser Tyr Glu Ile Tyr Ser Leu Pro Trp Asn Arg Gln Gln
        35   40   45

Gly Val Cys Asp His Ser Leu Glu Tyr Leu Ser Ser Arg Ile Ser Glu
    50   55   60

Arg Lys Leu Gln Gly Ser Trp Leu Pro Ala Ser Arg Gly Asn Leu Glu
65   70   75   80

Lys Pro Phe Leu Gly Pro Arg Gly Pro Val Val Pro Leu Phe Cys Pro
                85   90   95

Arg Asn Gly Leu His Ser Ala His Pro Glu Asn Ser Pro Leu Lys Pro
                100   105   110

Arg Val Val Thr Val Val Lys Leu Gly Gly Gln Arg Pro Arg Lys Ile
            115   120   125

Thr Leu Leu Leu Asn Arg Arg Ser Val Gln Thr Phe Glu Gln Leu Leu
        130   135   140

Ala Asp Ile Ser Glu Ala Leu Gly Ser Pro Arg Trp Lys Asn Asp Arg

```
145                    150                    155                    160

Val Arg Lys Leu Phe Asn Leu Lys Gly Arg Glu Ile Arg Ser Val Ser
            165                    170                    175

Asp Phe Phe Arg Glu Gly Asp Ala Phe Ile Ala Met Gly Lys Glu Pro
            180                    185                    190

Leu Thr Leu Lys Ser Ile Gln Val Ala Val Glu Glu Leu Tyr Pro Asn
            195                    200                    205

Lys Ala Arg Ala Leu Thr Leu Ala Gln His Ser Arg Ala Pro Ser Pro
    210                    215                    220

Arg Leu Arg Ser Arg Leu Phe Ser Lys Ala Leu Lys Gly Asp His Arg
225                    230                    235                    240

Cys Gly Glu Thr Glu Thr Pro Lys Ser Cys Ser Glu Val Ala Gly Cys
            245                    250                    255

Lys Ala Ala Met Arg His Gln Gly Lys Ile Pro Glu Glu Leu Ser Leu
            260                    265                    270

Asp Asp Arg Ala Arg Thr Gln Lys Lys Trp Gly Arg Gly Lys Trp Glu
            275                    280                    285

Pro Glu Pro Ser Ser Lys Pro Pro Arg Glu Ala Thr Leu Glu Glu Arg
    290                    295                    300

His Ala Arg Gly Glu Lys His Leu Gly Val Glu Ile Glu Lys Thr Ser
305                    310                    315                    320

Gly Glu Ile Ile Arg Cys Glu Lys Cys Lys Arg Glu Arg Glu Leu Gln
            325                    330                    335

Gln Ser Leu Glu Arg Glu Arg Leu Ser Leu Gly Thr Ser Glu Leu Asp
            340                    345                    350

Met Gly Lys Gly Pro Met Tyr Asp Val Glu Lys Leu Val Arg Thr Arg
            355                    360                    365

Ser Cys Arg Arg Ser Pro Glu Ala Asn Pro Ala Ser Gly Glu Glu Gly
    370                    375                    380
```

Trp Lys Gly Asp Ser His Arg Ser Ser Pro Arg Asn Pro Thr Gln Glu
385   390   395   400

Leu Arg Arg Pro Ser Lys Ser Met Asp Lys Lys Glu Asp Arg Gly Pro
                405   410   415

Glu Asp Gln Glu Ser His Ala Gln Gly Ala Ala Lys Ala Lys Lys Asp
            420   425   430

Leu Val Glu Val Leu Pro Val Thr Glu Glu Gly Leu Arg Glu Val Lys
        435   440   445

Lys Asp Thr Arg Pro Met Ser Arg Ser Lys His Gly Gly Trp Leu Leu
    450   455   460

Arg Glu His Gln Ala Gly Phe Glu Lys Leu Arg Arg Thr Arg Gly Glu
465   470   475   480

Glu Lys Glu Ala Glu Lys Glu Lys Lys Pro Cys Met Ser Gly Gly Arg
            485   490   495

Arg Met Thr Leu Arg Asp Asp Gln Pro Ala Lys Leu Glu Lys Glu Pro
        500   505   510

Lys Thr Arg Pro Glu Glu Asn Lys Pro Glu Arg Pro Ser Gly Arg Lys
        515   520   525

Pro Arg Pro Met Gly Ile Ile Ala Ala Asn Val Glu Lys His Tyr Glu
    530   535   540

Thr Gly Arg Val Ile Gly Asp Gly Asn Phe Ala Val Val Lys Glu Cys
545   550   555   560

Arg His Arg Glu Thr Arg Gln Ala Tyr Ala Met Lys Ile Ile Asp Lys
            565   570   575

Ser Arg Leu Lys Gly Lys Glu Asp Met Val Asp Ser Glu Ile Leu Ile
        580   585   590

Ile Gln Ser Leu Ser His Pro Asn Ile Val Lys Leu His Glu Val Tyr
        595   600   605

Glu Thr Asp Met Glu Ile Tyr Leu Ile Leu Glu Tyr Val Gln Gly Gly
    610   615   620

```
Asp Leu Phe Asp Ala Ile Ile Glu Ser Val Lys Phe Pro Glu Pro Asp
625             630             635             640

Ala Ala Leu Met Ile Met Asp Leu Cys Lys Ala Leu Val His Met His
            645             650             655

Asp Lys Ser Ile Val His Arg Asp Leu Lys Pro Glu Asn Leu Leu Gly
            660             665             670

Cys Glu Pro Ala Met Lys Ala Gln Pro Gly Lys Thr Glu Pro Trp Lys
        675             680             685

Thr Thr Leu Ser His Ser Glu Ile Met Glu Gly Lys Lys Ser Val Leu
    690             695             700

Gly Ser Leu Val Lys Glu Lys Thr Leu Arg Ser Ser Lys Cys Gly Thr
705             710             715             720

Lys Cys Pro Met Val Leu Leu Phe Ile Phe Lys Gly Val Asp Lys Ala
            725             730             735

Glu Lys Gln Ser Asp Val Gln Pro Phe Asn Asp Phe Tyr Glu Gly
            740             745             750
```

<210> 8

<211> 2256

<212> DNA

<213> Homo sapiens

<400> 8
```
atggcggaag gcaaggaagg gcaagtccca tcttacatgg atggcagcag gcaaagagag     60

aatgaggaag atgcaaaagc ggaaacccct gatgtaacca tcagatctta tgagatttat    120

tcactaccat ggaacagaca gcaaggcgta tgtgaccatt ctctagaata tttaagctcg    180

agaatctcag agcggaagct gcaaggctcc tggctgcctg ccagccgagg gaatctggag    240

aaaccattcc tggggccgcg tggccccgtc gtgcccttgt tctgccctcg gaatggcctt    300

cactcagcac atcctgagaa cagccctctg aagcccaggg tcgtgaccgt agtgaagctg    360

ggtgggcagc gcccccgaaa gatcactctg ctcctcaaca ggcgatcagt gcagacgttc    420

gagcagctct tagctgacat ctcagaagcc ttgggctctc ccagatggaa gaatgaccgt    480
```

```
gtgaggaaac tgtttaacct caagggcagg gaaatcagga gcgtctctga tttcttcagg    540

gaaggggatg ctttcatagc tatgggcaaa gaaccactga cactgaagag cattcaggtg    600

gctgtagaag aactgtaccc caacaaagcc cgggccctga cactggccca gcacagccgt    660

gccccttctc caaggctgag gagcaggctg tttagcaagg ctctgaaagg agaccaccgc    720

tgtggggaga ccgagacccc caagagctgc agcgaagttg caggatgcaa ggcagccatg    780

aggcaccagg ggaagatccc cgaggagctt tcactagatg acagagcgag gacccagaag    840

aagtggggga gggggaaatg ggagccagaa cccagtagca agccccccag ggaagccact    900

ctggaagaga ggcacgcaag gggagagaag catcttgggg tggagattga aaagacctcg    960

ggtgaaatta tcagatgcga gaagtgcaag agagagaggg agctccagca gagcctggag   1020

cgtgagaggc tttctctggg gaccagtgag ctggatatgg ggaagggccc aatgtatgat   1080

gtggagaagc tggtgaggac cagaagctgc aggaggtctc ccgaggcaaa tcctgcaagt   1140

ggggaggaag ggtggaaggg tgacagccac aggagcagcc ccaggaatcc cactcaagag   1200

ctgaggagac ccagcaagag catggacaag aaagaggaca gaggcccaga ggatcaagaa   1260

agccatgctc agggagcagc caaggccaag aaggaccttg tggaagttct tcctgtcaca   1320

gaggaggggc tgagggaggt gaagaaggac accaggccca tgagcaggag caaacatggt   1380

ggctggctcc tgagagagca ccaggcgggc tttgagaagc tccgcaggac ccgaggagaa   1440

gagaaggagg cagagaagga gaaaaagcca tgtatgtctg gaggcagaag gatgactctc   1500

agagatgacc aacctgcaaa gctagaaaag gagcccaaga cgaggccaga agagaacaag   1560

ccagagcggc ccagcggtcg gaagccacgg cccatgggca tcattgccgc caatgtggaa   1620

aagcattatg agactggccg ggtcattggg gatgggaact ttgctgtcgt gaaggagtgc   1680

agacaccgcg agaccaggca ggcctatgcg atgaagatca ttgacaagtc cagactcaag   1740

ggcaaggagg acatggtgga cagtgagatc ttgatcatcc agagcctctc tcaccccaac   1800

atcgtgaaat tgcatgaagt ctacgaaaca gacatggaaa tctacctgat cctggagtac   1860

gtgcagggag gagacctttt tgacgccatc atagaaagtg tgaagttccc ggagcccgat   1920

gctgccctca tgatcatgga cttatgcaaa gccctcgtcc acatgcacga caagagcatt   1980

gtccaccggg acctcaagcc ggaaaacctt ttgggatgtg agccagccat gaaagcacaa   2040

cctgggaaaa cagaaccatg gaaaacaaca ctcagtcact cagagattat ggaagggaag   2100

aagtctgtgt tgggaagcct ggtaaaggaa aaaaccctca gaagcagcaa atgtgggaca   2160

aaatgtccca tggtgcttct gtttattttc aagggagtag acaaagcgga gaaacagagt   2220
```

gatgttcagc ccttcaacga tttttatgag ggctga   2256

<210>   9

<211>   301

<212>   DNA

<213>   Homo sapiens

<220>

<221>   misc_feature

<222>   (184)..(184)

<223>   n=a, c, g or t

<400>   9
ccgccaatgt ggaaaagcat tatgagactg gccgggtcat tggggatggg aactttgctg   60

tcgtgaagga gtgcagacac cgcgagacca ggcaggccta tgcgatgaag atcattgaca   120

agtccagact caagggcaag gaggacatgg tggacagtga gatcttgatc atccagagcc   180

tctntcaccc caacatcgtg aaattgcatg aagtctacga aacagacatg gaaatctacc   240

tgatcctgga gtacgtgcag ggaggagacc tttttgacgc catcatagaa agtgtgaagt   300

t   301

<210>   10

<211>   505

<212>   DNA

<213>   Homo sapiens

<400>   10
acagctggca agaccaatac agtgaaacga cagaagcagg tgtcccccag cagcgagggt   60

cacttccgga gccagcacaa gagggttgtg gagcaggtat catagtcacc accttgggaa   120

tctgtccagc ccccagttct gctcaaggac agagaaaagg atagaagttt gagagaaaaa   180

caatgaaaga ggcttctttc acataattgg tgaatcagag ggagagacac tgagtatatt   240

ttaaagcata ttaaaaaaat taagtcaatg ttaaatgtca caacatattt ttagatttgt   300

atatttaaag cctttaatac atttttgggg ggtaagcatt gtcatcagtg aggaattttg   360

```
gtaataatga tgtgttttgc ttccccttttg taaccaagtt tattctgtac tacaggagtg      420

gtgcttacca gggtctaaac tcccctgtg agattaataa ggtgcattgt ggtctttctg       480

tgttaataaa atgtgctctg aataa                                            505
```

<210> 11

<211> 467

<212> DNA

<213> Homo sapiens

<400> 11
```
tctgttattc agagcacatt ttattaacac agaaagacca caatgcacct tattaatctc       60

acaggggggag tttagaccct ggtaagcacc actcctgtag tacagaataa acttggttac      120

aaaggggaag caaaacacat cattattacc aaaattcctc actgatgaca atgcttaccc       180

cccaaaaatg tattaaaggc tttaaatata caaatctaaa aatatgttgt gacatttaac       240

attgacttaa ttttttttaat atgctttaaa atatactcag tgtctctccc tctgattcac      300

caattatgtg aagaagcctc tttcattgtt tttctctcaa acttctatcc ttttctctgt       360

ccttgagcag aactgggggc tggacagatt cccaaggtgg tgactatgat acctgctcca       420

caaccctctt gtgctggctc cggaagtgac cctcgctgct gggggac                     467
```

<210> 12

<211> 22

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Forward primer

<400> 12
```
caacatcgtg aaattgcatg aa                                                22
```

<210> 13

<211> 23

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Reverse primer

<400> 13
tttctatgat ggcgtcaaaa agg   23